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In the developed world, age-related macular degeneration (AMD) is the most common cause 
for severe visual loss and legal blindness in the elderly. In this progressive disease, 
degeneration of the retinal pigment epithelium (RPE) results in the death of photoreceptors 
and secondary loss of central vision. Two late manifestations of AMD can be distinguished, 
neovascular AMD and atrophic AMD. Neovascular AMD is characterized by rapid visual loss 
secondary to VEGF-mediated ingrowth of choroidal neovascularizations (CNV). In contrast, 
atrophic AMD causes slowly progressive central visual decline by RPE cell degeneration 
known as geographic atrophy. Anti-VEGF treatment has proven highly effective in 
neovascular AMD and is now widely used clinically. In contrast, there is still no treatment 
available for atrophic AMD. Several lines of evidence indicate that oxidative and lipofuscin-
mediated photooxidative damage play an important role in AMD pathology. Further 
characteristics of the disease include the formation of extracellular deposits called drusen, 
and chronic low-grade immune processes including complement activation in the sub-RPE 
space. Inflammation is recognized as a major driving force in atrophic AMD. However, the 
mechanisms triggering and maintaining the retinal inflammation remain incompletely 
understood. Recent studies have shown that the NLRP3 inflammasome, a key mediator of 
the innate immune system, is activated in the RPE of patients with atrophic and neovascular 
AMD. The NLRP3 inflammasome is a multiprotein complex, which induces caspase-1 
activation resulting in secretion of the pro-inflammatory cytokines Interleukin-1β (IL-1β) and 
Interleukin-18 (IL-18). An initial priming signal in combination with a subsequent activation 
signal, such as reactive oxygen species or lysosomal membrane permeabilization (LMP), 
leads to assembly of the NLRP3 inflammasome. Studies demonstrated that phototoxic 
damage mediated by intralysosomal accumulation of photoreactive lipofuscin leads to LMP in 
RPE cells. The present thesis investigated whether lipofuscin-mediated phototoxicity 
activates the NLRP3 inflammasome in RPE cells in vitro and aimed to identify a novel 
mechanism of inflammasome activation by light damage that may provide new treatment 
targets for blinding diseases such as AMD. For this purpose, lipofuscin-loaded primary 
human RPE cells and human RPE cell line ARPE-19 cells were irradiated with blue light 
(dominant wavelength 448 nm, irradiance 0.8 mW/cm2 , duration 6 h) to induce 
photooxidative stress. The obtained results, presented in chapter IV demonstrate that 
accumulation of lipofuscin rendered RPE cells in vitro susceptible to phototoxic 
destabilization of lysosomes and cytosolic leakage of lysosomal enzymes. This resulted in 
NLRP3 inflammasome activation as evidenced by caspase-1 activation, processing and 
release of IL-1β and IL-18. Investigating the secretion profile of inflammatory cytokines after 
   
Summary 
 
3 
 
inflammasome activation revealed predominantly apical secretion of inflammatory cytokines, 
that corresponds to the neuoretinal side in vivo. In addition, secreted cytokines exerted a 
chemotactic effects on microglia cells as well as reduced constitutive secretion of VEGF 
(chapter V). In contrast to inflammasome activation, the mechanism of inflammasome 
priming in AMD has been little investigated so far. A recent study in patients with early or 
intermediate AMD demonstrated the complement factor H risk genotype to be associated 
with significantly increased plasma levels of the inflammasome-regulated cytokine IL-18, 
suggesting a role for activated complement components in inflammasome activation in AMD. 
Inflammasome priming by complement activation products has also been proposed in the 
context of other diseases such as atherosclerosis and gout. The thesis further reveales the 
capacity of activated complement components to prime human RPE cells for inflammasome 
activation. Obtained results, presented in chapter VI demonstrate that incubation of ARPE-19 
cells with complement-competent normal human serum (NHS) induced expression of pro-IL-
1β and enabled secretion of IL-1β in response to lipofuscin phototoxicity, indicating 
inflammasome priming by NHS. For further delineation of the relevant priming competent 
component in NHS, complement factors were heat inactivated or blocked by complement 
inhibitors which enabled the identification of complement activation product C5a as the 
priming signal for RPE cells. Likewise, conditioned media of inflammasome-activated RPE 
cells provided a priming effect that was mediated by the IL-1 receptor, thus suggesting a 
paracrine amplification loop of inflammasome activation. Further investigation demonstrated 
that cell priming by IL-1α or C5a increased susceptibility of RPE cells to 
oxidative/photooxidative damage-mediated cell death (chapter VII). Morphological 
observations and investigation of the underlying cell death mechanism revealed a change in 
cell death mode from apoptosis to pyroptosis. Moreover, conditioned media of pyroptotic 
ARPE-19 cells increased cell death by photooxidative damage in other cells in an interleukin-
1 receptor (IL-1R) dependent fashion. These results make it conceivable that in situations of 
localized RPE cell death such as in atrophic AMD, this mechanism could result in increased 
susceptibility of immediate bystander RPE cells to inflammasome-mediated cell death, thus 
contributing to the centrifugal progression pattern of RPE cell loss in AMD. In summary, this 
study identified a novel mechanism of inflammasome activation by light damage and 
provides a functional link between key factors of AMD pathogenesis including lipofuscin 
accumulation, photooxidative damage, complement activation, and RPE degeneration. 
Thereby, this study provide new potential treatment targets for blinding diseases such as 
AMD.  
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3.1 Age-related macular degeneration  
Age-related macular degeneration (AMD) is the leading cause blindness in all industrialized 
countries, affecting primarily persons aged 50 years and above. The disease affects roughly 
four and a half million people in Germany and vaguely 30 million in the rest of the world.1 A 
further significant increase in incidence and prevalence of the disease is predicted as a result 
of demographic development.2 AMD is a progressive and degenerative condition that affects 
cells and structures of the outer retina resulting in damage to the macula lutea.3 The macula 
lutea, further referred as “macula” is described as a small oval area that is characterized by 
the rich and close packing with cone photoreceptors. The macula accounts for fine spatial 
resolution and spatially differentiated perception, - the vision that is critical for activities such 
as reading, driving, and facial recognition.4 Characteristic for the commonly asymptomatic 
initial stage of AMD is the occurrence of drusen, deposits of extracellular debris and 
inflammatory material at the interface of the retinal pigment epithelium (RPE) and Bruch´s 
membrane that comprise lipid- and protein-rich debris.5 Drusen deposition is also part of a 
normal phenomena during natural aging,6 and usually do not affect visual function. But due to 
lipoidal character, drusen may act as a diffusion barrier that affects the transport of fluids and 
nutrients from the choroid to the retina. By this, the presence of drusen may contribute to an 
age-related degeneration of the RPE.7 Presumably, degenerative dysfunctions of the RPE 
and oxidative stress play a crucial role in drusen formation.8 However, an increase in 
number, size, and confluence of drusen, that is accompanied by retinal hyperpigmentation, is 
a significant risk factor for the sight-threatening advanced forms of AMD. A representative 
funduscopic image with drusen is presented in figure III.1a. Their presence may be 
accompanied by RPE cell death,9 but the connection between these AMD related events is 
not fully understood yet.  
Due to their clinical manifestation, AMD is characterized by two types, the slowly developing 
atrophic AMD and the fast developing neovascular AMD. The atrophic form is an advanced 
form of AMD that culminates in geographic atrophy (GA). GA is characterized by the loss of 
the RPE and the formation of atrophic patches within the macula. Adjacent photoreceptors 
also degenerate due to their metabolic dependence on RPE cell function. This causes a slow 
but continuous progressive loss of central vision.10,11 As atrophic patches increase in size 
and may become confluent, they eventually progress into central scotomas and areas of 
central vision loss with relative sparing of the surrounding peripheral retina.12 Despite 
extensive efforts, there are currently no available treatment options for atrophic AMD, 
although randomized clinical trials have reported that oral supplementation of various 
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antioxidants (i.e., vitamins C and E, beta carotene, zinc, lutein and zeaxanthin) may reduce 
the odds of disease progression from early to late stage AMD.3,13 A representative eye with 
GA is shown in figure III.1b. The neovascular form is an advanced form of AMD that 
culminates in the formation of choroidal neovascularizations (CNV) and fibrovascular 
scarring primarily affecting the macula.12 CNV is characterized by newly formed vessels that 
penetrate the Bruch's membrane and sprout into the sub-retinal space.14 Unlike physiological 
blood vessels, neovascular vessels are leaky and blood components drain into the sub-
retinal space. Therefore, this form of AMD may include lipid deposition, hemorrhage, sub-
retinal fluid accumulation, RPE detachment and fibrotic scarring, as presented in figure III.1c. 
The neovascularizations are initiated by an increased secretion of vascular endothelial 
growth factor (VEGF).15 If left untreated, they can lead to severe blindness with scarring 
within several months. Progression of neovascular AMD may be halted by VEGF inhibiting 
drugs, which represent an important CNV treatment option.16 However, these advanced 
stages of AMD should not be seen as stationary, since neovascular lesions may be present 
in the periphery of eyes with geographic atrophy and vice versa.17  
 
 
Figure III.1. Funduscopic images from AMD patients demonstrating hallmarks of disease. (A) Fundus 
photography in intermediate AMD showing drusen. (B) Fundus autofluorescence in atrophic AMD showing 
geographic atrophy. (C) Fluorescein angiography in neovascular AMD showing choroidal neovascularisation. 
 
While aging represents its primary determinant, environmental factors such as cigarette 
smoking,18,19 dietary habits,20–22 and light exposure,23–25 together with genetic 
predispositions26–32 contribute to the risk of AMD occurrence. In addition, oxidative stress, by 
releasing reactive oxygen species, represents another trigger in AMD pathogenesis.3,33 
Numerous findings suggest RPE dysfunction and degeneration as a critical event in AMD 
pathogenesis.34 
 
 General Introduction 
 
10 
 
3.2 Retinal pigment epithelium cells as primary disease target in AMD  
The RPE and the neuroretina constitute the retina, the neural portion of the eye. The 
neuroretina comprises five types of layered neurons: (1) photoreceptor cells, (2) bipolar cells, 
and (3) ganglion cells, which together provide the most direct route of transmitting visual 
information to the brain via the optic nerve, as well as (4) horizontal cells and (5) amacrine 
cells. Other cells present in the retina are glia cells: astrocytes, Müller cells, and microglia 
(figure III.2). The latter are located in the inner retina but transmigrate into and out of the 
subretinal space in diseases such as AMD.35 The RPE is built of a single layer of melanin-
pigmented cells of cuboidal form located on the Bruch’s membrane between the neural retina 
and the choriocapillaries. The RPE together with the Bruch´s membrane form the outer 
blood-retinal barrier (BRB) which is highly indispensable for sustaining vision. Tight junctions 
are strengthening the RPE laterally. Therefore, the BRB prevents the migration of immune 
cells and macromolecules from the underlying choroid into the photoreceptor layer.36 The 
RPE features a variety of metabolic functions that are of crucial importance for the healthy 
retina, such as exchange of nutrients, metabolites and fluids between the neuroretina and 
choriocapillaris,37 synthesis of vitamin-A metabolites (retinoid recycling) and protection 
against oxidative stress. Another function is the phagocytosis of shed photoreceptor outer 
 
 
Figure III.2: Structure of the human eye and organization of the retina. a) Profile of the human eye. b) Normal 
retinal architecture is comprised of the neuroretina that consists of photoreceptor cells, neuronal cells and glia 
cells (Müller cells, astrocytes, and microglia); the retinal pigment epithelium (RPE), the Bruch´s membrane and 
a choroidal vascular network. Microglia transmigrate into and out of the subretinal space (as shown by the 
dashed arrow). c) Geographic atrophy and d) Neovascular AMD demonstrate the advanced forms of AMD. 
Further information will be given in the text. Images modified from Ambati et al., 2013.
38
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segments (POS). These POS are digested and thereby essential substances such as the 
aldehyde all-trans-retinal get regenerated. After transformation into the photoactivated 
isomer 11-cis-retinal the POS is returned to the photoreceptors to rebuild light-sensitive POS 
from the basic constituents of the photoreceptors.39–42 Therefore, as a consequence of its 
strategic location and vital roles, the RPE is the primary site associated with AMD 
pathology.7,43,44 RPE degeneration results in loss of sensory retina, leading to vision loss in 
advanced AMD. The lysosomal compartment of the RPE is responsible for breaking down 
POS into their basic components for recycling. However, as aging is characterized by a 
gradual functional decline of all organ systems,45 likewise lysosomes are affected by age-
dependent decline in degradative capacity, resulting in incompletely degraded material.46 In 
addition, oxidative stress has been shown to be implicated in decreased lysosomal function, 
again promoting the accumulation of incompletely degraded material.47 Incomplete 
degradation of oxidized material has been proposed to be the beginning bud for aggregate 
formation that further cross-link to ultimately emerge in lipofuscin, one of the main hallmark 
features in AMD pathology. The accumulation of lipofuscin has been demonstrated to 
precede RPE dysfunction and degeneration with concurrent severe functional loss.48 This 
RPE degeneration is thought to be mediated, at least in part, by photoreactive properties of 
lipofuscin that accumulate in RPE over a lifetime. Therefore, as a consequence of its 
strategic location and vital roles, the RPE is the primary site associated with AMD 
pathology.7,43,44 
 
 
3.3 Oxidative stress in AMD  
As mentioned above, oxidative processes are a powerful feature in formation of lipofuscin.8,49 
Oxidative stress is related to a number of age-dependent diseases such as atherosclerosis,50 
and Alzheimer's disease,51 as well as several ocular diseases, such as diabetic 
retinopathy,52,53 cataract,54 and age-dependent macular degeneration.55 Oxidative stress is 
characterized as an imbalance in reactive oxygen species (ROS) and antioxidants.56,57 ROS 
can arise endogenously by the activity of NADPH oxidases in inflammatory process,58 in 
small amounts by normal mitochondrial activity59 or due to ionizing radiation, ultraviolet rays, 
tobacco smoke or photosensitizers.60,61 Antioxidant systems have evolved to protect 
biological systems against the deleterious effects of a wide array of ROS. Antioxidant 
enzymes such as peroxidase, catalase, and superoxide dismutase,62 as well as the 
antioxidant protection mechanisms of the vitamins E, C and glutathione reduce the harmful 
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effects of ROS.63 In addition, the RPE contains various pigments that are specified for 
different wavelengths64,64 such as the carotenoids lutein and zeaxanthin that possess 
antioxidant properties by filtering short-wavelength light.65 The outer retina is particularly 
vulnerable to photooxidative damage due to the age-dependent decline in RPE antioxidant 
defense66,67 as well as their high oxygen concentration, the intense light exposure combined 
with the presence of photosensitizers and the high content of polyunsaturated fatty acids 
(PUFA) such as docosahexaenoic acid,64,68,69 permitting oxidative stress to ultimately 
overwhelm RPE cell defenses, leading to oxidative damage and retinal aging.64,70–72 
Oxidative stress is an important mediator of damage to cell structures (termed oxidative 
damage), including single- and double desoxyribonucleic acid (DNA)-strand breaks, DNA–
protein and protein–protein cross-linking, protein fragmentation and oxidation of lipids, 
reffered to as lipid peroxidation.73–75  
3.3.1 Lipid peroxidation 
Lipid peroxidation is the oxidative degradation of lipids and proceeds by a complex free 
radical chain reaction by utilizing the interaction of ROS with PUFAs. PUFA are particularly 
prone to oxidation due to their multiple double bonds, that are more vulnerable to oxidation 
than saturated ones. Membrane and organelle surroundings are constituted by phospholipid 
layers that are rich in PUFAs, making them a vulnerable target for lipid peroxidation. 
Therefore, this process is particularly detrimental to cellular functions as it disturbs 
membrane fluidity, integrity and function.68 Free radicals exhibit an unstable and reactive 
status, due to an unpaired electron in the outer orbital shell.76 Therefore, free radicals aim to 
achieve a stable state. This can be achieved by abstracting an electron from other 
molecules. By this, unsaturated fatty acids are susceptible to free radical attack, due to their 
unsaturated carbon double bonds. Carbon double bonds constitute electrons bonds, in which 
one of those (allylic) bonds has loosely held electrons. Initially, lipid peroxidation occurs 
when ROS is generated in close proximity to a PUFA containing structure, such as the 
lysosomal membrane or phagocytosed POS. The radical immediately abstracts the allylic 
hydrogen forming water and a peroxyl radical. This lipid radical itself abstracts a hydrogen 
from another lipid molecule, generating a new lipid hydroperoxide. This leads to an 
autocatalytic chain reaction of oxidants. The peroxyl radical turns into a lipid hydro-
peroxidase, while simultaneously a new peroxyl radical is generated.77 As a part of these 
reactions, the valuable unsaturated fatty acids are cleaved in cytotoxic effective lipid 
peroxidation products. Termination of the chain reaction can only occur when either an 
antioxidant scavenger (e.g. vitamin E) donates a hydrogen atom to a radical, or if two 
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radicals react with each other to produce a non-radical species. The vitamin E radical reacts 
with another forming non-radical products.78 If not terminated fast enough, these reactions 
lead to cleavage of unsaturated fatty acids in cytotoxic effective lipid peroxidation products 
and irreparable damage to membranes under attack, with ensuing leakage of enclosed 
components (e.g. ions, proteins and lysosomal enzymes). The POS membranes are highly 
enriched by PUFAs. Docosahexaenoic acid, a precursor of α-linolenic acid with six double 
bonds, dominates among the fatty acids of the phospholipids.79 Therefore, the POS 
membranes are a sensitive site for oxidative damage. Phagocytosis of spent POS by RPE 
cells would be expected to introduce pre-formed lipid peroxidation products-modified POS 
proteins, and PUFAs prone to subsequent peroxidation into the RPE lysosomal 
compartment.  
Two prevalent lipid peroxidation products are malondialdehyde (MDA) and 4-hydroxynonenal 
(HNE). MDA predominantly arises from oxidation of the polyunsaturated fatty acids 
docosahexaenoic acid and arachidonic acid.68 HNE usually emerge by oxidation of 
arachidonic acid and linoleic acid.68 MDA and HNE attach covalently to proteins by forming 
adducts with lysine, histidine or cyteine residues. In this way, MDA and HNE stabilize POS 
proteins against degradation, resulting in accumulation of undigested POS within the 
lysosomes.80 Cross-linkage of oxidized proteins by HNE or MDA as well as decreased 
proteolysis of modified proteins leads to the formation of aggregates that may be the 
underlying mechanisms of lipofuscinogenesis. In addition, detection of HNE- and MDA-
modified proteins in a proteomic analysis of human RPE lipofuscin confirmed the 
intralysosomal occurrence of these aldehydes and brought attention to the pivotal role of lipid 
peroxidation products in the induction of lysosomal dysfunction and lipofuscinogenesis in 
RPE.47,81 
3.3.2 Lipofuscin-mediated photooxidative stress 
Lipofuscin accumulates in non-dividing metabolically active cells like neurons, 
cardiomyocytes and RPE cells82,83 and is associated with a variety of pathological conditions 
such as ceroid-lipofuscinosis, cirrosis of the liver, cardiac hypertrophy, as well as with ocular 
diseases such as AMD, Stargardt disease and Best’s disease.84–86 Unlike most cell types 
cells, in which lipofuscin is produced through the lysosomal degradation of intracellular 
organelles,39 the major substrate for RPE lipofuscin is the undegradable end product 
resulting from POS phagocytosis.87 Due to several fluorophores, RPE lipofuscin has a 
characteristic broad-band fluorescence.88 RPE lipofuscin autofluorescence facilitates the 
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detection of lipofuscin accumulation and distribution in the living eye89,90 by means of fundus 
spectrophotometry, a noninvasive measurement of intrinsic fluorescence and reflectance of 
the ocular fundus.91 The signal for lipofuscin accumulation in the RPE is augmented in the 
macula, maximally in the parafoveal ring where rods are densest.92–95 Additionally, 
autofluorescence increases linearly with age in the healthy retina,95 demonstrating age-
dependent increase in lipofuscin accumulation. It still needs to be proven whether lipofuscin 
is the causal factor in retinal degeneration. However, a growing number of evidence propose 
lipofuscin as detrimental factor, influencing RPE function and viability. The observation of 
lipofuscin fluorescence and progression of atrophic areas in AMD patients revealed that 
excessive lipofuscin accumulation preceeds RPE atrophy with concurrent damage to 
photoreceptors and choriocapillaris, leading to GA.48 A feasible approach is provided by 
studies that revealed increased RPE susceptibility to light-induced cell damage by 
accumulation of lipofuscin.96–98 In a consequence, a role of light-induced RPE cell damage 
has been postulated for AMD pathogenesis. However, several clinical studies that 
investigated the association of daylight exposure and the formation of AMD reported 
ambiguous results. Some studies demonstrated a relationship, whereas others failed to do 
so. Among the positive results, the Beaver Dam Eye Study reported that early signs of AMD 
positively correlate with excessive exposure to sunlight (> 5 hours per day) during the 
teenage years and beyond.99 Similarly, the Chesapeake Bay Watermen Study revealed that 
late AMD positively correlate to cumulative sunlight exposure.100 Ultraviolet radiation (UV) 
turns out not to be the causative agent for retinal damage, as UV is almost completely 
absorbed by the crystalline lens. However, shorter wavelengths of the visible spectrum (i.e. 
blue-light, 400 to 480 nm) demonstrate strong effects, possibly due to photooxidative 
damage to the RPE.100–102  
Lipofuscin represent the main photosensitizer in the retina, beside the visual pigments in 
photoreceptor cells.60 As soon as a photosensitizing molecule (e.g. lipofuscin, riboflavin, 
retinal) absorbs light in its particular wavelength, it gets converted into an excited state. In 
order to return to its ground state, the photosensitizer transfers the increase in energy to an 
adjacent oxygen molecule, creating a singlet oxygen. The singlet oxygen is highly aggressive 
and immediately seeks to attack and damage its surroundings when formed.103 Lipofuscin 
accumulation can be a result of photooxidative damage to the retina. Furthermore, once 
present in the RPE, lipofuscin can itself propagate photooxidative stress.104 Especially when 
excited by blue light, lipofuscin exerts photoreactive properties that induce oxidative stress to 
the lysosomal membrane via massive peroxidation of lysosomal membrane lipids.104 
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3.3.3 Lysosomal membrane permeabilization  
Lysosomes are membrane-bound acidic organelles, present in virtually all eucaryotic cells.105 
The endolysosomal system comprise early endosomes, with an slight acidic intra-lumenal pH 
of 6.0-6.6, late endosomes, with a more acidic pH (~5), and lysosomes with the most acidic 
compartment (pH ~4.5). The size of the lysosomes is approximately between 0.5 and 2 
micrometers depending on the content and stage of the degradation process.106,107 
Lysosomes are considered the major site for degradation of exo- and endogenously derived 
material.108 For this purpose, lysosomes comprise a variety of hydrolases including 
cathepsins, nucleases, glycosidases, sulfatases, and lipases. Of the lysosomal hydrolases, 
the cathepsin family of proteases is the best characterized. The cathepsins are subdivided, 
according to their active site amino acids, into cysteine (cathepsins B, C, F, H, K, L, O, S, V, 
W, and X), serine (cathepsins A and G), and aspartic cathepsins (cathepsins D and E).109 
Lysosomal enzymes are regulated by the pH of their surrounding environment that dictates 
enzymatic activity.105 The material to be digested is delivered to the endolysosomal 
compartment via endocytosis, autophagocytosis, and in specialized cells, through 
phagocytosis.110–112. The degraded material pass out of the lysosome via membrane 
transporter proteins and is reused by the cell. Lysosomes are limited by a single 7–10 nm 
phospholipid-bilayer.113 The lysosomal membrane provides an essential physical barrier from 
the acidic hydrolases to protect the interior of the cell from degradation. This is achieved by 
lysosome-specific expression of the highly glycosylated lysosome-associated membrane 
proteins (LAMPs) and lysosomal integral membrane proteins (LIMPs), that are considered 
responsible for lysosomal resistance to self-degradation from the inside.114,115 The lysosomal 
membrane harbors a proton pump that uses energy from ATP hydrolysis to maintain 
intralysosomal acidic conditions. 116–118  
Photosensitizers that are located in lysosomes and generate singlet oxygen upon radiation 
have been shown to cause LMP via massive peroxidation of lysosomal membrane lipids.119–
121 Another mechanisms leading to LMP may be induced by application of lysosomotrophic 
agents such as L-Leucyl-L-leucine methyl ester (Leu-Leu-OMe),122 or ciprofloxacin123. These 
agents accumulate within the lysosomes and permeabilize the membrane via a detergent 
mechanism. In addition, lipofuscin fluorophore A2E was also proposed to exert 
lysosomotrophic features.124 Lysosome membrane permeabilization leads to subsequent 
relocation of lysosomal constituents into the cytosol125 that triggers various cellular 
responses, such as inflammasome activation, autophagy, and apoptotic cell death.108,126 The 
idea of lysosomal involvement in cell death was first suggested by de Duve and Wattiaux in 
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1966.108 The importance of the cytosolic location of cathepsins for their pro-apoptotic function 
is highlighted by studies in which microinjection of cathepsins into the cytosol was sufficient 
to induce apoptosis. In each of these cases, a specific inhibitor of cathepsin B or D 
attenuated cell damage.127–129 Cathepsins have the ability to participate in both the initiation 
and execution phases of apoptosis but may in some cases also directly activate caspases.130  
 
 
3.4. Complement system in AMD 
Over the past decade, studies revealed that inflammation plays a crucial role in the 
pathogenesis of AMD. The most convincing evidence for the contribution of inflammation to 
AMD comes from studies that have strongly implicated the complement system. As an 
integral part of the innate immune system, the complement system plays a pivotal role in the 
innate defense against common pathogens as well as in the clearance of cellular debris from 
host tissues and other roles related to tissue homeostasis.131 The complement system is 
comprised of over 50 blood-circulating, mostly liver-derived, and membrane-bound proteins, 
regulators and effector molecules (figure III.3). The latter largely exist in a precursor state 
that is activated rapidly in a cascade-like fashion following activation of the system via any of 
three pathways: the classical pathway, the lectin pathway and the alternative pathway (AP) 
of the complement system.132 The classical pathway can be initiated by the binding of the 
pattern recognition molecule C1q to immunglobulin (IgG or IgM) in antibody:antigen 
complexes. It can also bind to C-reactive protein (CRP) on self or microbial surfaces or 
directly to molecules expressed on microbial membranes. The lectin pathway is independent 
of antibody binding and is triggered by interaction of mannose-binding lectin (MBL) with 
mannose residues or ficolin with N-acetyl glucosamine residues both present in bacterial cell 
walls.133 C1q and MBL are structurally similar molecules, and both the classical and lectin 
pathways require C2 and C4 complement components for the generation of the C3 
convertase. While the classical or lectin pathway are largely dependent on 
protein:carbohydrate or protein:protein interaction, the AP is constantly autoactivated in the 
fluid phase, a process referred to as „tickover“.134 AP activation by tickover appears at low 
rates by hydrolysis of complement component C3, leading to the formation of C3(H2O) and 
the binding of small amounts of C3b to cell surface carbohydrates or proteins of target cells 
such as bacterial cells, followed by the binding of factor B, which is then cleaved by Factor D 
to form the C3 convertase complex C3bBb. Once deposited on the surface of cells or 
pathogens, C3b binds more factor B, and this binding gradually amplifies the activation 
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cascade. The binding of properdin (P) stabilizes the C3 convertase and enhances the 
process.135 Although triggered by different signals, all activated pathways cumulate into the 
generation of a C3 convertase, a protein complex that cleaves the key complement effector 
molecule C3 into the anaphylatoxin C3a and the bioactive opsonin C3b. The latter 
contributes to the formation of the C5 convertase, which in turn cleaves C5 to C5a and C5b. 
The complement system not only helps the cell to defend against pathogens, but also has 
the potential to harm self-tissues. Therefore, it is particularly important for the cell to balance 
complement activation and inhibition.136 
 
 
Figure III.3: Complement system activation. (a) Complement system activation. Local effects of the inhibitors 
on complement components. (b) Complement system in the eye. Local production of the complement 
inhibitors by retinal cells. Image from Kawa et al., 2014.
137
 
 
Complement factor H is the major soluble regulator of the alternative complement pathway, 
and has a pivotal role because of the constant activation of that pathway.138 A single 
nucleotide polymorphism (SNP) in CFH that changes amino acid residue 402 from a tyrosine 
(Y402) to a histidine (402H) leads to functional consequences. The 402H variant binds with 
reduced affinity to several of its ligands which reduces the effectiveness by restricting 
activation of the alternative pathway. Therefore, there is a greater AP activation level in the 
retina of an individual carrying the negatively effecting risk variant 402H than in individuals 
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with Y402.139–147 This results in constant induction of the inflammatory cascade resulting in 
tissue damage and ultimately drusen formation in AMD.148 Evidence for complement 
activation in AMD were provided by the identification of complement proteins including C3, 
and the products of its activation and degradation, such as the anaphylatoxins C3a and C5a 
in drusen from eyes of AMD patients.149,150 The anaphylatoxins C3a and in particular C5a, are 
potent inflammatory factors, stimulating secretion of cytokines, proteolytic enzymes, reactive 
oxygen species, and other pro-inflammatory molecules that lead to amplification of 
inflammatory responses151,152 and aplenty other physiological responses that range from 
chemoattraction to apoptosis.153,154 The anaphylatoxins operate through their respective 
receptors, namely C3aR and C5aR. These receptors belong to the seven membrane-
spanning G-protein-coupled receptors.152 A recent study demonstrated activation of the NF-
κB pathway in RPE cells after stimulation with C5a.155 Due to the sub-retinal deposition of 
drusen, RPE cells may be constantly stimulated by these inflammatory factors.38,150 
 
 
3.5. The Inflammasome  
The inflammasome is a key pro-inflammatory signaling pathway primarily discovered in cells 
of the innate immune system. The name “inflammasome” refers to structural and functional 
similarities with an apoptotic signaling pathway, the “apoptosome”.156,157 Both pathways 
involve cytoplasmic sensor molecules that upon activation assemble large, cytosolic, 
multiprotein complexes. The activation and subsequent assembly of inflammasomes is 
induced by divers stimuli which are often microbial products or subjects associated with 
cellular damage.158,159 Beside cells of the innate immune system such as dendritic cells and 
neutrophils,160,161 varying levels of inflammasome activity have also been demonstrated in 
certain nonimmune cells, such as keratinocytes and RPE cells.162 Although NLRP3 
inflammasome activity frequently plays a protective role, such as mediating host defense 
against intracellular microbes and viruses as well as tissue and wound repair,163–166 it 
contributes to pathology in some instances. Impaired inflammasome pathway function was 
first associated with a group of rare autoinflammatory diseases called cryopyrin-associated 
periodic syndromes (CAPS), and are caused by mutations in one of the inflammasome 
sensor molecules, the NLRP3 (also known as cryopyrin).167,168 Evidence indicates that the 
NLRP3 inflammasome is also implicated in a growing number of common metabolic 
diseases involving chronic inflammation169 such as atherosclerosis, and type 2 diabetes.170–
172 
 General Introduction 
 
19 
 
3.5.1 Inflammasomes activate caspase-1 resulting in IL-1β and IL-18 processing  
Caspase-1 is a cysteine protease that use cysteine as the nucleophilic group for substrate 
cleavage and cleaves the peptide bond carboxy-terminal to aspartic acid residues.173 The 
best known substrates of caspase-1 are the cytosolic zymogens pro-IL-1β and pro-IL-18.174. 
Cleavage by caspase-1 generates the mature and biologically active pro-inflammatory 
cytokines IL-1β and IL-18. Therefore, caspase-1 is characterized as an inflammatory 
caspase in contrast to apoptotic caspases. Furthermore, caspase-1 does not play a role in 
apoptosis; it is responsible for induction of a distinct form of programmed cell death, referred 
to as pyroptosis. However, caspase-1 resemble the apoptotic cell death initiating caspases 
8,9 and 10, as caspase-1 has large prodomains, the “death domain” that enable homotypic 
interaction with other proteins.175,176 This interaction domain typically consist of six or seven 
antiparallel α-helices, the relative orientation determines their classification as a caspase 
activation and recruitment domain (CARD) or pyrin domain (PYD). Caspase-1 is expressed 
as an inactive zymogen that needs to be activated before it can exert its function as a 
protease. An essential step in caspase-1 activaion is the assembly of the inflammasome.177  
 
 
Figure III.4: Domain structure of inflammasome proteins. The image presents the best known inflammasome 
forming PRRs that belong to two families, the NLR family and the PYHIN family. The NLR familiy (NLRP1, NLRP3 
and NLRC4) contain a nucleotide-binding oligomerization domain (NOD), carboxy-terminal leucine-rich repeat 
(LRR), and contain either a pyrin domain (PYD) or a caspase activation and recruitment domain (CARD) or both. 
NLRP1 has C-terminal an additional function-to-find domain (FIIND domain) and a CARD. The PYHIN familiy 
(AIM2) contain an N-terminal PYD that is followed by a C-terminal PYHIN family signature domain, the 
hematopoietic interferon-inducible nuclear protein domain (HIN200). The image was adapted from Walsh et 
al., 2014.
178
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The inflammasome is an intracellular multiprotein complex that consists of pro-caspase-1, 
the adapter ASC (apoptosis-associated speck-like protein containing a CARD), and a pattern 
recognition receptors (PRR). The best known PRRs that are capable of forming an 
inflammasome complex belong either to the cytosolic nucleotide-binding oligomerization 
domain receptors, in short NOD-like receptors (NLRs), such as NLRP1 (NOD-, LRR- and 
pyrin domain-containing 1), NLRP3 or NLRC4 (NOD-, LRR- and CARD-containing 4) or to 
the AIM2 like receptor (ALR) family, namely AIM2 (absent in melanoma 2).175,177,179 With the 
exception of NLRP1, all NLR proteins have a tripartite domain structure.180 This structure is 
composed of a central nucleotide-binding oligomerization domain (NOD), C-terminal series of 
leucine-rich repeats (LRRs), and a N-terminal protein-protein interaction domain, either a 
PYD or a CARD. The human NLRP1 has C-terminal an additional function-to-find domain 
(FIIND) and a CARD. Therefore, NLRP1 possess two interaction domains for homotypic 
protein-protein interaction. AIM2 harbours a N-terminal PYD that is followed by a C-terminal 
PYHIN family signature domain, the hematopoietic interferon-inducible nuclear protein 
domain (HIN200).181 Figure III.4 demonstrates the domain structure of inflammasome 
proteins. 
3.5.2 Inflammasome activation  
Inflammasome activation is regulated by a “two-signal” mechanism. Classically, the first 
signal is referred as inflammasome priming and involves the transcription of pro-IL-1β that is 
induced by activation of the transcription factor nuclear factor-κB (NF-κB). Therefore, priming 
can be accomplished by NF-κB agonists such as the TLR4 ligand lipopolysaccharide (LPS), 
tumor necrosis factor α (TNF-α), and the cytokines IL-1α and IL-1β.182–185 Although, in many 
cells pro-IL-18 is constitutively expressed and does not need priming,186 its expression is 
increased by cellular activation.187 In contrast, the NLRP3 protein demonstrates a basal 
expression that is not sufficient for inflammasome activation in a resting cell.183,188 Thus, 
similarly to IL-1β generation, a priming step is required to drive the NLRP3 transcription. 
Interestingly, various immune cells regulate IL-1 production differently. Macrophages require 
a two signal process (TLR ligand and NLR stimuli), whereas monocytes possess a 
constitutively activated form of caspase-1 through the release of endogenous ATP, and that 
is why monocytes only need cell priming by stimulation with TLR2 or TLR4 ligands.189 NLRP3 
transcription can be activated by diverse immune signalling or cytokine receptors, such as 
the tumor necrosis factor receptor (TNFR) or interleukin-1 receptor (IL-1R). By this, immune 
cells are influenced by their susceptibility to NLRP3 inflammasome triggers.183,188 Once 
primed, the “second signal” triggers inflammasome activation that results in oligomerization 
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of the inflammasome constituents, recruitment of the adapter protein ASC and pro-caspase-1 
as well as subsequent cleavage of pro-IL-1β and pro-IL-18 into its mature forms.190  
Each inflammasome scaffold is activated by particular PAMPs or DAMPS. The sensor 
molecules of inflammasomes can directly detect distinct signals such as the bacterial cell 
wall component muramyl dipeptide (MDP) by NLRP1191 and double stranded DNA by AIM-
2.188,192–194 NLRC4 is activated by flagellin and certain components of bacterial secretion 
systems.195 However, NLRP3 responds to a diverse array of PAMPs and DAMPs.170,196 
Therefore, it is unlikely that all bind directly to NLRP3. For this reason, a common molecule 
or pathway that is responsible for NLRP3 inflammasome activation has been proposed. 
Studies indicate three possible pathways. The first model for NLRP3 inflammasome 
activation suggest ROS as a proximal trigger since increased ROS level have been 
demonstrated upon treatment with NLRP3 activators.197–199 The second model proposes a 
drop in intracellular potassium (K+) concentration due to pore-forming bacterial toxins or the 
formation of endogenous ion channels that cause inflammasome activaiton.200 A third model 
suggests disruption of the lysosomal membrane as NLRP3 inflammasome activation signal. 
Phagocytosis of particles or live pathogens may result in lysosomal membrane rupture that 
leads to release of lysosomal components and the putative NLRP3-activating molecule into 
the cytosol. The lysosomal protease cathepsin B or a cytosolic substrate of cathepsin 
proteolytic activity are most likely to activate the NLRP3 inflammasome.126,170,201  
The inflammasome-forming NLR´s, and the HIN domain in the case of AIM2, are stabilized in 
an inactive but signaling-competent state in the absence of an activating stimulus. With 
ligand binding, the auto-inhibitory state undergoes a conformational change, leading to 
exposure of the N-terminal PYD or CARD domain202,203 that enables homotypic interaction 
(CARD-CARD or PYD-PYD) with other CARD or PYD possessing proteins. Pro-caspase-1 
possess a CARD, thus scaffolding proteins that also have a CARD, such as NLRP1 and 
NLRC4, can directly bind pro-caspase-1.204 Inflammasome scaffolds that lack a CARD, such 
as NLRP3, AIM2 and NLRP1 at its C-terminal side, have a PYD domain instead. This 
domain allows interaction with the adapter molecule ASC, which has both a PYD domain and 
a CARD, and provides the connection to the CARD domain of caspase-1.205 Although 
NLRP1 and NLRC4 can each recruit pro-caspase-1 independently of ASC via their CARDs, 
ASC might enhance inflammasome activation.191,206 The association of caspase-1 with the 
inflammasome components allows its processing and activation. Pro-caspase-1 is a 44 kDa 
protein that consist of one large subunit (20 kDa) and one small subunit (10 kDa).  
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Figure III.5: Generic model of inflammasome activation. Cytosolic nucleotide-binding domain, leucine-rich 
repeat (NOD-LRR) proteins are maintained in an autoinhibited state until ligand recognition and ATP binding 
drive oligomerization via the NOD domain. Recruitment of caspas-1 to form the inflammasome complex occurs 
directly via CARD-CARD interactions or indirectly via the adaptor ASC (a, modified from Lu et al., 2014;
207
 b, 
modified from Moltke et al., 2013.
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Recruitment of pro-caspase-1 to the inflammasome results in a high local concentration of 
the zymogen. This pro-caspase-1 clustering triggers proximity-induced oligomerization of 
caspase-1,209 resulting in autoproteolysis, release of the CARD domain and tetramerization 
of two large and two small subunits, leading to the formation of the active enzyme.210,211 
Figure III.5 gives an generic model of the NLRP3 inflammasome and its polymerization 
mechanism. Upon activation, caspase-1 cleaves pro-IL-1β and pro-IL-18, generating the 
corresponding mature, biologically active cytokines IL-1β and IL-18. Both, pro-IL-1β and pro-
IL-18 lack a signal peptide for protein secretion by the ER-Golgi secretory pathway. 
Therefore, these cytokine precursors reside in the cytosol of the cell. Nevertheless, following 
processing of the mature forms (IL-1β and IL-18), the cytokines are secreted from the cells 
by a poorly understood pathway termed unconventional protein secretion, which occurs 
independently of the classical Golgi pathway.212  
3.5.3 Pyroptosis versus Apoptosis 
Cell death is generally described dichotomously as either passive or programmed cell death. 
Necrosis (from the Greek ‘necro’, meaning death, and ‘sis’, meaning a condition of) is a 
passive form of cell death that is induced by accidental damage of tissue. During necrosis no 
activation of caspases or any cell death specific program occurs.  
Apoptosis (from the Greek ‘apo’, meaning away from, and ‘ptosis’, meaning falling) 
represents the best-studied form of programmed cell death that needs activation of 
caspases. Apoptosis represents an active and programmed cell death mechanism that is 
observed during homeostatic cell processes such as normal cell turnover in healthy adult 
tissues as well as during embryonic development.213 Meanwile, it has been appreciated that 
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various non-apoptotic forms of programmed cell death also exist, such as pyroptosis. 
Apoptosis and pyroptosis differ in terms of molecular and morphological changes of the 
affected cells as presented in table III.1. Morphologically, apoptotic cell death is 
characterized by cytoplasmic shrinkage and chromatin condensation (pyknosis) that is 
followed by nuclear fragmentation (karyorrhexis). During apoptosis, caspase-mediated 
proteolysis of inhibitor of caspase-activated DNase (ICAD) releases caspase-activated 
DNase (CAD). The activated DNase CAD cleaves DNA between nucleosomes. As a result, 
characteristic oligonucleosomal DNA fragments of about 180 bp occure.214 In addition, during 
apoptosis the plasma membrane forms cytoplasmic blebs and cell membrane enclosed cell 
fragments (apoptotic bodies). In healthy cells, phosphatidylserine (PS) is actively restricted to 
the inner leaflet of the plasma membrane by aminophospholipid translocase activity. In 
apoptosis, a combined effect of decreased phospholipid translocase activity and activation of 
a phospholipid scramblase215 leads to PS externalization. PS exposure on the cell surface 
can be recognized by phagocytes as a signal for engulfment.216,217 Therefore, apoptosis is 
considered to be immunologically silent.218 Importantly, apoptotic cells retain their membrane 
integrity and therefore do not evoke acute inflammation.  
 
 Characteristics Apoptosis Pyroptosis 
Morphology Cell lysis – + 
Cell swelling – + 
Pore formation – + 
Membrane blebbing + – 
DNA fragmentation + + 
Mechanism Caspase-1 activation – + 
ICAD cleavage + – 
Outcome inflammation – + 
 
Table III.I: Differences between pyroptosis and apoptosis. Despite sharing characteristics with apoptosis, the 
morphological, mechanistic and physioloical features of pyroptosis make it a distinct form of programmed cell 
death. The table was adapted from Labbé and Saleh, 2011. 
219
 
 
Pyroptosis (from the Greek ‘pyro’, relating to fire or fever, and ‘ptosis’, meaning falling) was 
first described as an atypical cell death mode of macrophages infected with Salmonella 
typhimurium by Brennan and Cookson in 2000.220 However, pyroptosis is not restricted to 
macrophages or bacterial infections.221 Pyroptosis is a caspase-1 dependent form of 
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programmed cell death. An important function of caspase-1 is its key role in the processing 
of inactive IL-β and IL-18 into mature inflammatory cytokines, demonstrating pyroptosis as an 
inherently pro-inflammatory cell death mode.222 Perhaps the most striking difference between 
pyroptosis and apoptosis is at the plasma membrane. Microscopically, pyroptotic cell death is 
characterized by an increase in cell size due to cytosolic swelling generated by the caspase-
1 dependent formation of plasma membrane pores followed by rapid mebrane rupture and 
release of cytosolic contents. Some of these components, such as ATP, pro-IL-1α, and 
HMGB1 become pro-inflammatory effectors which are able to recruit neutrophils and induce 
inflammation.223 Although cleavage of chromosomal DNA was assumed to indicate apoptotic 
cell death,224 DNA damage also occures during pyroptosis. 220,225–228 However, DNA cleavage 
during pyroptosis is carried out by an unidentified nuclease that does not induce ICAD 
degradation and does not display the oligonucleosomal pattern characteristic of 
apoptosis.214,225,229 
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3.5 Aims of the study  
 
Rationale 
Various studies demonstrated that oxidative and lipofuscin-mediated photooxidative damage 
play an important pathophysiological role in AMD. Further characteristics of the disease 
include a chronic low-grade immune process including complement activation in the sub-
RPE space. Yet the identity of a molecular link between hallmark features of AMD 
pathogenesis including lipofuscin accumulation, photooxidative damage, innate immune 
response in sub-RPE space, and RPE cell degeneration remains unclear. Recent studies 
have shown that the NLRP3 inflammasome, a key mediator of the innate immune system, is 
activated in the RPE of patients with atrophic and neovascular AMD. However, the triggers 
for NLRP3 inflammasome activation in AMD pathology remain unknown.  
The purpose of this study was to examine NLRP3 inflammasome activation by oxidative/ 
photooxidative damage in human RPE cells as a potential link between hallmark pathogenic 
features in age-dependent macular degeneration. 
 
 
The specific aims of this study were: 
 to test whether lipofuscin-mediated photooxidative stress activates the inflammasome 
pathway and induces IL-1β and IL-18 secretion in human cultured RPE cells via 
lysosomal membrane permeabilization (chaper IV),  
 
 to investigated the effects of LMP-induced inflammasome activation on the secretion 
profile of inflammation-related cytokines and VEGF as well as their secondary effects 
on microglial and vascular endothelial cells in vitro (chapter V),  
 
 to identify a potential priming effect for activated complement in human serum and to 
further delineate the responsible complement component (chapter VI), 
 
 to elucidate the effects of inflammasome priming on mechanism and extent of 
photooxidative damage-induced cytotoxicity in RPE cells (chapter VII). 
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4.1 Abstract 
Photooxidative damage and chronic innate immune activation have been implicated in retinal 
pigment epithelium (RPE) dysfunction, a process that underlies blinding diseases such as 
age-related macular degeneration (AMD). To identify a potential molecular link between 
these mechanisms, we investigated whether lipofuscin-mediated phototoxicity activates the 
NLRP3 inflammasome in RPE cells in vitro. We found that blue light irradiation (dominant 
wavelength 448 nm, irradiance 0.8 mW/cm2, duration 6 h) of lipofuscin-loaded primary 
human RPE cells and ARPE-19 cells induced photooxidative damage, lysosomal membrane 
permeabilization (79.5 % of cells vs. 3.8 % in nonirradiated controls), and cytosolic leakage 
of lysosomal enzymes. This resulted in activation of the inflammasome with activation of 
caspase-1 and secretion of interleukin-1β (14.6 vs. 0.9 pg/ml in nonirradiated controls) and 
interleukin-18 (87.7 vs. 0.2 pg/ml in nonirradiated controls). Interleukin secretion was 
dependent on the activity of NLRP3, caspase-1, and lysosomal proteases cathepsin B and L. 
These results demonstrate that accumulation of lipofuscin-like material in vitro renders RPE 
cells susceptible to phototoxic destabilization of lysosomes, resulting in NLRP3 
inflammasome activation and secretion of inflammatory cytokines. This new mechanism of 
inflammasome activation links photooxidative damage and innate immune activation in RPE 
pathology and may provide novel targets for therapeutic intervention in retinal diseases such 
as AMD. 
 
 
4.2 Introduction 
Age-related macular degeneration (AMD) is a neurodegenerative disease of the retina that 
represents the most common cause of blindness in all industrialized countries.230 The 
molecular pathogenesis of AMD is still not completely resolved which hinders the 
development of effective therapies, in particular for the atrophic subtype of the disease. In 
AMD, the retinal pigment epithelium (RPE) becomes progressively dysfunctional and 
eventually degenerates, resulting in photoreceptor death and visual function loss. 
Experimental and clinical studies identified oxidative and photooxidative damage to the RPE 
as a contributing factor.3,33 This damage is thought to be mediated, at least in part, by the 
phototoxic properties of lipofuscin that accumulate in RPE cells over a lifetime as a result of 
constant photoreceptor outer segment phagocytosis and degradation. Moreover, genetic and 
histochemical evidence supports a role of chronic innate immune activation at the level of the 
RPE in AMD pathology.149,231 A candidate innate immune signaling receptor for RPE cell 
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pathology in AMD pathogenesis is the nucleotide-binding oligomerization domain-like 
receptor family, pyrin domain-containing protein 3 (NLRP3) inflammasome.185,232 Two steps 
are required for activation of the NLRP3 inflammasome.186 First, a priming signal results in 
the transcriptional induction of NLRP3 and pro-interleukin (IL)-1β. Second, an activation 
signal triggers the assembly of NLRP3, apoptosis-associated speck-like protein containing a 
caspase recruitment domain (ASC), and pro-caspase-1 into the inflammasome protein 
complex. The activated inflammasome mediates caspase-1 activation, which in turn 
proteolytically activates pro-IL-1β and pro-IL-18 into their mature forms. These highly pro-
inflammatory cytokines have pleiotropic autocrine and paracrine effects on a variety of cell 
types. NLRP3 inflammasome activation in the RPE has been reported in both atrophic and 
neovascular AMD.185,232 Several substances have been suggested to provide the signal for 
inflammasome activation in AMD including drusen components such as C1q233 and amyloid-
beta,234 Alu RNA accumulation secondary to DICER1 deficiency,232 the lipofuscin component 
Nretinylidene-N-retinyl-ethanolamine (A2E),235 and the lipid peroxidation product 4-
hydroxynonenal (HNE).236 A key pathway upstream of the NLRP3 inflammasome is 
lysosomal membrane permeabilization (LMP) and subsequent cytosolic leakage of lysosomal 
components.126,186 Indeed, this mechanism has been reported to activate the inflammasome 
in RPE cells following chemical induction of LMP.185 Another mechanism resulting in LMP in 
RPE cells is phototoxic damage mediated by intralysosomal accumulation of photoreactive 
lipofuscin.96,97 In this study, we investigated whether blue light-induced photooxidative stress 
in human RPE cells, intensified by accumulated lipofuscin, and subsequent lysosomal 
membrane permeabilization result in activation of the NLRP3 inflammasome by leaking 
lysosomal enzymes. Thereby, this study aimed to identify a novel mechanism of 
inflammasome activation by light damage that may provide new treatment targets for blinding 
diseases such as AMD. 
 
 
4.3 Material and methods 
4.3.1 Cell culture and treatments 
Human fetal primary RPE cells (pRPE) were obtained from Lonza (Cologne, Germany), 
cultured as recommended by the manufacturer, and used in experiments for a maximum of 
six passages. The human nontransformed RPE cell line ARPE-19 (CRL-2302; ATCC, 
Rockville, MD, USA) was cultured as previously reported.237 The immortalized murine 
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wildtype and NLRP3 knockout macrophage cell lines used in our study have been 
characterized previously126 and were cultured as described.80 For inhibition of photooxidative 
damage, the singlet oxygen scavenger 1,4-diazabicyclooctane (DABCO; SigmaAldrich, 
Munich, Germany) was added to the culture media at a concentration of 30 mM during blue 
light irradiation. Lysosomal membrane permeabilization was induced by incubation of cells 
with 1 mM ciprofloxacin (Sigma-Aldrich, Munich, Germany) for 3 h or 1 mM L-leucyl-L-leucine 
methylester (Leu-Leu-OMe; Bachem, Bubendorf, Switzerland) for 3 h. Cathepsin B inhibitor 
CA-074 (Calbiochem, Darmstadt, Germany) and cathepsin L inhibitor Z-Phe-Phe-
fluoromethylketone (Z-FF-FMK; Calbiochem) were used for cell treatment at a concentration 
of 10μM each for 1 h prior to and during irradiation treatment. For inhibition of caspase-1, we 
applied 10μM of Z-Tyr-Val-Ala-Asp-fluoromethylketone (Z-YVAD-FMK; BioVision, Munich, 
Germany) 30 min prior to and during irradiation. 
4.3.2 Induction of lipofuscin accumulation 
Isolated porcine POS were modified with lipid peroxidation products malondialdehyde (MDA) 
or 4-hydroxynonenal (HNE) as described.80 Lipofuscin accumulation was induced by 
incubation of cells with modified POS for 7 days or, alternatively, by incubation with native 
POS and concomitant lysosomal inhibition by ammonium chloride (NH4Cl; Sigma-Aldrich, 
Munich, Germany) as reported previously.237 Intracellular lipofuscin granules were 
documented by fluorescence microscopy (IX71; Olympus, Hamburg, Germany) using a 
fluorescein filter set (excitation filter wavelength 480/40 nm, emission filter wavelength 
535/50 nm). For flow cytometric quantification (FACS Canto II; BD Biosciences, Heidelberg, 
Germany), we employed the FITC channel (excitation laser wavelength 488 nm, detection 
filter wavelength 530/30 nm). Data was acquired and analyzed by appropriate software 
(DIVA; BD Bioscience, Heidelberg, Germany; FlowJo; Tree Star, Ashland, OR, USA).  
4.3.3 Blue light irradiation  
For blue light irradiation of RPE cells, we employed a 3×3 array of blue LEDs (XLamp XP-E 
royal blue; Cree, Durham, NC, USA). The LED spectrum as measured by a 
spectroradiometer (PR-655 SpectraScan; Photo Research, Chatsworth, CA, USA) exhibited 
a peak wavelength of 448 nm with a full width at half maximum (FWHM) of 24 nm. Cells were 
irradiated from a distance of 35 cm within a cell culture incubator for the indicated times. In 
this setup, cells were exposed to an irradiance of 0.8 mW/cm2 as measured using a power 
meter (FieldMax-TOP with PM10V1 sensor; Coherent, Santa Clara, CA, USA). 
Measurements confirmed that irradiation did not affect the temperature of the cell culture 
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medium. A dose–response curve of the phototoxic effect of irradiation treatment on RPE 
cells is provided in Fig. IV.2b (control group). Photooxidative damage in blue light-irradiated 
cells was assessed by immunostaining of protein carbonyls using a commercially available 
kit (OxyICC Oxidized Protein Detection Kit; Merck Millipore, Darmstadt, Germany) according 
to manufacturer’s instructions, followed by quantification by flow cytometry (FACS Canto II; 
BD Bioscience, Heidelberg, Germany). 
4.3.4 Cell death detection assays 
Blue light-induced cell death was documented by light microscopy. Cell death-associated 
plasma membrane disintegration was assessed by means of release of cytoplasmic lactate 
dehydrogenase (LDH). Measurements of LDH release were performed in cell supernatants 
48 h after the start of irradiation using a calorimetric assay (Cytotoxicity Detection Kit; Roche, 
Mannheim, Germany) according to the manufacturer’s instructions. As an additional cell 
death assay, we quantified loss of cell attachment 48 h after the start of irradiation by crystal 
violet assay as previously described.238  
4.3.5 Analysis of lysosomal membrane permeabilization  
Cells were incubated with 1μg/ml acridine orange (Sigma-Aldrich, Munich, Germany) for 15 
min and washed two times with PBS. Lysosomal staining (red) was documented by 
fluorescence microscopy. Lysosomal permeabilization was quantified by flow cytometry 
(FACS Canto II; BD Bioscience, Heidelberg, Germany) as percentage of cells with loss of 
lysosomal staining. For analysis of leakage of lysosomeal enzymes, lysosomal and cytosolic 
cell fractions wereseparated following plasma membrane permeabilization using digitonin 
(SigmaAldrich, Munich, Germany) as reported.239 Subsequently, cytosolic activity of 
lysosomal acid phosphatase was assessed by measuring cleavage of a specific substrate 
using a commercially available assay (Sigma-Aldrich, Munich, Germany). 
4.3.6 Analysis of inflammasome activation 
RPE cells were primed with 4 ng/ml human recombinant IL-1α (R&D Systems, Wiesbaden, 
Germany) for 48 h185 and macrophages with 200 ng/ml lipopolysaccharide (LPS, from 
Escherichia coli0127:B8; Sigma-Aldrich, Munich, Germany) for 6 h. For analysis of caspase-
1 activity, a fluorochrome-labeled inhibitor of caspase (FLICA) detection assay specific for 
caspase-1 [carboxyfluorescein-Tyr-Val-Ala-Asp-fluoromethylketone (FAM-YVAD-FMK); 
Immunochemistry Technologies, Bloomington, MN] was used according to the 
manufacturer’s instructions. Caspase-1 activation was documented by fluorescence 
microscopy and quantified by flow cytometry (FACS Canto II; BD Bioscience, Heidelberg, 
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Germany). Interleukin secretion following inflammasome activation in RPE cells was 
measured by specific ELISAs for human IL-1β (BD Biosciences, Heidelberg, Germany) and 
human IL-18 (BD Bioscience). Inflammasome activation in murine macrophages was 
assessed by an ELISA against murine IL-1β(R&D Systems, Wiesbaden, Germany).  
4.3.7 NLRP3 siRNA knockdown  
Lipofuscin accumulation was induced in ARPE-19 cells by incubation with HNE-modified 
POS as described above. Then, cells were transfected with 100 nM small interfering RNA 
(siRNA) targeting human NLRP3 (Ambion Silencer Select siRNA, ID s41556; Life 
Technologies, Darmstadt, Germany) or 100 nM nonspecific siRNA (Ambion Silencer Select 
Negative Control siRNA; Life Technologies) for 24 h using a transfection reagent (Invitrogen 
Lipofectamin RNAiMax; Life Technologies) according to the manufacturer’s instructions.240 
Subsequently, cells were primed with IL-1α and irradiated with blue light as described above. 
4.3.8 Statistical analysis 
Experiments were performed in doublets (Figs. IV.5 and IV.6) or triplets (all other 
experiments). Results are presented as mean ± standard deviation. Statistical analysis was 
performed using one-tailed (Fig. IV.7c) or two-tailed (all other experiments) unpaired 
Student’st tests. Differences were considered statistically significant at p<0.05. In all figures, 
significance levels as compared to controls are indicated using * for p<0.05, ** for p<0.01, 
and *** for p<0.001. 
 
 
4.4 Results  
4.4.1 Blue light irradiation of lipofuscin-loaded RPE cells induces photooxidative 
damage  
Lipofuscinogenesis was induced in pRPE cells and ARPE-19 cells either by incubation with 
isolated photoreceptor outer segments (POS) and simultaneous inhibition of lysosomal 
degradation by ammonium chloride (NH4Cl) or by incubation with POS stabilized against 
lysosomal degradation by covalent modification with lipid peroxidation products 
malondialdehyde (MDA) or 4-hydroxynonenal (HNE) as described.80,237,241 
Lipofuscinogenesis was evaluated by assessing the accumulation of granular material with 
lipofuscin-like autofluorescence using fluorescence microscopy and flow cytometry (Fig. 
IV.1a,b). Consistent with our previous reports, lipofuscin accumulation was significantly 
increased in all three treatment groups compared to control groups of cells treated with either 
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native POS alone, with the lysosomal inhibitor alone, or left untreated. The finding that cells 
treated with the lysosomal inhibitor generate some amount of lipofuscin even in the absence 
of POS is attributable to impaired autophagy as described before.237 The spectral profiles of 
lipofuscin generated in this in vitro model have been reported.237 Following lipofuscin loading, 
RPE cells were irradiated with blue light to induce photooxidative stress. Immuno-
cytochemistry confirmed that blue light irradiation resulted in oxidative damage by lipid 
peroxidation-mediated formation of protein carbonyls (Fig. IV.1c,d). Even control cells 
exhibited some photooxidative damage secondary to blue light irradiation. 
 
 
Figure IV.1: Blue light irradiation of lipofuscin-loaded RPE cells induces photooxidative damage. (A) 
Intracellular lipofuscin accumulation (yellow) was documented in ARPE-19 cells by fluorescence microscopy. 
Nuclei were visualized by DAPI staining (blue). (B) Lipofuscinogenesis was quantified in pRPE cells and ARPE-19 
cells by flow cytometry measurements of mean cellular autofluorescence intensity. An example result is shown 
as an insert. Cells were left untreated (control) or incubated with the lysosomal inhibitor ammonium chloride 
(NH4Cl), unmodified photoreceptor outer segments (POS), POS and ammonium chloride (POS+NH4Cl), 
malondialdehyde-modified POS (MDA-POS), and 4-hydroxynonenal-modified POS (HNE-POS). (C) Photo-
oxidative damage was assessed in ARPE-19 cells by immunocytochemical detection of protein carbonyls (red). 
Nuclei were labeled by staining with DAPI (blue). (D) Mean cellular fluorescence of immunocyto-chemically 
labeled protein carbonyls was quantified by flow cytometry. Scale bars, 50 μm. 
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However, photooxidative damage was significantly increased in lipofuscin-loaded cells as 
compared to controls, consistent with the known photoreactive properties of lipofuscin. 
Moreover, cells incubated with MDA- or HNEmodified POS exhibited significantly more 
photooxidative damage compared to cells treated with unmodified POS. We thus verified that 
the lipofuscin-like material generated by RPE cells in our in vitro model possesses 
photoreactive properties that result in photooxidative cell damage, similar to lipofuscin 
generated in human RPE in vivo.96 
4.4.2 Blue light irradiation of lipofuscin-loaded RPE cells causes phototoxic cell death 
As excessive photooxidative damage may result in cell death, we aimed to determine the 
phototoxic threshold in our cell culture model by measuring cytotoxicity following increasing 
durations of irradiation of up to 24 h (Fig. IV.2a,b). Cytotoxicity was assessed in parallel by 
means of loss of plasma membrane integrity (LDH release assay) and loss of cell adhesion 
(crystal violet assay). Consistently in both assays, cytotoxicity in creased with blue light dose 
up to an irradiation time of 24 h when cytotoxicity was nearly complete (90–99 %) in all three 
lipofuscin-loaded treatment groups. Reduction of photooxidative damage by cell incubation 
with the singlet oxygen scavenger DABCO during irradiation treatment suppressed the 
cytotoxic effect (Fig. IV.2c). These results confirm that in our RPE cell culture model, 
lipofuscin generation from phagocytosed POS renders the cells susceptible to photooxidative 
damage. Based on the results, we selected an irradiation duration of 3 and 6 h for our further 
experiments as for these irradiation times the detected cytotoxic effect of irradiation is limited. 
4.4.3 Lipofuscin-mediated photooxidative damage results in lysosomal membrane 
permeabilization with cytosolic leakage of lysosomal enzymes 
Photoreactivity of intralysosomal lipofuscin can induce lysosomal destabilization.96,97 We 
therefore investigated the effects of lipofuscin photoreactivity on lysosomal membrane 
stability in our model. Lysosomal staining by acridine orange demonstrated intact lysosomes 
in lipofuscin-loaded cells without irradiation treatment as well as in irradiated cells without 
lipofuscin loading (Fig. IV.3a). In contrast, cell treatment with both lipofuscin loading and blue 
light irradiation resulted in a significant loss of lysosomal staining, indicating lysosomal 
membrane permeabilization. Quantification of lysosomal staining by flow cytometry 
demonstrated that loss of lysosomal membrane integrity increased with both light dose and 
lipofuscin load as measured by means of lipofuscin-like autofluorescence (Fig. IV.3b). 
Cytosolic activity of leaked lysosomal enzymes has been proposed as a mechanism of 
inflammasome activation.126 
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Figure IV.2: Blue light irradiation of lipofuscin-loaded RPE cells causes phototoxic cell death. (A) 
Photooxidative damage-induced cytotoxicity was documented in ARPE-19 cells by light microscopy. (B) To 
quantify the phototoxic effect, both loss of plasma membrane integrity and loss of cellular adhesion were 
analyzed by measuring LDH release and crystal violet staining, respectively. (C) Photooxidative damage 
secondary to irradiation was reduced by incubation with the singlet oxygen scavenger DABCO.Scale bar,250μm. 
 
To assess whether lysosomal enzyme leakage occurs in light-exposed RPE cells, we 
separated cytosolic and lysosomal cellular fractions by plasma membrane permeabilization 
using digitonin. We employed a digitonin concentration of 20μg/ml as for this concentration 
the isolated cytosolic fraction of untreated control cells exhibited a near maximum 
concentration of the cytosolic marker enzyme LDH while at the same time contamination by 
the lysosomal marker enzyme acid phosphatase was low (Fig. IV.3c). Consistent with the 
results of acridine orange staining, acid phosphatase activity in the isolated cytosolic cell 
fractions increased with light dose and lipofuscin load (Fig. IV.3d). The observed background 
cytosolic acid phosphatase activity that was detectable even in nonirradiated control cells 
may be explained by partial lysosomal membrane permeabilization by the digitonin treatment 
as indicated by the digitonin titration curve. Our results demonstrate that lipofuscin-mediated 
photooxidative damage in RPE cells is associated with lysosomal membrane 
permeabilization and cytosolic leakage of lysosomal enzymes. 
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Figure IV.3: Lipofuscin-mediated photooxidative damage results in lysosomal membrane permeabilization 
with cytosolic leakage of lysosomal enzymes. (A) Intact lysosomes (red) and nuclei (green) were visualized in 
ARPE- 19 cells by means on acridine orange staining. (B) Lysosomal membrane permeabilization resulted in a 
loss of lysosomal staining that was quantified by flow cytometry. (C) Digitonin effect on ARPE-19 cells was 
titrated for maximum plasma membrane permeabilization (release of cytosolic LDH) and at the same time 
minimal lysosomal membrane permeabilization (release of lysosomal acid phosphatase, AP). (D) A digitonin 
concentration of 20 μg/ml was selected for separation of cytosolic and lysosomal cellular fractions, and 
cytosolic leakage of lysosomal enzymes was assessed by analyzing the activity of lysosomal marker enzyme acid 
phosphatase in the cytosolic fractions. Scale bar, 50 μm. 
 
4.4.4 Lysosomal membrane permeabilization by lipofuscin phototoxicity induces 
inflammasome activation with activation of caspase-1 and secretion of IL-1β and IL-18  
We then investigated inflammasome activation in RPE cells in response to light treatment. As 
inflammasome activation requires a priming signal, cells were treated with IL-1α that has 
been shown to induce NRLP3 inflammasome priming in RPE cells.185 IL-1α-primed cells 
were irradiated with blue light, and inflammasome activation was assessed subsequently by 
measuring caspase-1 activation using the FLICA probe FAMYVAD-FMK (Fig. IV.4).  
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Figure IV.4: Lipofuscin-mediated photooxidative damage results in lysosomal membrane permeabilization 
with cytosolic leakage of lysosomal enzymes. (A) Intact lysosomes (red) and nuclei (green) were visualized in 
ARPE- 19 cells by means on acridine orange staining. (B) Lysosomal membrane permeabilization resulted in a 
loss of lysosomal staining that was quantified by flow cytometry. (C) Digitonin effect on ARPE-19 cells was 
titrated for maximum plasma membrane permeabilization (release of cytosolic LDH) and at the same time 
minimal lysosomal membrane permeabilization (release of lysosomal acid phosphatase, AP). (D) A digitonin 
concentration of 20 μg/ml was selected for separation of cytosolic and lysosomal cellular fractions, and 
cytosolic leakage of lysosomal enzymes was assessed by analyzing the activity of lysosomal marker enzyme acid 
phosphatase in the cytosolic fractions. Scale bar, 50 μm. 
 
We detected significantly increased amounts of activated caspase-1 in lipofuscin-loaded, 
light-irradiated cells compared to controls. Moreover, secretion of inflammasome-regulated 
cytokines IL-1β and IL-18 was significantly increased in both pRPE and ARPE-19 cells as 
measured by ELISA (Fig. IV.5a,b). Similar to LMP, inflammasome activation increased with 
light dose and lipofuscin load asmeasured by autofluorescence. LMP by other means such 
as treatment with ciprofloxacin123 or Leu-Leu-OMe126 likewise induced inflammasome 
activation in RPE cells (Fig. IV.5c). Suppression of photooxidative damage by cell incubation 
with the singlet oxygen scavenger DABCO during irradiation resulted in a significant 
reduction of irradiation-induced IL-1β secretion (Fig. IV.5d), thus confirming that 
photooxidative damage is the critical mechanism underlying inflammasome activation in our 
experiments. 
4.4.5 Inflammasome activation by lipofuscin phototoxicity is dependent on prior 
priming, activity of caspase-1, cathepsin B and cathepsin L, and expression of NLRP3 
To further delineate the mechanism by which blue light irradiation induces inflammasome 
activation in RPE cells, we subjected cells to different inhibitor treatments before and during 
irradiation (Fig. IV.6). No inflammasome-mediated secretion of IL-1β and IL-18 was 
detectable when inflammasome priming by IL-1α prior to irradiation was omitted. Likewise, 
inhibition of caspase-1 activity by Z-YVAD-FMK suppressed inflammasome activation. 
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Finally, inhibition of the lysosomal proteases cathepsin B or cathepsin L resulted in a 
significant inhibition of IL-1β and IL-18 secretion, supporting a role of lysosomal enzyme 
leakage in inflammasome activation in our experiments. Next, we aimed to investigate 
whether inflammasome activation by lipofuscin phototoxicity is mediated by the NLRP3 
inflammasome as opposed to other inflammasome subtypes. For this, we knocked down 
NLRP3 expression in lipofuscinloaded RPE cells by transfection with siRNA against NLRP3 
prior to blue light irradiation (Fig. IV.7a). NLRP3 knockdown resulted in a significant reduction 
of irradiation-induced IL-1β secretion as compared to control cells transfected with 
nonspecific siRNA. These results demonstrate that inflammasome activation secondary to 
lipofuscin phototoxicity in RPE cells is mediated by NLRP3. To verify this result in a knockout 
model, we employed a NLRP3-deficient immortalized murine macrophage cell line126 as 
NLRP3-deficient RPE cells were not available to us. Macrophages have been shown to 
generate lipofuscin secondary to POS phagocytosis in vitro similarly to RPE cells.242 We 
confirmed lipofuscin accumulation in macrophages secondary to incubation with POS by 
fluorescence microscopy (Fig. IV.7b). Lipofuscin-loaded wild-type macrophages. responded 
to blue light irradiation similar to RPE cells, i.e., by inflammasome activation with increased 
IL-1βsecretion that was dependent on prior priming of the cells (Fig. IV.7c). In NLRP3 
knockout cells, however, irradiation-induced IL-1β secretion was significantly suppressed 
compared to wildtype controls, consistent with the results of NLRP3 knockdown in human 
RPE cells. 
 
 
4.5 Discussion 
In the yet unresolved pathogenesis of AMD, oxidative damage and chronic immune response 
have been demonstrated to be centrally involved. However, the connection between these 
two mechanisms is unclear. Using an RPE cell culture model, we demonstrated for the first 
time that photooxidative stress by irradiation with blue light activates the NLRP3 
inflammasome. This activation is mediated by permeabilization of lysosomal membranes with 
subsequent cytosolic leakage of lysosomal enzymes. It is amplified by the photosensitizer 
lipofuscin which accumulates in the RPE in vivo with age and has the highest concentration 
in the macula. Thus, the molecular mechanism of light-induced inflammasome activation in 
the RPE links key pathogenic factors of AMD and may provide new targets for therapeutic 
strategies. Multiple lines of evidence indicate that lipofuscin accumulation has adverse 
effects on RPE cell homeostasis and function.243,244 Moreover, both in vitro and in vivo  
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Figure IV.5: Lysosomal membrane permeabilization by lipofuscin phototoxicity results in inflammasome 
activation with secretion of IL-1β and IL-18. Inflammasome-mediated secretion of mature IL-1β (A) and IL-18 
(B) was analyzed by ELISA in pRPE cells and ARPE-19 cells. (C) Lysosomal membrane permeabilization by 
ciprofloxacin and Leu-Leu-OMe in APRE-19 cells served as positive controls. (D) To assess the role of 
photooxidative damage in irradiation-induced inflammasome activation, ARPE- 19 cells were incubation with 
the singlet oxygen scavenger DABCO during blue light treatment. 
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studies demonstrated that lipofuscin accumulation increases the susceptibility of the RPE to 
light-induced cell damage and cell loss.96–98 Based on this body of experimental data, a role 
of light-induced RPE cell damage in AMD pathogenesis has been postulated, and several 
clinical studies have investigated a possible association of visible light exposure and AMD 
development. However, results so far have been ambiguous with some studies 
demonstrating an association while others failed to do so. Among the positive results, the 
Chesapeake Bay Watermen Study reported a significant association between long-term 
visible or blue light exposure and geographic atrophy or disciform scarring.100 In the Beaver 
Dam Study, sunlight exposure was significantly associated with early AMD.99 Finally, the 
European Eye Study found a significant association of blue light exposure and neovascular 
AMD in patients with low antioxidant levels.245 While the clinical data regarding the role of 
light damage in AMD pathogenesis remains controversial, the contribution of oxidative 
damage has been clearly established in interventional clinical studies such as the age-
related eye disease study (AREDS).3 In our experiments, we employed a model of blue light-
induced photooxidative damage, enhanced by cellular loading with lipofuscin-like material, to 
study the effects of LMP in RPE cells. Different models for the in vitro study of lipofuscin 
effects in RPE cells have been described.246 We and others have used A2E-loaded RPE 
cells as a model of lipofuscin phototoxicity in the past97 as A2E is considered the major 
fluorophore of macular lipofuscin. However, recent data derived from human donor eyes has 
questioned this role.247 In this study, we therefore employed a system of endogenous 
lipofuscin generation from phagocytosed POS in human RPE cells. Cellular 
lipofuscinogenesis was enhanced by POS modifications with products of lipid peroxidation 
such as HNE and MDA that result in lysosomal dysfunction by mechanisms described before 
in detail.80,237,241 The levels of POS protein modifications used in our cell culture were 
quantified previously80 and were chosen to correspond to the range of carbonyl modifications 
detected in human cells in vivo.248 While this model was designed to closely resemble the in 
vivo situation, the composition of lipofuscin-like material generated in this model over a 
period of 7 days is likely to differ from the composition of lipofuscin generated in RPE cells in 
vivo over a human lifetime. However, the aim of this study was to investigate the 
consequences of light-induced LMP in RPE cells, and our model of lipofuscin generation was 
appropriate to achieve LMP by blue light irradiation, similar to what has been reported for 
RPE cells loaded with lipofuscin granules generated in human RPE in vivo.96 Hence, 
potential differences in lipofuscin composition in our model compared to lipofuscin granules  
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Figure IV.6: Inflammasome activation by lipofuscin phototoxicity is dependent on inflammasome priming 
and activity of caspase-1, cathepsin B, and cathepsin L. Secretion of IL-1β (A) and IL-18 (B) by pRPE cells and 
ARPE-19 cells was assessed by ELISA in primed cells incubated with HNEPOS (Control), unprimed cells incubated 
with HNE-POS (Unpr.), primed cells incubated with HNE-POS and caspase-1 inhibitor Z-YVAD-FMK (Casp.- 1), 
primed cells incubated with HNE-POS and cathepsin B inhibitor CA-074 (Cath. B), and primed cells incubated 
with HNE-POS and cathepsin L inhibitor ZFF-FMK (Cath. L). 
 
from human RPE in vivo do not seem to affect light-induced LMP that was the focus of this 
study. In our experiments, the control group of RPE cells exhibited some degree of 
inflammasome activation following blue light irradiation even in the absence of POS, albeit 
considerable less compared to the treatment groups incubated with modified POS (Figs. IV.4 
and IV.5). An explanation for this unexpected finding may be lipofuscin generation as a result 
of incomplete autophagy of endogenous cellular material in control cells 237 an effect that 
would be pronounced in cells cultured for several weeks in a confluent state as in our 
experiments. Indeed, fluorescence microscopy demonstrated low amounts of granules with 
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lipofuscin-like autofluorescence even in control cells (Fig. IV.1a). Consistent with this 
explanation, both lipofuscin accumulation and inflammasome activation increased further in 
cells treated with ammonium chloride in the absence of POS compared to control cells (Fig. 
IV.1b and IV.5), likely as a result of autophagy inhibition by ammonium chloride as previously 
described.237 Secondary to light-induced LMP, we detected leakage of lysosomal enzymes 
into the cytosol of RPE cells. Inhibition of lysosomal proteases cathepsin B and L suppressed 
inflammasome activation associated with light-induced LMP. The finding of 
cathepsindependent NLRP3 inflammasome activation secondary to LMP is consistent with 
previous studies in silica crystalchallenged macrophages.126 These results suggest a 
cytosolic substrate of cathepsin proteolytic activity as a critical component of NLRP3 
inflammasome activation. However, the molecular mechanism by which cytosolic activity of 
cathepsins or other lysosomal enzymes induce inflammasome activation has not yet been 
resolved. Isolated HNE was reported to activate the NLRP3 inflammasome in RPE cells.236 In 
our experiments, we used covalent modification of POS by HNE to induce 
lipofuscinogenesis. As POS were thoroughly washed following modification to remove 
unbound HNE, cells were not exposed to isolated HNE in our experiments. Furthermore, we 
did not observe inflammasome activation in cells incubated with HNE-modified POS without 
additional irradiation treatment (Fig. IV.5). This indicates that inflammasome activation by 
isolated HNE did not play a role in our study. Similarly, lipofuscin component A2E alone has 
been demonstrated to induce NLRP3 inflammasome activation in RPE cells.235 The amount 
of A2E within the POS-derived lipofuscin in our experiments is unknown but likely to be small 
compared to RPE lipofuscin in vivo that accumulates over a lifetime. The low A2E content 
may explain why we did not see an effect of lipofuscin accumulation alone, without additional 
irradiation treatment, on inflammasome activation in our experiments (Fig. IV.5). These 
results suggest that direct, nonphototoxic effects of A2E did not contribute to inflammasome 
activation in our study. Proteins modified by lipid peroxidation products, such as 
carboxyethylpyrrole (CEP)-modified serum albumin, have been reported to be capable of 
providing the priming signal for subsequent NLRP3 inflammasome activation.233 We did not 
investigate CEP-modified albumin in our study, but we did ot observe a priming effect of 
MDA- or HNE-modified POS proteins in our experiments. Indeed, we found that omission of 
IL-1α priming prevented inflammasome activation in RPE cells despite incubation of the cells 
with HNE-POS (Fig. IV.6). Similar results were obtained for MDA-POS (unpublished data). 
Thus, HNE- and MDA-modified proteins do not seem to be capable of inducing 
inflammasome priming in RPE cells.  
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Figure IV.7: Inflammasome activity by lipofuscin phototoxicity is mediated by NLRP3. (A) In ARPE-19 cells 
incubated with HNE-POS prior to blue light irradiation, the effect of siRNA-mediated NLRP3 knockdown on IL-
1β secretion was assessed as compared to control cells transfected with nonspecific siRNA. (B) Accumulation of 
lipofuscin-like material (yellow) following incubation with POS was documented by fluorescence microscopy in 
murine macrophages as a substitute model of RPE lipofuscinogenesis. (C) Following POS-induced lipofuscin 
accumulation, inflammasome priming with LPS, and subsequent blue light irradiation for 4 h, secretion of IL-1β 
by wild-type (NLRP3+/+) and NLRP3 knockout (NLRP3−/−) macrophages was analyzed by ELISA.Scale bar, 50μm. 
 
In this study, we demonstrate that photooxidative damage to human RPE cells, intensified by 
accumulated lipofuscin, causes lysosomal membrane permeabilization and subsequent 
activation of the NLRP3 inflammasome by leaking lysosomal enzymes, resulting in secretion 
of inflammatory cytokines IL-1β and IL-18. These results identify blue light damage as a new 
mechanism of inflammasome activation and thus contribute to our understanding of light 
damage to the RPE. Moreover, this mechanism represents a novel molecular link between 
hallmark features of AMD pathogenesis such as photooxidative damage, innate immune 
response, and RPE cell dysfunction that may provide new therapeutic targets against this 
blinding disease. 
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5.1 Abstract 
PURPOSE: Activation of the NLRP3 inflammasome has been implicated in the pathogenesis 
of AMD. Lipofuscin phototoxicity activates the inflammasome in RPE cells by inducing 
lysosomal membrane permeabilization (LMP). We investigated the effects of LMP-induced 
inflammasome activation on the secretion of inflammation-related cytokines and VEGF by 
RPE cells.  
METHODS: In primary human RPE cells and ARPE-19 cells, the inflammasome was 
activated by L-leucyl-L-leucine methyl ester (Leu-Leu-OMe)- or lipofuscin phototoxicity-
induced LMP. Cytokine secretion was measured by protein dot blot and enzyme-linked 
immunosorbent assays. The polarization of cytokine secretion was assessed in RPE 
monolayers on permeable membranes. We analyzed the chemotactic and angiogenic effects 
of secreted cytokines on murine embryonic stem cell–derived microglia cells and human 
umbilical vascular endothelial cells, respectively. 
RESULTS: Inflammasome activation in RPE cells was associated with caspase-1–
dependent secretion of IL-1β, IL-6, IL-18, GM-CSF, and GRO (CXCL1/2/3), whereas 
constitutive secretion of VEGF was reduced. Secretion of IL-1β and IL-18 was highly 
polarized to the apical cell side. Incubation with conditioned media of inflammasome-
activated RPE cells induced directed migration of microglia cells (11.0-fold increase) and 
diminished vascular endothelial cells proliferation (39.0% reduction) and migration (69.3% 
reduction) as compared with conditioned media of untreated control RPE cells. 
CONCLUSIONS: Lysosomal membrane permeabilization–induced activation of the NLRP3 
inflammasome in RPE cells results in apical secretion of inflammatory cytokines with 
chemotactic effects on microglia cells and reduced constitutive secretion of VEGF. Via these 
mechanisms, lipofuscin phototoxicity may contribute to local immune processes in the outer 
retina as observed in AMD. 
 
 
5.2 Introduction  
In the developed world, AMD is the most common cause for severe visual loss and legal 
blindness.230 Age-related macular degeneration is a disease of the central retina that typically 
affects elderly people. Age-related macular degeneration is characterized by progressive 
degeneration of the RPE and secondary loss of photoreceptors in the macula leading to loss 
of central vision. Two late manifestations of AMD can be distinguished, atrophic AMD and 
neovascular AMD. Atrophic AMD causes slowly progressive central visual decline by RPE 
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cell degeneration known as geographic atrophy.12. In contrast, neovascular AMD is 
characterized by rapid visual loss secondary to VEGF-mediated ingrowth of choroidal 
neovascularizations (CNV).249 Anti-VEGF treatment has proven highly effective in 
neovascular AMD and is now widely used clinically. In contrast, there is still no treatment 
available for atrophic AMD. Age-related macular degeneration is associated with oxidative 
and photooxidative damage of the RPE that is believed to be mediated at least in part by the 
phototoxic properties of lipofuscin that progressively accumulates in the RPE over a 
lifetime.47,250 Further characteristics of the disease include the formation of extracellular 
deposits called drusen5,251 and a chronic low-grade immune processes including complement 
activation in the sub-RPE space.149,231 Thus, chronic innate immune activation plays a crucial 
role in AMD pathogenesis. Recent studies have shown that the NLRP3 inflammasome, a key 
mediator of the innate immune system, is activated in the RPE of patients with atrophic and 
neovascular AMD.185,232 Clinical studies demonstrated increased intravitreal and systemic 
levels of the inflammasome-controlled cytokines IL-1β and IL-18 in AMD patients.252,253 
Based on these findings, a role of the NLRP3 inflammasome in AMD pathogenesis has been 
hypothesized. The NLRP3 inflammasome is a multiprotein complex, which induces caspase-
1 activation resulting in secretion of inflammatory cytokines IL-1β and IL-18.186,205 An initial 
priming signal in combination with a subsequent activation signal, such as reactive oxygen 
species or lysosomal membrane permeabilization (LMP), leads to assembly of NLRP3, ASC, 
and procaspase-1 to the active inflammasome. We previously have identified photooxidative 
damage, intensified by accumulated lipofuscin, with secondary LMP and enzyme leakage as 
a mechanism of NLRP3 inflammasome activation in human RPE cells.254 Currently, there is 
only little data available regarding the profile of secreted cytokines in RPE cells following 
inflammasome activation as well on their paracrine effects. Doyle and coworkers233 reported 
that incubation with inflammasomeregulated IL-18 reduces secretion of VEGF in RPE cells 
and suggested a protective effect against CNV formation. Consistently, they demonstrated 
increased laser-induced CNV formation in NLRP3 and IL-18 knockout mice.233 In contrast, 
another inflammasome-regulated interleukin, IL-1β, has been shown to induce VEGF 
secretion in RPE cells18 and to promote laser-induced CNV formation in mice.255 To 
elucidate the effects of inflammasome activation on pathologic processes in the outer retina, 
we induced inflammasome activation by LMP in human RPE cells and investigated the 
resulting secretion profile of inflammatory cytokines and VEGF as well as their secondary 
effects on microglial and vascular endothelial cells in vitro. 
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5.3 Material and Methods  
5.3.1 Cell Culture  
Human primary retinal pigment epithelial (pRPE) cells (H-RPE; Lonza, Cologne, Germany) 
were cultured as recommended by the manufacturer and used in experiments for a 
maximum of five cell culture passages. The human nontransformed RPE cell line ARPE-19 
(ATCC CRL-2302; ATCC, Rockville, MD, USA) was cultured as previously reported.237 
Murine embryonic stem cell– derived microglia cells were a generous gift by Harald 
Neumann (Institute of Reconstructive Neurobiology, University of Bonn, Germany) and had 
been generated and cultured as described.256 Human umbilical vein endothelial cells 
(HUVEC; Provitro, Berlin, Germany) were cultured as recommended by the manufacturer 
and used for experiments at culture passages 5 to 10.  
5.3.2 Inflammasome Activation by L-leucyl-L-leucine methyl ester  
For inflammasome activation, pRPE cells and ARPE-19 cells were primed with 4 ng/mL IL-1α 
(R&D Systems, Wiesbaden, Germany) for 48 hours as described by Tseng and coworkers.185 
Subsequently, cells were treated with 1 mM L-leucyl-L-leucine methyl ester (Leu-Leu-OMe; 
Bachem, Bubendorf, Switzerland) for 1.5 (pRPE) or 3 hours (ARPE-19) to induce LMP. 
Lysosomal membrane permeabilization was assessed by acridine orange staining as 
previously described.10,16 Briefly, cells were incubated with 5 lM acridine orange (AO; 
SigmaAldrich, Munich, Germany) for 30 minutes and washed with PBS immediately before 
beginning of the Leu-Leu-OMe treatment. For documentation of AO staining by fluorescence 
microscopy the rhodamine filter set (excitation 550 nm, emission 650 nm) and fluorescein 
filter set (excitation 502 nm; emission 526 nm) of an IX71 fluorescence microscope 
(Olympus, Hamburg, Germany) was used to detect intact lysosomes and nuclei, respectively. 
For inhibition experiments, RPE cells were treated with 20 lM of specific caspase-1 inhibitor 
Z-YVAD-FMK (BioVision, Munich, Germany) for 60 minutes or with 50 lM of specific 
cathepsin B inhibitor CA-074 (Calbiochem, Darmstadt, Germany) for 30 minutes prior to Leu-
Leu-OMe treatment. Inflammasome Activation by Lipofuscin Phototoxicity The cell culture 
model used to induce LMP by lipofuscin phototoxicity has been described in detail.254 Briefly, 
isolated porcine photoreceptor outer segments (POS) were incubated with 4-hydroxynonenal 
(HNE) to generate covalently modified POS (HNE-POS) that are stabilized against lysosomal 
degradation by RPE.237,241 Cells were incubated with unmodified POS or HNE-POS 
(concentration equivalent to 4 lg total POS protein per cm2 cell growth area) daily for 7 days 
to induce lipofuscinogenesis. For inflammasome priming, 4 ng/mL IL-1α (R&D Systems, 
 Inflammasome-Related Cytokine Secretion in RPE 
 
47 
 
Wiesbaden, Germany) was added to the mediafor the last 48 hours of POS incubation. 
Lipofuscin-loaded and primed cells were then irradiated with blue light-emitting diode (LED) 
light (wavelength, 455–460 nm; irradiance in our experimental setting, 0.8mW/cm2; XLamp 
XP-E royal blue; Cree, Durham, NC, USA) for 6 hours to induced LMP and inflammasome 
activation. Inhibition of caspase-1 or cathepsin B was performed immediately before blue 
light irradiation as described above.  
5.3.3 Cytokine ELISA Analysis  
For quantification of cytokine secretion, we employed specific ELISA assays against human 
IL-1β (BD OptEIA Human IL-1β ELISA Kit II; BD Biosciences, Heidelberg, Germany), human 
IL-18 (MBL Human IL-18 ELISA Kit; R&D Systems, Minneapolis, USA), and human VEGF 
(Human VEGF Quantikine ELISA Kit; R&D Systems) according to the manufacturers’ 
instructions. The lower limit of detection of the IL-1β ELISA as determined by the 
manufacturer is 0.8 pg/mL, and thus well below the concentrations measured in treated cells 
in our experiments. For collection of media for cytokine analysis, cell culture media was 
replaced before the experimental treatment (LeuLeu-OMe or blue light irradiation) and 
collected thereafter. For VEGF measurements, the new media contained 1% fetal bovine 
serum as recommended by the ELISA manufacturer. In control groups, untreated cells were 
incubated for a time corresponding to the respective experimental treatment before media 
were collected.  
5.3.4 Cytokine Dot Blot Analysis  
Confluent ARPE-19 cells in 6-well plates were primed with IL- 1a and subsequently 
incubated with Leu-Leu-OMe in 1000 lL serum-free media. Conditioned media were collected 
immediately after treatment, and concentrations of 42 inflammationand angiogenesis-related 
cytokines were measured using a protein dot blot assay (RayBio Human Cytokine Antibody 
Array 3; RayBiotech, Norcross, GA, USA) according to the manufacturer’s instructions. 
Appropriate films (Kodak BioMax Light Film; Sigma-Aldrich, Munich, Germany) were 
exposed to the membranes, and developed films were scanned (Perfection V700 Photo 
Scanner; Epson, Meerbusch, Germany) before image analysis by ImageJ software 
(http://imagej.nih.gov/ij/; provided in the public domain by the National Institutes of Health, 
Bethesda, MD, USA).  
5.3.5 Analysis of Polarization of Cytokine Secretion  
Polarized RPE cell monolayers on permeable membranes were generated as described 
before.257 Briefly, permeable membrane cell culture inserts (polyester membrane; diameter, 
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12 mm; pore size, 0.4 lm; Transwell-Clear; Corning, Kaiserslautern, Germany) were coated 
with 1.8 lg/cm2 laminin (SigmaAldrich) for 2 hours at 378C according to the manufacturer’s 
recommendation. Postconfluent, stationary pRPE or ARPE-19 cells were seeded onto the 
membranes at a confluent density of 1.66 3 105 cells/cm2. Cells were cultured for another 4 
weeks before use in experiments. Cell priming and Leu-LeuOMe treatment were performed 
as described above with addition of the Leu-Leu-OMe to both the apical and the basolateral 
media. Paracellular permeability of the RPE cell monolayer after Leu-Leu-OMe treatment 
was analyzed by means of marker dye leakage from the apical to the basolateral 
compartment using FITC-dextran (molecular weight, 20 kDa; Sigma-Aldrich) as described.257 
5.3.6 Microglia Chemotaxis Assay  
To obtain conditioned media, ARPE-19 cells were priming with IL-1α and then treated with 
Leu-Leu-OMe for 1 hour. Cells were washed to remove Leu-Leu-OMe and new media 
without Leu-Leu-OMe were added for another 2 hours. Control cells were primed with IL-1α 
but not treated with Leu-Leu-OMe and likewise incubated for 2 hours. Subsequently, 
conditioned media of treated and control cells were collected for use in the following 
experiments. For assessment of the chemotactic effects of secreted cytokines on microglia 
cells, 7 x 104 microglia cells in serumfree medium were added to the upper compartment of a 
permeable membrane cell culture insert (polycarbonate membrane; diameter, 24 mm; pore 
size, 8 lm; Transwell; Corning) while the RPE-conditioned media was applied to the lower 
compartment of the insert. In positive control experiments, unconditioned medium containing 
1 lM chemotactic peptide N-formyl-methionine-leucine-phenylalanine (fMLP; Sigma-Aldrich) 
was applied to the lower compartment. For coculture experiments, ARPE-19 cells were 
cultured in the lower compartment, primed with IL-1α, and treated with LeuLeu-OMe for 1 
hour, before medium was changed and the upper compartment of the cell culture insert 
containing the microglia cells was added. All experimental groups were incubated for 6 hours 
to allow for migration of the microglia cells. Subsequently, cells adherent to the upper side of 
the permeable membrane were mechanically removed using a cotton swab. Cells that had 
migrated through the membrane onto its lower surface were stained with crystal violet as 
described.238 The dye was then eluted from the cells using 1% SDS. The number of 
transmigrated microglia cells was assessed by photometric quantification of the eluted dye.  
5.3.7 Vascular Endothelial Cell Proliferation and Migration  
Retinal pigment epithelium conditioned media were generated as described above for the 
microglia chemotaxis assay. The effect of conditioned media on vascular endothelial cell 
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proliferation was analyzed by BrdU cell proliferation assay (Merck, Darmstadt, Germany). 
Human umbilical vein endothelial cells were seeded onto 96-well plates at a subconfluent 
density of 1.6 x 104 cells/cm2 and incubated for 6 hours to allow for cellular attachment. 
Subsequently, media was replaced by RPE cell conditioned media containing the BrdU label 
and incubated for another 24 hours. BrdU assay analysis was performed as recommended 
by the manufacturer. Vascular endothelial cell migration was assessed by scratch assay as 
described elsewhere.258 In brief, confluent HUVEC monolayers were scraped with a 200-µL 
pipet tip to create a scratch of defined width. Cells were washed to remove detached cells 
before incubation with RPE conditioned media for 24 hours. Cell migration was documented 
by light microscopy (Olympus CKX41 microscope; Olympus) and the number of cells within 
the scratch area was counted. In each experiment, five wells were analyzed per treatment 
group.  
5.3.8 Paracrine Cytokine Effects on VEGF Secretion  
Conditioned media were collected from ARPE-19 cells after 3 hours of incubation with either 
Leu-Leu-OMe or medium alone. In addition, conditioned media were collected of 
lipofuscinloaded ARPE-19 cells following irradiation with blue light for 6 hours or following 
incubation without irradiation for 6 hours. Vascular endothelial growth factor content of 
conditioned media was measured by ELISA. Untreated ARPE-19 cells were incubated with 
conditioned media for 24 hours, and VEGF concentration was quantified again. The initial 
VEGF concentration was subtracted from the final VEGF concentration to allow for specific 
assessment of VEGF secretion during the 24- hours incubation time.  
5.3.9 Statistical Analysis  
Experiments were performed in duplicates (see Figs. V.1B, V.2, V.4F) as recommended by 
the assay manufacturers, triplicates (see Figs. V.3, V.4A–E), or quintuplicates (see Fig. 
V.4G), and results are presented as mean 6 SD. For statistical analysis, we employed 2-
tailed unpaired Student’s t-test, and P less than 0.05 was considered statistically significant.  
 
 
5.4 Results 
5.4.1 Leu-Leu-OMe Induces LMP and Inflammasome  
Activation in ARPE-19 and pRPE Cells We have demonstrated that blue light irradiation of 
lipofuscinloaded RPE cells activates the NLRP3 inflammasome secondary to induction of 
LMP and cytosolic leakage of lysosomal enzymes.16 In the current study, we employed a 
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model of chemically induced LMP by Leu-Leu-OMe that has been demonstrated to likewise 
result in inflammasome activation in ARPE-19 cells.10 To assess lysosomal membrane 
integrity, cells were labeled with acridine orange, a fluorescent dye that both intercalates into 
DNA (green fluorescence) and stains intact lysosomes (red fluorescence). In both ARPE-19 
cells and pRPE cells, we observed a marked loss of lysosomal staining after incubation with 
Leu-Leu-OMe compared with untreated controls, indicating effective induction of LMP by 
Leu-Leu-OMe in both cell types (Fig. V.1A). When RPE cells were primed with IL-1α as 
described by Tseng and coworkers,185 LMP induction by Leu-Leu-OMe resulted in 
inflammasome activation with significantly increased secretion of inflammatory cytokines IL-
1β and IL-18 in both ARPE-19 and pRPE cells (Fig. V.1B). Inhibition of the inflammasome 
component caspase-1 by Z-YVAD-FMK suppressed the release of IL-1β and IL-18. Leakage 
of lysosomal enzymes, particularly cathepsin B, has been described to be involved in NRLP3 
inflammasome activation secondary to LMP.126,185 Indeed, inhibition of cathepsin B by CA-
074 also suppressed IL-1β and IL-18 release. These findings demonstrate that Leu-Leu-
OMe-induced LMP induces caspase-1- and cathepsin B–dependent inflammasome 
activation in both ARPE-19 and pRPE cells.  
 
 
Figure V.1: Leu-Leu-OMe induces LMP and inflammasome activation in RPE cells. (A) Acridine orange staining 
visualizes LMP in pRPE cells and ARPE-19 cells by loss of red lysosomal staining after incubation with Leu-Leu-
OMe. Nuclei are labeled green by acridine orange. Scale bar: 200 µm. (B) Interleukin-1b and IL-18 secretion was 
analyzed by ELISA in IL-1α–primed RPE cells following Leu-Leu-OMe treatment. Caspase-1 and cathepsin B were 
inhibited in Leu-Leu-OMe–treated cells by Z-YVAD-FMK and CA-074, respectively. 
 
5.4.2 Profile of Secreted Cytokines  
Secondary to Inflammasome Activation in RPE Cells After detecting an increased secretion 
of the inflammasomeregulated cytokines IL-1β and IL-18, we performed a screening analysis 
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to identify potential additional cytokines induced by inflammasome activation in RPE cells. 
For this, protein levels of 42 inflammation- and angiogenesis-related cytokines were 
analyzed in conditioned media of IL-1α–primed and Leu-Leu OMe–treated ARPE-19 cells by 
dot blot analysis. Leu-Leu-OMe treatment resulted in significantly increased secretion of 
GMCSF (2.8-fold increase, P = 0.027), GRO (CXCL1/2/3; 5.2-fold, P = 0.020), and IL-6 
(13.6-fold, P = 0.031) compared with an IL- 1a–primed but not Leu-Leu-OMe–treated control 
group (Fig. V.2). These results were found consistently in two independent experiments. 
Inflammasome inhibition by incubation with the caspase-1–specific inhibitor Z-YVAD-FMK 
partially suppressed the Leu-Leu-OMe–induced increase in secretion of GM-CSF, GRO, and 
IL-6. In summary, Leu-Leu-OMe–induced LMP in RPE cells resulted in a caspase-1–
dependent release of IL-1β, IL-18,GM-CSF, GRO, and IL-6. 
 
 
Figure V.2: Profile of secreted cytokines following LMP-induced inflammasome activation in RPE cells. 
Conditioned media of Leu-Leu-OMe–treated ARPE-19 cells was screened for 42 inflammation- and 
angiogenesis-related cytokines by dot blot analysis. Results for detected cytokines are shown. Significantly 
increased secretion was observed for GM-CSF, GRO (CXCL1/2/3), and IL-6. Caspase-1 inhibition by Z-YVAD-FMK 
partially suppressed this effect. The inset shows consistent results from a second, independent experiment. 
 
5.4.3 Polarization of Cytokine Secretion by RPE Cells and Chemotactic Effects on 
Microglia Cells  
The effects of secreted inflammatory cytokines on adjacent cells and tissues may differ 
considerably depending on whether the secretion is directed to the apical (neuroretinal) or 
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basolateral (choroidal) side of the RPE monolayer. To identify the predominant direction of 
cytokine secretion after inflammasome activation we cultured ARPE-19 and pRPE cells on 
permeable membranes. We demonstrated previously that the culture conditions employed 
result in the formation of a polarized cell monolayer with apical microvilli and intercellular tight 
junctions.257 To verify that Leu-Leu-OMe treatment does not compromise RPE barrier 
function, we incubated RPE cells with the marker dye FITC-dextran of a molecular weight of 
20 kDa, similar to that of IL-1β (17 kDa). FITC-dextran was added in the apical cell culture 
compartment, and dye leakage into the basolateral compartment was monitored during 
treatment with Leu-Leu-OMe. The assay demonstrated that the ARPE-19 cell monolayers 
almost completely prevented leakage between the two compartments and that effects of Leu-
Leu-OMe treatment on this barrier function were minimal (Fig. V.3A). We then treated 
polarized monolayers of pRPE cells and ARPE-19 cells on permeable membranes with Leu-
Leu-OMe added to both the apical and basolateral media to induce cytokine secretion. Unlike 
in Figure 1, secretion levels in Figure 3 are displayed as total cytokine mass instead of 
cytokine concentration to account for different volumes of the apical and basolateral 
compartments of the cell culture insert. The cells exhibited a significant increase in IL-1β 
secretion that was predominantly directed to the apical side (Fig. V.3B). Apical secretion of 
IL-1β in pRPE cells and ARPE-19 cells accounted for at least 69% and 75% of total IL-1β 
secretion, respectively. The lower IL-1β levels in pRPE cells compared with ARPE-19 cells 
may correspond to the different durations of Leu-Leu-OMe treatment of 1.5 and 3 hours, 
respectively. Similarly to IL-1β, IL- 18 in ARPE-19 cells was predominantly secreted to the 
apical side, with at least 92% of total secreted IL-18 detectable in the apical medium (Fig. 
V.3C). Of note, IL-1β and IL-18 in the basolateral medium were almost exclusively detectable 
in the group treated with 1.0 mM Leu-Leu-OMe that was also the only group that 
demonstrated some compromise of RPE barrier function in FITC-dextran leakage assay. In 
contrast, the 0.5 and 0.75 mM Leu-Leu-OMe– treatment groups exhibited both intact barrier 
function and near-complete lack of cytokines in the basolateral medium. It thus appears 
possible that cytokines in the 1.0 mM Leu-LeuOMe–treatment group may have reached the 
basolateral medium by transcellular leakage rather than basolateral secretion and that IL-1β 
and IL-18 release after Leu-Leu-OMe treatment occurs in fact almost entirely to the apical 
side. As apical secretion of inflammatory cytokines in vivo may affect retinal microglia 
activation and recruitment, we assessed the effects of secreted cytokines on microglia 
migration in vitro. For this assay, we placed murine embryonic stem cell–derived microglia 
cells in the upper compartment of a permeable membrane cell culture insert. The number of 
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microglia cells that transmigrated through the membrane was significantly increased (11.0-
fold, P = 0.0003) when conditioned media of Leu-Leu-OMe–treated ARPE-19 cells was 
applied to the lower compartment as compared with conditioned media of untreated control 
cells (Fig. V.3D). Cocultures of Leu-Leu-OMe–treated ARPE-19 cells in the lower 
compartment likewise resulted in a chemotactic effect on microglia cells in the upper 
compartment. The observed effects were comparable to that of the chemotactic peptide 
fMLP that was used as a positive control. Together, these results suggest that secretion of 
inflammatory cytokines by RPE cells secondary to inflammasome activation is directed 
predominantly to the apical side, corresponding to the neuroretinal side in vivo, and that the 
secreted cytokines exert a chemotactic effect on microglial cells.  
5.4.4 Effects of Inflammasome Activation on VEGF Secretion by RPE Cells and 
Secondary Effects on Vascular Endothelial Cells 
Vascular endothelial growth factor plays a central role in CNV formation in neovascular AMD. 
Inflammasome activation has been suggested to be involved in this process, although the 
reported effects of different inflammasome-controlled cytokines on VEGF secretion and 
angiogenesis are divergent.233,255,259 Therefore, we investigated the effects of LMP-induced 
inflammasome activation on VEGF secretion in RPE cells. Interestingly, the constitutive 
secretion of VEGF was significantly reduced in both pRPE and ARPE-19 cells following 
inflammasome activation by Leu-Leu-OMe (Figs. V.4A, V.4B). Inhibition of caspase-1 by Z-
YVAD-FMK reversed this effect. When LMP was induced in ARPE-19 cells by lipofuscin-
mediated photooxidative damage as described,254 we likewise detected significantly reduced 
VEGF secretion (Fig. V.4C). These findings demonstrate that inflammasome activation in 
RPE cells secondary to LMP, both by Leu-Leu-OMe and by lipofuscin phototoxicity, results in 
a reduction of constitutive VEGF secretion. Inflammasome-regulated cytokine IL-18 has been 
shown to reduce VEGF secretion in RPE cells.17 We therefore sought to investigate whether 
the reduction of VEGF secretion observed in our experiments was a direct effect of 
inflammasome activation or rather a secondary effects mediated by secreted IL-18. To test 
for this, we incubated untreated RPE cells with conditioned media of Leu-Leu-OMe–treated 
RPE cells or conditioned media of untreated control cells (Fig. V.4D). Vascular endothelial 
growth factor content of conditioned media before incubation was subtracted from VEGF 
content after incubation to allow for a selective quantification of VEGF secretion by the 
incubated RPE cells. With this experimental design, we did not detect a significant effect of 
conditioned media on VEGF secretion. When LMP was induced by lipofuscin phototoxicity  
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Figure V.3: Polarization of inflammasome-related cytokine secretion in RPE cells and chemotactic effects on 
microglia cells. (A) The effect of LeuLeu-OMe on barrier function of ARPE-19 monolayers was assessed by 
permeability assay. For this, a marker dye (FITC-dextran, 20 kDa) with a molecular weight corresponding to that 
of IL-1β (17 kDa) was added to the apical compartment only, and dye leakage into the basolateral 
compartment was measured following Leu-Leu-OMe treatment. (B) Polarized monolayers of pRPE cells and 
ARPE-19 cells on permeable membranes were treated with Leu-Leu-OMe for 1.5 and 3 hours, respectively. 
Subsequently, separate analysis of IL-1β in the apical and basolateral media revealed that the cytokine was 
predominantly secreted to the apical cell side. Induction of cytokine secretion by Leu-Leu-OMe was dose-
dependent, and IL-1β secretion to the basolateral side was detectable only at higher concentrations of Leu-Leu-
OMe. (C) Similarly, secretion of IL-18 in ARPE-19 cells occurred predominantly toward the apical side. (D) To 
assess chemotactic effects of the released cytokines, murine embryonic stem cell–derived microglia cells were 
placed in the upper compartment of a permeable membrane cell culture insert. Migration of microglia cells 
across the membrane into the lower compartment was assessed following application of the following 
substances or cells to the lower compartment for 6 hours: conditioned media of untreated control ARPE-19 
cells (Co), conditioned media of untreated ARPE-19 cells for the first 3 hours and conditioned media of 
LeuLeuOMe-treated ARPE-19 cells for the last 3 hours (Le3), conditioned media of LeuLeuOMe-treated ARPE-
19 cells for the entire 6 hours (Le6), Leu-Leu-OMe–treated ARPE-19 cells (RPE), and unconditioned media 
containing the chemotactic peptide fMLP as positive control (fMLP). Migration of microglia cells onto the lower 
side of the permeable membrane was quantified by crystal violet assay and documented by light microscopy. 
Scale bar: 100 µm. Significance levels as compared with the respective controls are indicated *P < 0.05, **P < 
0.01, and ***P < 0.001. 
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instead of Leu-Leu-OMe, we likewise did not find VEGF secretion to be significantly affected 
by conditioned media (Fig. V.4E). These results suggest the reduced VEGF secretion 
observed in our experiments to be a direct effect of inflammasome activation, rather than a 
secondary effect mediated by released cytokines such as IL-18. Inflammasome-regulated IL-
1β has been reported to exert angiogenic effects.255,260 Although our experiments 
demonstrated that inflammasome-induced release of IL-1β by RPE cells occurs 
predominantly toward the apical side, we also detected a significant increase in basolateral 
secretion (Fig. V.3B) that could contribute to choroidal angiogenesis in AMD. To determine 
the prevailing effect on angiogenesis of combined increased IL-1β release and reduced 
VEGF secretion as observed after inflammasome activation in RPE cells, we incubated 
HUVEC with conditioned media of Leu-Leu-OMe– treated RPE cells. Measurements by BrdU 
assay revealed that incubation with conditioned media of Leu-Leu-OMe–treated cells 
reduced vascular endothelial cell proliferation by 61% compared with conditioned media of 
untreated control cells (P ¼ 0.0013; Fig. V.4F). Likewise, analysis by scratch assay 
demonstrated a reduction of vascular endothelial cell migration by 31% (P ¼ 0.0009; Fig. 
V.4G). Thus, conditioned media of RPE cells after inflammasome activation reduced 
vascular endothelial cell proliferation and migration compared with conditioned media of 
untreated control RPE cells, consistent with the observed reduction in constitutive VEGF 
secretion. 
 
 
5.5 Discussion  
Various lines of evidence indicate that the chronic innate immune response in the sub-RPE 
space that is detectable as both local deposition and increased systemic levels of activated 
complement components represents a key pathogenetic factor in AMD.149,231 In a study 
examining AMD patients with the AMD risk polymorphism of the complement factor H (CFH) 
gene, increased systemic concentrations have also been reported for the cytokine IL-18, 
which represents a product of inflammasome activation.261 Inflammasome activation in the 
RPE has been detected in patients with both atrophic and neovascular AMD,185,232 and 
increased intravitreal and systemic levels of the inflammasome-controlled cytokines IL-1β 
and IL-18 in AMD patients have been reported.252,253 However, clinical data regarding 
inflammasome activation in AMD is still sparse, and more research is needed on the 
potential contribution of the inflammasome to AMD pathogenesis. Also, the signal for 
inflammasome activation in AMD is yet unknown, and substances that have been suggested 
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to provide this signal include drusen components such as C1q233 and amyloid-β,234 Alu RNA 
accumulating secondary to DICER1 deficiency,232 the lipofuscin component N-retinylidene-N-
retinyl-ethanolamine (A2E)235 and the lipid peroxidation product 4-hydroxynonenal (HNE).236 
A well-established mechanism of inflammasome activation in various cell types is induction 
of LMP, for example, by viruses, bacteriotoxins, and phagocytosed crystalline substances.186 
Inflammasome activation by LMP has also been reported to occur in RPE cells.185 In the 
aging RPE, lipofuscin accumulates within the lysosomal compartment, and we and others 
have demonstrated that photoreactive properties of lipofuscin induce LMP in RPE cells.96,97 
We also demonstrated that lipofuscin phototoxicity, via induction of LMP and cytosolic 
leakage of lysosomal enzymes, results in inflammasome activation in RPE cells.254 These 
results make it conceivable that with age, progressive accumulation of lipofuscin together 
with a declining defensive capacity against photooxidative stress may trigger inflammasome 
activation in the RPE that contributes to the development of AMD. In contrast to the 
mechanisms of inflammasome activation in the RPE, the consequences of this mechanism 
have been investigated less intensively so far, in particular with regard to AMD pathogenesis. 
In this study, we addressed this question by analyzing the profile of cytokines that are 
secreted by RPE cells following inflammasome activation. For this, we used an established 
model for LMP-induced inflammasome activation that employs Leu-Leu-OMe for chemical 
destabilization of lysosomes.126,185 Tseng and coworkers185 demonstrated that incubation of 
ARPE-19 cells with Leu-Leu-OMe as also employed in our study induces characteristic 
features of inflammasome activation such as caspase-1, maturation and release of IL-1β, 
and cell death by pyroptosis.185 Using the same model in pRPE and ARPE-19 cells, we 
observed a significant and caspase-1–dependent increase in secretion of the inflammation-
related cytokines IL-1β, IL-6, IL- 18, GM-CSF, and GRO family cytokines (CXCL1, CXCL2, 
CXCL3) secondary to LMP-induced inflammasome activation in RPE cells. The cytokines IL-
1β and IL-18 are directly regulated by the inflammasome, and thus their increased secretion 
is most likely a direct result of inflammasome activation. In contrast, IL-6, GM-CSF, and GRO 
are not considered to be controlled by the inflammasome but are rather upregulated 
secondary to IL-1β or IL-18 activity. In particular, IL-1β has been demonstrated to induce 
secretion of IL-6, GM-CSF, and GRO in RPE cells.262–265 The IL-1β concentrations measured 
in inflammasomeactivated RPE cells in our experiments are in the range of those determined 
by previous studies.233,235,254 Likewise, the concentrations of IL-18 measured in our study 
correspond to the range of previously reported levels.232,236,254 Secretion of IL- 1β was 
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Figure V.4: Effect of inflammasome activation on RPE cell VEGF secretion and vascular endothelial cell 
proliferation and migration. For induction of inflammasome activation by LMP, (A) pRPE cells and (B) ARPE-19 
cells were treated with Leu-Leu-OMe alone (Le) or Leu-Leu-OMe and the caspase-1 inhibitor Z-YVAD-FMK (LþZ). 
Control cells (Co) were left untreated. In both cell types, inflammasome activation resulted in a significant 
reduction of constitutive VEGF secretion that was dependent on caspase-1 activity. (C) Lysosomal membrane 
permeabilization induced by lipofuscin-mediated photooxidative damage similarly reduced VEGF secretion in 
ARPE-19 cells. For this, low or high lipofuscin accumulation was induced by incubation with native 
photoreceptor outer segments (POS) and HNE-modified POS (HNE-POS), respectively, and lipofuscin-loaded 
cells were irradiated with blue light for 6 hours. Incubation of untreated ARPE-19 cells with conditioned media 
of ARPE-19 cells subjected to either (D) Leu-Leu-OMe treatment or (E) lipofuscin phototoxicity did not result in 
a significant reduction of VEGF secretion, suggesting a direct effect of inflammasome activation on VEGF 
secretion rather than an indirect effect mediated by the secreted interleukins. The effect of inflammasome-
induced cytokines on human vascular endothelial cell proliferation and migration was assessed by (F) BrdU and 
(G) scratch assays, respectively. Consistent with the observed reduction in VEGF secretion, incubation with 
conditioned media of Leu-Leu-OMe–treated ARPE-19 cells resulted in a significant reduction of vascular 
endothelial cell proliferation and migration as compared with conditioned media of untreated control cells. 
Scale bar: 250 µm. 
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significantly higher in polarized RPE cells (Fig. V.3B) compared with unpolarized cells (Fig. 
V.1B). The observation that polarization increases cytokine expression in RPE cells has 
been described before. For example, secretion of pigment epithelium-derived factor (PEDF) 
and VEGF has been reported to be increased 34-fold and 6-fold, respectively, in polarized 
compared with unpolarized RPE cells.266 Polarization may thus likewise be the cause for the 
increased secretion of IL-1β observed in our polarized RPE cell experiments. The identified 
cytokines may contribute to RPE cell pathology in AMD in various ways. IL-18 has been 
reported to exert a direct cytotoxic effect on RPE cells in vivo,232 although this observation 
has been questioned by others.267 In vitro, no cytotoxic effects on RPE cells have been 
observed for IL-18 concentrations of up to 10 lg/mL.39 This concentration is five orders of 
magnitude higher than the IL-18 concentrations measured in conditioned media in our 
experiments (Fig. V.1B). Therefore, cytotoxic effects of IL-18 in our experiments are notto be 
expected. Similar to IL-18, IL-6 was described as capable of inducing degeneration of RPE 
cells.268 In addition to their direct effects on RPE cells, the identified cytokines could induce 
activation and recruitment of microglia cells, monocytes, and macrophages, which may exert 
secondary effects on the RPE. We found that secretion of IL-1β and IL-18 was predominantly 
directed toward the apical side of the RPE monolayer, corresponding to the neuroretinal side 
in vivo. This is in accordance with the results of previous studies that likewise reported a 
predominantly apical secretion of inflammatory cytokines by RPE cells following induction by 
various stimuli.269–271 Retinal cell populations that may be affected by the observed apical 
cytokine secretion include resident microglia cells and infiltrating macrophages. Indeed, 
activation of these cell types and their migration into the subretinal space has been observed 
in AMD patients and animal models and have been discussed as a factor contributing to 
AMD pathogenesis.35,272,273 Our experiments demonstrated a significant chemotactic effect of 
conditioned media from Leu-Leu-OMe– treated RPE cells on microglia cells, supporting a 
role of inflammasome-related cytokines in microglia recruitment. Via the apically polarized 
secretion of inflammatory cytokines and the chemotactic effects on microglia cells, LMP-
mediated inflammasome activation in the RPE as observed secondary to lipofuscin 
phototoxicity may contribute to microglia/macrophages activation and recruitment in vivo in 
retinal pathologies such as AMD. For the evaluation of the inflammasome as a potential new 
therapeutic target in neovascular AMD, the knowledge of downstream effects of 
inflammasome activation is crucial. However, previous reports on the effects of 
inflammasome activation on CNV formation are ambiguous. The two classical 
inflammasome-induced cytokines, IL-1β and IL-18, have been reported to induce and inhibit 
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VEGF secretion by RPE cells, respectively.233,259 Similarly, IL-1β and IL-18 have been 
demonstrated to promote and suppress CNV formation in mice, respectively,233,255 whereas 
others did not find CNV formation to be affected by IL-18.274 We sought to elucidate the 
angiogenesisrelated effects of inflammasome activation in the RPE. Interestingly, we found 
that LMP-induced inflammasome activation in RPE cells does not result in an increase but 
rather in a significant reduction of the cells’ constitutive secretion of VEGF. Consistently, 
conditioned media of RPE cells following inflammasome activation reduced proliferation and 
migration of vascular endothelial cells compared with conditioned media of untreated control 
cells. In addition to the reduction in VEGF secretion, the released IL-18 may add to this effect 
due to its suggested antiangiogenic properties.233 While our experiments demonstrate 
reduced VEGF secretion by RPE cells following inflammasome activation, inflammatory 
cytokines released by RPE cells after inflammasome activation in vivo may exert indirect 
angiogenic effects via other cell types such as recruited microglia cells.35 Both a priming 
signal and an activation signal are required for inflammasome activation. In IL-1α–primed 
RPE cells, we found that LMP induced by lipofuscin phototoxicity results in activation of the 
NLRP3 inflammasome254 and in the current study this mechanism was associated with a 
significant reduction in constitutive VEGF secretion. In contrast, the isolated lipofuscin 
component A2E has been shown to induce VEGF secretion in unprimed ARPE-19 cells.275 
After priming of ARPE-19 cells with IL-1α, A2E treatment resulted in both inflammasome 
activation and induction of VEGF secretion.235 Similar to lipofuscin, phototoxicity of A2E has 
been shown to induce LMP97 and blue light irradiation of unprimed A2E-loaded ARPE-19 
cells induced an increase in VEGF secretion.276 Whether A2E phototoxicity in primed cells 
results in a reduction of VEGF secretion similar to our results for lipofuscin phototoxicity still 
needs to be investigated. Following up on our previous investigation describing the 
mechanism of LMP-induced inflammasome activation induced by lipofuscin-mediated 
photooxidative damage in RPE cells, our current study identifies the cytokine profile secreted 
by RPE cells following LMP-induced inflammasome activation. While secretion of VEGF is 
suppressed after inflammasome activation, several inflammatory cytokines are significantly 
induced and secreted predominantly to the apical RPE side. Via this mechanism, 
photooxidative damage to the RPE may trigger local immune processes such as activation 
and recruitment of retinal microglia/macrophages, and thus contribute to the chronic innate 
immune response in AMD.  
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6.1 Abstract 
Complement activation, oxidative damage, and activation of the NLRP3 inflammasome have 
been implicated in retinal pigment epithelium (RPE) pathology in age-related macular 
degeneration (AMD). Following priming of RPE cells, the NLRP3 inflammasome can be 
activated by various stimuli such as lipofuscin-mediated photooxidative damage to lysosomal 
membranes. We investigated whether products of complement activation are capable of 
providing the priming signal for the inflammasome in RPE cells. Incubation of primary human 
RPE cells and ARPE-19 cells with complement-competent human serum resulted in 
upregulation of C5a receptor, but not C3a receptor. Furthermore, it induced expression of 
pro-IL-1β and enabled IL-1β secretion in response to lipofuscin phototoxicity, thus indicating 
inflammasome priming by human serum. Complement heat-inactivation, C5 depletion, and 
C5a receptor inhibition suppressed the priming effect of human serum whereas recombinant 
C5a likewise induced priming. Conditioned media of inflammasomeactivated RPE cells 
provided an additional priming effect that was mediated by the IL-1 receptor. These results 
indicate that complement activation product C5a represents a priming signal for RPE cells 
that allows for subsequent inflammasome activation by stimuli such as lipofuscin-mediated 
photooxidative damage. This molecular pathway provides a functional link between key 
factors of AMD pathogenesis including lipofuscin accumulation, photooxidative damage, 
complement activation, and RPE degeneration and may provide novel therapeutic targets in 
this disease. 
 
 
6.2 Introduction  
Age-related macular degeneration (AMD) is the leading cause of blindness in all 
industrialized countries.230 For the majority of patients, in particular those affected by the 
intermediate stage and the atrophic late stage of the disease, there is currently no effective 
treatment available. Elucidating the still unresolved pathogenesis of this multifactorial, 
complex disease will help to identify potential targets for therapeutic intervention. The retinal 
pigment epithelium (RPE), a monolayer of post-mitotic support cells essential for 
photoreceptor function, is primarily affected by AMD. Oxidative/photooxidative damage to the 
RPE contributes to AMD, and antioxidative treatment has been demonstrated to slow 
disease progression in clinical trials.3 This damage is believed to be mediated at least in part 
by the photoreactive properties of lipofuscin and lipofuscin component A2E that accumulate 
in the macular RPE in large amounts over a lifetime.277,278 In addition, several lines of 
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evidence indicate that processes of the innate immune system play a critical role in the 
pathogenesis of AMD. Activated components of the complement system such as C3a and 
C5a are detectable both locally in the sub-RPE space and systemically in plasma of AMD 
patients. 149,231 Genetic polymorphisms in several complement components and regulators 
such as CFH, C2, C3, and CFB are strongly associated with AMD.279 Another part of the 
innate immune system, the NLRP3 inflammasome, has recently been proposed to also 
contribute to AMD pathogenesis. Activation of the NLRP3 inflammasome in RPE cells was 
demonstrated in both atrophic and neovascular AMD,185,232 and increased intravitreal and 
systemic levels of the inflammasome activation products IL-1β and IL-18 have been reported 
in AMD patients.252,253 The inflammasome protein complex serves as an intracellular sensor 
for various signals of cell damage. 186 Its activation results in the secretion of highly 
proinflammatory cytokines such as IL-1β and IL-18 and eventually in cell death by pyroptosis. 
Activation of the NLRP3 inflammasome is a two-step process that requires an initial priming 
signal and a subsequent activation signal. 186 The priming signal results in NF-κB–dependent 
transcriptional induction of NLRP3 and pro-IL- 1β. The activation signal subsequently triggers 
assembly of NLRP3 and other protein components into the active inflammasome protein 
complex that results in caspase-1- mediated cleavage of pro-IL-1β and pro-IL-18 into mature 
IL-1β and IL-18. Several substances have been suggested to provide the inflammasome 
activation signal in AMD including drusen components such as C1q233 and amyloid-beta,234 
Alu RNA accumulation secondary to DICER1 deficiency,232 the lipofuscin component N-
retinylidene-N-retinylethanolamine (A2E),235 and the lipid peroxidation product 4-
hydroxynonenal (HNE).236 We have recently suggested an additional mechanism by 
demonstrating that photooxidative damage to the RPE, enhanced by accumulated lipofuscin, 
can activate the NLRP3 inflammasome by inducing lysosomal membrane permeabilisation 
and cytosolic leakage of lysosomal enzymes.254,280 In contrast to inflammasome activation, 
the mechanism of inflammasome priming in AMD has been little investigated so far. 
Interestingly, a recent study in patients with early or intermediate AMD demonstrated the 
CFH risk genotype to be associated with significantly increased plasma levels of the 
inflammasomeregulated cytokine IL-18, suggesting a role for activated complement 
components like C3a and C5a in inflammasome activation in AMD.261 Inflammasome priming 
by complement activation products has also been proposed in the context of other diseases 
such as atherosclerosis and gout.281,282 In this study, we investigated the capacity of 
activated complement components to prime human RPE cells for inflammasome activation 
by lipofuscin-mediated photooxidative damage. 
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6.3 Experimental Procedures 
6.3.1 Cell culture and treatments.  
Human fetal primary RPE (pRPE) cells (Clonetics H-RPE; Lonza, Cologne, Germany) were 
cultured in medium provided by the manufacturer (Clonetics RtEGM; Lonza) containing 2% 
heat-inactivated fetal bovine serum (FBS) and were used in experiments for a maximum of 6 
cell culture passages. The human non-transformed RPE cell line ARPE-19 (CRL-2302; 
ATCC, Rockville, MD, USA) was cultured as previously reported using medium containing 
10% heat-inactivated FBS.237 For inflammasome priming, culture medium was exchanged by 
FBS-free medium supplemented with the indicated priming agents as described below. For 
analysis of C5a receptor (C5aR) expression, cells were treated with 50 ng/ml C5a (R&D 
Systems, Wiesbaden, Germany).283,284 Cathepsin B inhibitor CA-074 (Merck/Calbiochem, 
Darmstadt, Germany) and cathepsin L inhibitor Z-FF-FMK (Merck/Calbiochem) were used at 
a concentration of 10 µM each for 1 h prior to and during irradiation treatment. For inhibition 
of caspase-1, we applied 10 µM of Z-YVAD-FMK (BioVision, Munich, Germany) 30 min prior 
to and during irradiation. Binding to C5aR was blocked using 0.5 µM of an inhibitory mouse 
monoclonal IgG antibody directed against human C5aR (clone S5/1; Biolegend, Fell, 
Germany). The drug anakinra (Kineret; Swedish Orphan Biovitrum, Langen, Germany) was 
used at a concentration of 100 ng/ml to inhibit the IL- 1 receptor (IL1R). 
6.3.2 Immunocytochemistry and western blot analysis  
For immunocytochemical detection of ZO-1 and C5aR, cells were stained with a rabbit 
polyclonal anti human ZO-1 antibody (Life Technologies, Darmstadt, Germany) and a mouse 
monoclonal anti human C5aR antibody (clone S5/1; Biolegend, Fell, Germany), respectively. 
Cells were fixed with 4% paraformaldehyde for immunocytochemistry. No cell 
permeabilisation agent was applied prior to immunodetection of C5aR to limit this staining to 
cell membrane proteins. For western blot analysis of C5aR and pro-IL- 1β, we employed a 
mouse monoclonal anti human C5aR antibody (clone S5/1; Biolegend, Fell, Germany) and a 
goat polyclonal anti human IL-1β antibody (R&D Systems, Wiesbaden, Germany), 
respectively. Cells were lysed using RIPA buffer, and total protein content of cell lysates was 
quantified by Bradford assay (Sigma-Aldrich, Munich, Germany). Equal amounts of 50 µg 
total protein per sample were separated by electrophoresis in 4-12% SDS–polyacrylamide 
gels (Lonza, Cologne, Germany) prior to transfer onto nitrocellulose membranes (Thermo 
Scientific) and subsequent immunodetection.  
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6.3.3 RT-PCR and quantitative real-time PCR 
For conventional RT-PCR, isolation of total RNA from RPE cells and reverse transcription 
into cDNA was carried out with the Power SYBR Green Cells-to-Ct Kit (Life Technologies, 
Darmstadt, Germany) as recommended by the manufacturer. PCR was performed with 40 
cycles using the KAPA2G Fast PCR Kit (PEQLAB Biotechnologie, Erlangen, Germany). The 
primers used for detection of C5aR, C3a receptor (C3aR), and C5a-like receptor 2 (C5L2) 
have been described.285 For human glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
we employed the sense primer 5´-CTCTGCTCCTCCTGTTCGAC-3´ and the antisense 
primer 5´-GCGCCCAATACGACCAAATC-3´. PCR products were run on 2% agarose gel with 
a 100 bp DNA ladder marker (Sigma-Aldrich, Munich, Germany). The negative control 
contained all PCR components but no cDNA template. Quantitative real-time PCR (qPCR) 
was performed using again the Power SYBR Green Cells-to-Ct Kit (Life Technologies, 
Darmstadt, Germany) according to the manufacturer’s protocol on a real-time PCR system 
(LightCycler 480 II; Roche, Basel, Switzerland) with the primers described above. The 
amount of target mRNA in test samples was normalized to GAPDH, and the comparative Ct 
method was used to evaluate gene expression.  
6.3.4 Inflammasome priming 
For inflammasome priming, cells were treated with the indicated priming agents during the 
last 48 h of incubation with photoreceptor outer segments (POS). For priming with 
interleukins, cells were treated with 4 ng/ml recombinant human IL-1α (R&D Systems, 
Wiesbaden, Germany)185 or 50 pg/ml recombinant human IL-1β (R&D Systems). For priming 
with normal human serum (NHS), full blood was drawn from a healthy donor into 
anticoagulant-free tubes. Blood samples were sedimented at room temperature for 30 
minutes. Serum was separated by centrifugation (2000g, 5 minutes) and immediately stored 
at -80°C. Heat inactivation of complement components was performed by incubating NHS in 
a water bath of 56°C for 30 min. For inflammasome priming, NHS, heat-inactivated NHS, or 
C5-depleted human serum (Sigma-Aldrich, Munich, Germany) was added to FBS-free cell 
culture media at a concentration of 25% each. In an additional treatment group, cell culture 
media containing C5-deficient serum were resupplemented with 50 ng/ml C5a (R&D 
Systems, Wiesbaden, Germany).  
6.3.5 Inflammasome activation 
Following inflammasome priming, inflammasome activation by lipofuscin-mediated 
photooxidative damage was induced in RPE cells as previously described.254 Briefly, isolated 
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porcine POS were covalently modified with the lipid peroxidation product HNE (5 mM) to 
stabilize them against lysosomal degradation.241 RPE cells were incubated with modified 
POS (concentration equivalent to 4 mg total POS protein per cm² cell growth area) daily for 7 
days, resulting in lipofuscinogenesis.237 During the last 48 h of POS treatment, cells were co-
incubated with the respective priming agent as indicated. Subsequently, medium was 
changed, and cells were irradiated with blue light (peak wave length, 448 nm; irradiance, 0.8 
mW/cm²) for the indicated times of up to 6 h to induce photooxidative lysosomal membrane 
permeabilisation and subsequent NLRP3 inflammasome activation.254 Irrespective of the 
duration of irradiation, media were collected 6 h after the medium change in all treatment and 
control groups. Secretion of IL-1β secondary to inflammasome activation was measured by 
specific ELISA (BD OptEIA Human IL-1β ELISA Kit II; BD Biosciences, Heidelberg, 
Germany). To analyze loss of plasma membrane integrity secondary to inflammasome-
mediated cell death, we assessed lactate dehydrogenase (LDH) release (Cytotoxicity 
Detection Kit; Roche, Mannheim, Germany).  
6.3.6 Priming by conditioned media.  
Conditioned media were obtained from ARPE-19 cells following inflammasome activation by 
lipofuscin phototoxicity. This was induced by HNE-POS incubation, IL-1α priming, and blue 
ight irradiation as described above. Before the start of irradiation, cells were washed and 
medium was changed. After 6 h of irradiation, conditioned media were collected for use in 
priming experiments. In control experiments, inflammasome activation was achieved by 
treatment with L-leucyl-L-leucine methyl ester (Leu-Leu-OMe).185 For this, ARPE-19 cells 
were primed by IL-1α, incubated with 1mM Leu-Leu-OMe (Bachem, Bubendorf, Switzerland) 
for 1 h, washed, and incubated with new medium without Leu-Leu-OMe for another 2 h 
before conditioned media were collected. For inflammasome priming by conditioned media, 
treatment-naive cells were incubated with conditioned media of HNE-POS/blue lighttreated 
or Leu-Leu-OMe-treated cells for 48 h.  
6.3.7 Statistical Analysis 
Experiments were performed in duplicates (Fig. VI.3A, VI.3C, VI.4A, VI.4C, VI.6A, VI.6B) 
following the assay manufacturer’s recommendation or in triplicates (Fig. VI.2, VI.3B, VI.3D, 
VI.4B, VI.4D). Results are presented as mean ± standard deviation. Statistical analysis was 
performed using paired (Fig. VI.2) or unpaired (Fig. VI.3, VI.4, VI.6) two-tailed Student’s t 
tests (Microsoft Excel 2013; Microsoft, Redmond, WA, USA). Differences were considered 
statistically significant at p<0.05. In experiments with multiple group comparisons (Fig. VI.3, 
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VI.4), significant differences were confirmed by additional analysis using one-way ANOVA 
with post-hoc analysis by Tukey’s range test (GraphPad InStat 3.06, GraphPad Software, La 
Jolla, CA, USA). 
 
 
6.4 Results 
6.4.1 Anaphylatoxin receptors C3aR, C5aR, and C5L2 are constitutively expressed by 
human RPE cells.  
C3a and C5a represent the two dominant anaphylatoxins during complement activation. C3a 
binds to C3aR. C5a is a ligand for both C5aR and C5L2 with most biological effects being 
mediated by C5aR. Expression of C5aR and C3aR has been demonstrated in ARPE-19 
cells.241,283,285 Expression of C5aR in RPE cells has also been detected by 
immunohistochemistry of human donor eyes where it was found to be localized 
predominantly on the basolateral cell side.286 We extended these previous studies by 
investigating the expression of C3aR, C5aR, and C5L2 on ARPE-19 and pRPE cells. Under 
the culture conditioned employed in our experiments, both cell types exhibited characteristics 
of differentiated RPE cells including epithelial monolayer formation, hexagonal cell 
morphology, and intracellular ZO-1-positive tight junctions (Fig. VI.1A). In both RPE cell 
types, we detected constitutive expression of all three anaphylatoxin receptors (Fig. VI.1B). 
6.4.2 C5aR, but not C3aR, is upregulated following incubation with activated 
complement.  
In normal human serum (NHS) in vitro, complement activation occurs rapidly when incubated 
at 37°C, and thus complementcompetent NHS in vitro is a rich source for complement 
activation products even without addition of complement activators such as zymosan.287 In 
contrast, heating of NHS to 56°C for 30 min inactivates complement components and 
prevents complement activation but preserves the activity of other less heat-labile serum 
proteins. To assess the effects of activated complement components on anaphylatoxin 
receptors in human RPE cells, we measured expression of C5aR and C3aR in ARPE-19 
cells and pRPE cells after incubation with complement-competent NHS and heatinactivated 
NHS (HI-NHS) by qPCR analysis. Studies investigating the time course of C5aR expression 
in ARPE-19 cells following stimulation with inflammatory cytokines reported a upregulation 
with a maximum after 6 hours for mRNA expression and after 24 hours for cell surface 
protein expression.283 We likewise found that incubation of ARPE-19 cells with complement- 
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Figure VI.1: Anaphylatoxin receptors C5aR, C3aR, and C5L2 are constitutively expressed by human RPE cells. 
(A) human RPE cell line ARPE-19 cells and primary human RPE cells (pRPE) were used for expression analysis. 
Both RPE cell types exhibited RPE-characteristic morphology in cell culture, including epithelial cell monolayer 
formation with polygonal cell shape and intercellular tight junction formation as evident from immunostaining 
of ZO-1 (green). Nuclei were visualized by DAPI staining (blue). Scale bar, 50 µm. (B), expression of C5aR (PCR 
product, 500 bp), C3aR (585 bp), and C5L2 (585 bp) in RPE cells was analyzed by RT-PCR. Expression of GAPDH 
(121 bp) was used as a positive control. PCR reaction mix without cDNA template served as negative control 
(Neg). 
 
competent NHS induced a significant upregulation of C5aR expression (p=0.007) with a peak 
6-fold induction after 6 hours (Fig. VI.2A). Heat inactivation of complement components 
completely prevented the effect of NHS on C5aR expression (Fig. VI.2B). In contrast to 
C5aR, expression of C3aR was not significantly affected by incubation with complement-
competent NHS (Fig. VI.2C). Similar to NHS, recombinant C5a induced a maximum 6-fold 
upregulation of C5aR expression in ARPE-19 cells (p=0.011) after 6 hours (Fig. VI.2D). This 
result was confirmed in pRPE cells which likewise exhibited a significant upregulation of 
C5aR epression (p=0.0097) following incubation with C5a (Fig. VI.2E). Western blot analysis 
performed in ARPE-19 cells at different time points up to 24 hours after beginning of an 
incubation with C5a for 6 hours confirmed that the observed mRNA induction resulted in 
increased C5aR protein expression (Fig. VI.2F). Similarly, immunocytochemistry performed 
without cell permeabilisation demonstrated increased C5aR cell surface staining in ARPE-19 
cells 24 hours following start of a C5a incubation for 6 hours (Fig. VI.2G). Our findings 
indicate that human RPE cells respond to incubation with activated complement components 
by upregulation of C5aR mRNA expression whereas expression of C3aR is not affected. 
These results suggest C5aR as a mediator of complement effects on RPE cells and triggered 
us to further investigate C5a as a potential priming signal for the NLRP3 inflammasome in 
RPE cells. 
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Figure VI.2: C5aR, but not C3aR, is up-regulated following incubation with activated complement. Using 
qPCR, we analyzed expression kinetics of (A) C5aR in ARPE-19 cells incubated with complement-competent 
NHS, (B) C5aR in ARPE-19 cells incubated with heat-inactivated NHS, (C) C3aR in ARPE-19 cells incubated with 
complement-competent NHS, (D) C5aR in ARPE-19 cells incubated with recombinant human C5a, and (E) C5aR 
in pRPE cells incubated with recombinant human C5a. Target mRNAs were normalized to GAPDH. Experiments 
were performed in triplicates, and results are presented as mean standard deviation. F, increased expression of 
C5aR protein (37 kDa) following priming with C5a was detected by (F) Western blot analysis and (G) 
immunocytochemistry in ARPE-19 cells. 
 
6.4.3 NHS primes RPE cells for inflammasome activation by lipofuscin-mediated 
photooxidative damage.  
We previously demonstrated that the in vitro model of lipofuscin-mediated photooxidative 
damage in RPE cells employed in this study results in activation of the NLRP3 
inflammasome with activation of caspase-1 and subsequent release of IL-1β and IL-18.254,280 
For our experiments, ARPE-19 cells and pRPE cells were incubated with unmodified POS or 
POS modified with the lipid peroxidation product HNE (HNE-POS) to induce intracellular 
accumulation of low and high levels of lipofuscin-like material, respectively. Subsequently, 
lipofuscin-loaded RPE cells were irradiated with blue light for up to 6 h. Inflammasome 
activation was assessed by means of inflammasome-regulated IL-1β secretion and 
inflammasome-induced pyroptotic cell death in both ARPE-19 cells (Fig. VI.3A, B) and pRPE 
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cells (Fig. VI.3C, D). Without prior inflammasome priming, no inflammasome activation was 
detectable in RPE cells following blue light irradiation. In contrast, in positive control cells 
treated with the priming agent IL-1α,185 blue light irradiation resulted in significant 
inflammasome activation with IL-1β secretion and pyroptosis. Inflammasome activation 
increased with light dose. Incubation with NHS exerted a strong priming effect similar to IL-
1α. Inflammasome activation of NHSprimed cells was dependent on activity of the 
inflammasome component caspase-1 and the lysosomal enzyme cathepsin B, consistent 
with the previously reported mechanism of inflammasome activation by lysosomal enzyme 
leakage.254 There was good agreement between results in ARPE-19 cells and pRPE cells. 
The data demonstrate that complementcompetent NHS contains a factor capable of 
providing the priming signal for subsequent inflammasome activation in RPE cells. 
6.4.4 Complement component C5a is the active priming agent in NHS.  
To identify the active priming agent in NHS, different complement components were inhibited 
during priming, and subsequent inflammasome activation by lipofuscin/blue light treatment 
was assessed again by means of IL-1β secretion and cell death in ARPE-19 cells (Fig. VI.4A, 
B) and pRPE cells (Fig. VI.4C, D). First, we inactivated all complement components in NHS 
by heating. We found that the priming effect of NHS was completely suppressed after heat 
inactivation, suggesting that heat-labile serum components such as complement components 
mediate inflammasome priming by NHS. To further delineate the responsible complement 
component in NHS, cells were treated with a C5aR inhibitor during priming with NHS with 
resulted in a significant reduction of the priming effect. Likewise, depletion of C5 prevented 
the priming effect of NHS. Supplementation with recombinant C5a resulted in complete 
restoration of the priming capacity of C5-depleted NHS. To confirm that the observed IL-1β 
secretion is indeed a result of inflammasome priming we analyzed the induction of pro-IL-1β 
protein expression that represents a key element of inflammasome priming. In agreement 
with our results regarding IL-1β secretion, pro-IL-1β protein expression in ARPE-19 cells was 
strongly induced by incubation with IL-1α, NHS, or C5a as compared with control cells 
incubated with heat-inactivated NHS or C5-depleted NHS (Fig. VI.5). As previous studies 
demonstrated that ARPE-19 cells, unlike other cell types, constitutively express NLRP3 even 
in unprimed conditions and do not induce NLRP3 expression after priming185 we did not 
include NLRP3 in this analysis. In summary, our results identify the complement component 
C5a as the active priming agent in NHS and demonstrate that C5a is capable of priming 
human RPE cells for inflammasome activation by lipofuscin-mediated photooxidative 
damage. 
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Figure VI.3: NHS primes RPE cells for inflammasome activation by lipofuscin-mediated photooxidative 
damage. ARPE-19 cells (A, B) and pRPE cells (C, D) were incubated with unmodified POS (POS) or HNE-modified 
POS (HNE) to induce lipofuscinogenesis whereas control cells were incubated without POS (Co.). Lipofuscin-
loaded cells were primed for inflammasome activation by treatment with IL-1, complement-competent normal 
human serum (NHS), NHS, and caspase-1 inhibitor Z-YVAD-FMK, or NHS and cathepsin B inhibitor CA-074. 
Subsequently, inflammasome activation was induced by cell irradiation with blue light for 3 or 6 h. 
Inflammasome activation under these experimental conditions was measured by means of inflammasome-
regulated secretion of IL-1 (A, C) and inflammasome-induced cytotoxicity (LDH release) (B, D). Experiments 
were performed in duplicates (A, C) following the assay manufacturer’s recommendation or in triplicates (B, D), 
and results are presented as mean S.D. 
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6.4.5 Inflammasome priming in RPE cells is enhanced by a paracrine amplification 
loop. 
Inflammasome priming involves induction of IL-1β expression, and IL-1β is known to induce 
ist own expression by an auto-/paracrine amplification loop.288,289 Therefore, we investigated 
whether inflammasome activation in RPE cells results in paracrine priming of the 
inflammasome in neighboring RPE cells. To test for this, we performed priming experiments 
with conditioned media of cells following inflammasome activation. First, ARPE-19 cells were 
incubated with HNE-POS to induce lipofuscin accumulation, primed with IL-1α, and 
subsequently irradiated with blue light to trigger inflammasome activation as described 
above. As a positive control, inflammasome activation was induced in ARPE-19 cells by IL-
1α priming and subsequent treatment with Leu-Leu-OMe185 We confirmed that 
inflammasome activation resulted in a significant induction of IL-1β secretion in both 
treatment groups (Fig. VI.6A). Conditioned media of lipofuscin/blue lighttreated and Leu-Leu-
OMe-treated RPE cells were collected for further priming experiments. In a second step, 
new, untreated ARPE-19 cells were loaded with lipofuscin by HNE-POS treatment, incubated 
with the collected conditioned media for 48 h, thoroughly washed to remove any IL-1β 
contained in the conditioned media, and irradiated with blue light. Subsequently, 
inflammasome activation was assessed by measuring IL-1β secretion. In these experiments, 
conditioned media derived from both lipofuscin/blue light-treated and LeuLeu-OMe-treated 
cells exerted a strong priming effect that enabled inflammasome activation (Fig. VI.6B). 
However, when cells were coincubated with the IL1R-inhibitory drug anakinra during priming 
with conditioned media from lipofuscin/blue light-treated cells, the priming effect was 
significantly reduced (p=0.020). This indicates that the priming effect of conditioned media is 
mediated by an IL1R ligand such as IL-1β. Indeed, incubation of RPE cells with recombinant 
IL-1β alone instead of conditioned media likewise resulted in a strong priming effect. 
Additional analysis of inflammasome priming by means of pro-IL-1β protein expression 
produces results consistent with IL-1β secretion measurements (Fig. VI.6C). As described 
above, conditioned media were collected from ARPE- 19 cells following priming with IL-1α, 
treatment with HNE-POS, and irradiation with blue light. Incubation of new, untreated ARPE-
19 cells with the conditioned media resulted in marked induction of pro-IL-1β protein 
expression as compared with unprimed control cells incubated with unconditioned media. 
The induction of pro-IL-1β was partially suppressed when cells were co-incubate with the 
IL1R inhibitor anakinra during priming.  
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Figure VI.4: Complement component C5a is the active priming agent in NHS. ARPE-19 cells (A,B) and pRPE 
cells (C,D) were examined. Treatment groups and labels are identical to Fig. VI.3. However, inflammasome 
priming in this experiment was performed by incubation with complement-competent normal human serum 
(NHS), heat-inactivated human serum (HI-NHS), NHS and a C5aR inhibitory antibody, C5-deficient NHS, or C5-
deficient NHS and recombinant human C5a. Inflammasome activation was assessed be means of secretion of 
IL-1 (A,C) and cytotoxicity (B,D). Experiments were performed in duplicates (A,C) following the assay 
manufacturer’s recommendation or in triplicates (B,D), and results are presented as mean S.D. 
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Together, these results indicate that during inflammasome activation in RPE cells in vitro, 
inflammasome-regulated cytokines such as IL-1β initiate a paracrine amplification loop of 
inflammasome priming that is amendable to intervention by IL1R-inhibitory drugs.  
 
 
6.5 Discussion  
Blue light irradiation of RPE cells in the presence of oxygen results in generation of reactive 
oxygen species in a lipofuscindependent manner.277 and subsequent permeabilisation of 
lysosomal membranes by oxidative damage.96,97 We have previously shown that lysosomal 
membrane permeabilisation by lipofuscin-mediated photooxidative damage activates the 
NLRP3 inflammasome in primed RPE cells.254,280 This mechanism may underlie the 
inflammasome activation observed in the RPE of AMD patients.185,232 and may contribute to 
RPE pathology in this disease. Activation of the NLRP3 inflammasome is a 
posttranscriptionally regulated event mediated by assembly of inflammasome components 
and subsequent proteolytic maturation of interleukin precursors. In most cells, however, 
inflammasome component NLRP3 and interleukin precursor proIL-1 are not expressed 
constitutively or only to low amounts. Therefore, inflammasome activation requires a prior 
priming signal to induce expression of these proteins. Most previous studies including our 
own investigated the mechanisms of inflammasome activation in RPE cells by utilizing well-
established priming agents such as LPS and IL-1α.185,235,236,254,280 However, the relevance of 
these substances as priming agents of the RPE in vivo in the context of AMD is unclear. We 
therefore investigate activated complement components as potential priming agents in RPE 
cells. Chronic complement activation is associated with AMD, and activated complement 
components like C3a and C5a are deposited in the sub-RPE space in AMD.149 Thus, RPE 
cells are in constant, direct contact with these bioactive substances that, therefore, represent 
candidates for the inflammasome priming signal in AMD via anaphylatoxin receptors such as 
C5aR that is expressed on the basolateral side of the RPE.286 Indeed, AMD patients with the 
CFH risk genotype exhibit significantly increased systemic levels of the 
inflammasomeregulated cytokine IL-18 as compared with AMD patients without the CFH risk 
genotype, supporting a role for activated complement components in inflammasome 
activation in AMD.261 In other autoinflammatory diseases such as atherosclerosis and gout, 
inflammasome priming by complement activation products has likewise been proposed.281,282 
To elucidate the role of complement activation products in inflammasome activation in AMD, 
we studied the capacity of activated complement components to provide the priming signal in  
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Figure VI.5: Priming by C5a induces expression of pro-IL-1β protein. Expression of pro-IL-1β protein (36 kDa) 
was assessed in ARPE-19 cells following priming with IL-1α, complement-competent normal human serum 
(NHS), recombinant human C5a, heat inactivated human serum (HI-NHS), or C5-deficient NHS. 
 
human RPE cells for subsequent NLRP3 inflammasome activation by lipofuscin-mediated 
photooxidative damage. Our experiments were performed in the human RPE cell line ARPE-
19 and primary fetal human RPE cells. In both cell types be detected constitutive expression 
of the anaphylatoxin receptors C5aR, C3aR, and C5L2. Employing inflammasome-regulated 
IL-1β secretion and inflammasome-mediated pyroptotic cell death as measures for 
inflammasome activation, we demonstrated distinct priming effects for activated complement 
in human serum as well as for recombinant C5a. Complement heatinactivation, C5 depletion, 
and C5a receptor inhibition suppressed the priming effect of human serum, indicating that 
C5a represents the active priming agent in complement-activated human serum. Priming by 
C5a enabled subsequent inflammasome activation by lipofuscin-mediated photooxidative 
damage. Inflammasome activation was dependent on activity of caspase-1 and cathepsin B. 
Unlike the priming signal, complement-activated serum and C5a were found to be unable to 
provide the activation signal and, thus, to directly induce inflammasome activation in RPE 
cells which is consistent with previous reports.290 Proteins covalently modified with the lipid 
peroxidation product carboxy-ethylpyrrole (CEP) have been reported to prime the NLRP3 
inflammasome via TLR2.233 However, subsequent reports have questioned the priming ability 
of CEP-adducted proteins and rather found it to potentiate inflammasome priming by other 
signals.291 In our experiments, we did not observe a priming effect of HNE-adducted POS in 
RPE cells. For example, inflammasome activation was not inducible in cells incubated with 
HNE-POS alone (Fig. VI.3, unprimed group) but only in cells co-incubated with the priming 
agent IL-1α (Fig. VI.3, IL-1α group). In similar experiments, we determined that POS 
modified by malondialdehyde (MDA) likewise did not induce inflammasome priming in RPE 
cells (data not shown). Thus, proteins modified by the lipid peroxidation products HNE and 
MDA do not seem to represent inflammasome priming signals for the RPE. While 
immunological and inflammatory processes are usually believed to contribute to AMD 
pathogenesis in a detrimental way, the role of inflammasome activation in AMD is still 
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controversial and may vary depending on disease stage and subtype. Inflammasome 
activation in retinal microglial cells and macrophages has been suggested to reduce 
choroidal neovascularization via IL-18 and thus to be protective in neovascular AMD.233,292 In 
contrast, inflammasome activation in RPE cells has been reported to result in RPE 
degeneration which may contribute to the development of atrophic AMD.232,293 While patients 
with neovascular AMD can be effectively treated with VEGF blocking drugs, no effective 
therapeutic options are currently available for atrophic AMD. Therefore, the unmed need for 
identification of potential pharmaceutical targets in atrophic AMD is of crucial importance for 
clinical ophthalmology. Inhibitors of C5 and C5a as well as of complement components 
upstream of C5a generation such as CFD and C3 are currently evaluated in clinical studies 
in patients with AMD. In our study, inhibition of the C5a/C5aR axis reduced inflammasome 
activation by lipofuscin phototoxicity in RPE cells.  
 
 
 
Figure VI.6: Inflammasome priming in RPE cells is enhanced by a paracrine amplification loop. A, 
inflammasome activation was induced in IL-1-α primed ARPE-19 cells by HNE-POS/blue light treatment or 
incubation with Leu-Leu-OMe. Cells treated with HNE-POS but without blue light irradiation served as controls. 
Conditioned medium of these cells was collected. B, subsequently, new ARPE-19 cells were primed with 
conditioned medium of HNE-POS-treated control cells, conditioned medium of HNE-POS/blue light-treated 
cells, conditioned medium of HNE-POS/blue light-treated cells, and the IL1R inhibitory drug anakinra, 
conditioned medium of Leu-Leu-OMe-treated cells or recombinant human IL-1β. Inflammasome activation in 
all treatment groups was induced by HNE-POS/blue light treatment and analyzed by means of IL-1 secretion. C, 
expression of pro-IL-1β protein (36 kDa) was assessed in ARPE-19 cells following priming with either 
conditioned medium of HNE-POS/blue light-treated cells or conditioned medium of HNE-POS/blue light-treated 
cells and co-incubation with the IL1R inhibitor anakinra, as well as in unprimed control cells. Experiments (A, B) 
were performed in duplicates following the assay manufacturer’s recommendation, and results are presented 
as mean  S.D. 
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This result supports the rational for therapeutic complement inhibition in atrophic AMD. 
Moreover, our results suggest the presence of a paracrine amplification loop of 
inflammasome priming in RPE cells via IL1R. Treatment by the IL1Rinhibitory drug anakinra 
significantly reduced inflammasome activation in our in vitro experiments, thus providing 
another potential treatment strategy. Finally, direct therapeutic interference with 
inflammasome activation has been demonstrated to be effective in vivo, for example using 
small molecules that provide specific inhibition of NLRP3,294 and could be tested in future 
clinical trials for AMD. In summary, our study identifies complement component C5a as a 
priming agent for the inflammasome in RPE cells that enables subsequent NLRP3 
inflammasome activation by stimuli such as lipofuscin-mediated photooxidative damage. This 
molecular pathway links hallmark events of AMD pathogenesis including complement 
activation, lipofuscin accumulation, oxidative damage, and RPE degeneration and may 
provide novel treatment targets. Inflammasome-inhibiting therapeutics may serve as a 
potential future means of prevention and treatment of atrophic AMD. 
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7.1 Abstract  
Progressive death of retinal pigment epithelium (RPE) cells is a hallmark of age-related 
macular degeneration (AMD), the leading cause of blindness in all developed countries. 
Photooxidative damage and activation of the NLRP3 inflammasome have been suggested as 
contributing factors to this process. We investigated the effects of inflammasome activation 
on oxidative damage-induced RPE cell death. In primary human RPE cells and ARPE-19 
cells, lipofuscin accumulated following incubation with oxidatively modified photoreceptor 
outer segments. Oxidative stress was induced by blue light irradiation (dominant wavelength: 
448 nm, irradiance: 0.8 mW/cm2, duration: 3 to 6 h) of lipofuscin-loaded cells and resulted in 
cell death by apoptosis. Prior inflammasome priming by IL-1α or complement activation 
product C5a altered the cell death mechanism to pyroptosis and resulted in a significant 
increase of the phototoxic effect. Following IL-1α priming, viability 24 h after irradiation was 
reduced in primary RPE cells and ARPE-19 cells from 65.3% and 56.7% to 22.6% (p = 
0.003) and 5.1% (p = 0.0002), respectively. Inflammasome-mediated IL-1β release occurred 
only in association with pyroptotic cell lysis. Inflammasome priming by conditioned media of 
pyroptotic cells likewise increased cell death. Suppression of inflammasome activation by 
inhibition of caspase-1 or cathepsins B and L significantly reduced cell death in primed cells. 
In summary, inflammasome priming by IL-1α, C5a, or conditioned media of pyroptotic cells 
increases RPE cell susceptibility to photooxidative damage-mediated cell death and changes 
the mechanism of induced cell death from apoptosis to pyroptosis. This process may 
contribute to RPE degeneration in AMD and provide new targets for intervention. 
 
 
7.2 Introduction  
Age-related macular degeneration (AMD) is the leading cause of blindness in all 
industrialized countries.230 For the late-stage atrophic form of the disease (geographic 
atrophy), there is currently no effective treatment available. Geographic atrophy secondary to 
AMD is characterized by progressive degeneration of the retinal pigment epithelium (RPE), 
resulting in corresponding secondary photoreceptor loss and visual impairment. The 
mechanism of RPE cell death in AMD has not yet been fully elucidated. Several lines of 
clinical and experimental evidence indicate that oxidative and lipofuscin-mediated 
photooxidative damage plays an important pathophysiological role.295 Recent studies 
suggest that the NLRP3 inflammasome also contributes to RPE cell death secondary to 
AMD.185,296 Indeed, NLRP3 inflammasome activation has been demonstrated in RPE cells 
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affected by AMD,185,232 and increased intravitreal and systemic levels of the inflammasome 
activation products IL-1β and IL-18 have been reported in AMD patients.252,253 We have 
identified a mechanism that links oxidative/photooxidative damage and inflammasome 
activation in RPE cells by demonstrating that lipofuscin phototoxicity results in oxidative 
damage to lysosomal membranes with subsequent cytosolic leakage of lysosomal enzymes 
and activation of the NLRP3 inflammasome.254 Inflammasome activation in RPE cells 
requires a prior priming signal that can be provided by complement activation product C5a.297 
Inflammasome activation can be accompanied by pyroptosis, a recently described type of 
programmed cell death that is distinct from other cell death mechanisms including apoptosis 
and necrosis. Pyroptosis is characterized by a combination of several features including 
caspase-1 dependence, DNA fragmentation, rapid loss of cell membrane integrity, and 
inflammatory cytokine release.298 Against the background of the interrelations between 
oxidative damage, inflammasome activation, and RPE cell death, we sought to elucidate the 
effects of inflammasome priming on mechanism and extent of photooxidative damage-
induced cytotoxicity in RPE cells. 
 
 
7.3 Methods 
7.3.1 Cell culture 
Human fetal primary RPE (pRPE) cells (Clonetics H-RPE; Lonza, Cologne, Germany) were 
cultured in medium provided by the manufacturer (Clonetics RtEGM; Lonza) containing 2% 
heat-inactivated fetal bovine serum and were used in experiments for a maximum of 6 cell 
culture passages. The spontaneously immortalized, non-transformed human RPE cell line 
ARPE-19 (CRL-2302; ATCC, Rockville, MD, USA) was maintained in a 1:1 mixture of 
Dulbecco's modified Eagle's medium (DMEM) and Ham's F-12 medium (PAN-Biotech, 
Aidenbach, Germany) containing 2.5 mM L-glutamine, 1.0 mM sodium pyruvate, and 17.5 
mM D-glucose, and supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin, and 10% 
heat-inactivated fetal bovine serum (Gibco/Thermo Fisher Scientific, Karlsruhe, Germany) at 
37 °C in a humidified atmosphere of 5% CO2 in air. 
7.3.2 Induction of photooxidative damage 
Lipofuscin-mediated photooxidative damage was induced in RPE cells using experimental 
conditions described previously in detail.254 Briefly, isolated porcine POS were covalently 
modified with the lipid peroxidation product 4-hydroxynonenal (HNE) at a concentration of 5 
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mM at room temperature over night to stabilize them against lysosomal degradation.241 
These treatment parameters result in a modification of 48 nmol/mg protein as previously 
determined by HNE-specific ELISA299 and were chosen to correspond to the range of 
carbonyl modifications detected in aged human cells in vivo300 as data for human POS in vivo 
is not yet available. RPE cells were incubated with modified POS (concentration equivalent 
to 4 mg total POS protein per cm² cell growth area) daily for 7 days, resulting in 
lipofuscinogenesis.237 Subsequently, cells were irradiated with blue light (dominant wave 
length, 448 nm; irradiance, 0.8 mW/cm2) as described previously.254 In all experiments, 
duration of irradiation was 3 h for pRPE cells and 6 h for ARPE-19 cells. 
7.3.3 L-Leucyl-leucine-methyl Ester (Leu-Leu-OMe) Treatment 
L-Leucyl-leucine-methyl ester (Leu-Leu-OMe) induces lysosomal membrane 
permeabilization (LMP) and inflammasome activation in RPE cells similar to lipofuscin 
phototoxicity.185,280 We treated cells with 1 mM Leu-Leu-OMe (Bachem, Bubendorf, 
Switzerland) for 3 h. 
7.3.4 Inflammasome priming 
Cells were primed with 4 ng/ml recombinant human IL-1α (R&D Systems, Wiesbaden, 
Germany), 50 ng/ml recombinant human C5a (R&D Systems), or 50 pg/ml recombinant 
human IL-1β (R&D Systems) for 48 h prior to irradiation or Leu-Leu-OMe treatment. 
7.3.5 Cell death detection assay 
To quantify cell death, we analyzed loss of plasma membrane integrity by means of lactate 
dehydrogenase (LDH) release into the media using a calorimetric assay (Cytotoxicity 
Detection Kit; Roche, Mannheim, Germany) according to the manufacturer's instructions. We 
expressed the assay results as percentage of total cellular viability. For this, LDH release 
was measured in cells lysed by 1% Triton X-100 and in untreated control cells, and the 
results were set as 0% and 100% cellular viability, respectively. 
7.3.6 Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) 
DNA strand breaks were demonstrated by terminal deoxynucleotidyl transferase-mediated 
dUTP nick end labeling (TUNEL) assay (TdT in Situ Apoptosis Detection Kit – DAB; R&D 
Systems, Wiesbaden, Germany) following the manufacturer's recommendations. For this, 
cells were fixed with 4% PFA, permeabilized with 0.1% Triton X-100, and incubated with 
TUNEL enzyme and labeling solution for one hour at 37 °C in the dark. 
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7.3.7 Annexin V-FITC and propidium iodide (PI) labeling 
Phosphatidylserine exposure and loss of membrane integrity was assessed simultaneous by 
labeling with FITC-coupled annexin V and propidium iodide (PI) (FITC Annexin V Apoptosis 
Detection Kit; Biolegend, Fell, Germany). Labeling was quantified by flow cytometry (FACS 
Canto II; BD Biosciences, Heidelberg, Germany). 
7.3.8 ELISA detection of IL-1β 
Secretion of IL-1β into the media was measured by specific ELISA (BD OptEIA Human IL-1β 
ELISA Kit II; BD Biosciences, Heidelberg, Germany) according to the manufacturer's 
instructions. 
7.3.9 Priming with conditioned media 
Inflammasome activation was induced by HNE-POS incubation, IL-1α priming, and blue light 
irradiation as described above. Before start of irradiation, cells were thoroughly washed to 
remove IL-1α and medium was changed. Immediately after the 6 h of irradiation, conditioned 
media were collected. New, treatment-naive cells were primed with the conditioned media for 
48 h. For inhibition of the IL-1 receptor (IL1R), 100 ng/ml anakinra (Kineret; Swedish Orphan 
Biovitrum, Langen, Germany) was added to conditioned media in the indicated groups. 
7.3.10 Inflammasome inhibition 
For inhibition of caspase-1, we applied 10 μM of the caspase-1, -4, and -5 inhibitor Z-YVAD-
FMK (BioVision, Munich, Germany) 30 min prior to and during irradiation. Cathepsin B 
inhibitor CA-074 (Merck/ Calbiochem, Darmstadt, Germany) and cathepsin B and L inhibitor 
ZFF-FMK (Merck/Calbiochem) were used at a concentration of 10 μM each for 1 h prior to 
and during irradiation treatment. 
7.3.11 Statistical analysis  
All LDH release assays were performed in triplets and all IL-1β ELISA experiments in 
doublets according to the assay manufacturers' recommendations. Results are presented as 
mean ± standard deviation. Statistical analyses were performed using two-tailed unpaired 
Student's t-test. Differences were considered statistically significant at p < 0.05. In all figures, 
significance levels as are indicated using ns for not significant, * for p < 0.05, ** for p < 0.01, 
and *** for p < 0.001. 
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7.4 Results 
7.4.1 Inflammasome priming increase cell death by lipofuscin phototoxicity 
The cell culture model used in this study was characterized previously in detail. Briefly, we 
demonstrated in pRPE cells and ARPE-19 cells that incubation with HNE-modified POS 
induces lipofuscin accumulation80,237 and that subsequent blue light irradiation results in 
photooxidative damage to lysosomal membranes and cell death.254 Substances such as IL-
1α or C5a represent priming signals for the inflammasome in RPE cells that induce 
expression of pro-IL-1β.185,297 In primed RPE cells, LMP by photooxidative damage results in 
activation of the NLRP3 inflammasome with release of IL-1β and IL-18.254,301 To investigate 
the effect of inflammasome priming on the extent of photooxidative damage-induced RPE 
cell death, we analyzed the timecourse of cell death-associated loss of plasma membrane 
integrity (LDH release) over 48 h in ARPE-19 cells treated by 6 h of irradiation (Fig. VII.1A) 
and pRPE cells irradiated for 3 h (Fig. VII.1B). At the beginning of the timecourse, all 
treatment groups exhibited full viability, including the HNEPOS group that had received 7 
days of HNE-POS treatment prior to the start of the experiment and the C5a and IL-1α 
groups that had been exposed to the respective substance for 48 h preceding the 
experiment. This indicates that none of these treatments alone had an effect on cell viability 
without irradiation. Likewise, irradiation alone did not significantly affect cell viability in 
lipofuscin-free unprimed control cells. Irradiation of lipofuscin-loaded unprimed cells, 
however, resulted in a significant reduction of cell viability. The measured loss of plasma 
membrane integrity occurred delayed with a peak between 12 and 24 h after the start of 
irradiation. Priming with either IL-1α or C5a prior to irradiation significantly altered the time 
course of induced cell death. Primed cells responded to irradiation with rapid cell lysis that 
was most pronounced within the first 6 h after the start of irradiation. More importantly, the 
extent of cell death was also affected by inflammasome priming with priming resulting in a 
significant amplification of the observed phototoxic effect. E.g. viability measured in 
lipofuscin-loaded ARPE-19 cells 24 h after the start of the 6 h irradiation treatment was 
reduced from 56.7% in unprimed cells to 28.3% in C5a-primed cells (p = 0.008) and 5.1% in 
IL-1α-primed cells (p = 0.0002; Fig. VII.1A). Similarly, priming by C5a and IL-1α reduced 
viability in lipofuscin-loaded pRPE cells 24 h after the start of the 3 h irradiation from 65.3% 
to 33.1% (p = 0.004) and 22.6% (p = 0.003), respectively (Fig. VII.1B). We have previously 
demonstrated that inflammasome-induced IL-1β release is stronger following IL-1α priming 
compared to C5a priming,254 possibly due to a stronger effect of IL-1α on the induction of 
inflammasome components such as pro-IL-1β. Our current observation that inflammasome- 
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Figure VII.1: Inflammasome priming increases cell death by lipofuscin phototoxicity. Inflammasome priming 
increases cell death by lipofuscin phototoxicity. (A) ARPE-19 cells and (B) pRPE cells were incubated with HNE-
POS to induce lipofuscin accumulation or were incubated without POS. In addition, cells were primed for 
inflammasome activation by C5a or IL-1α or left unprimed. Subsequently, all treatment groups were irradiated 
with blue light for 6 h (ARPE-19) or 3 h (pRPE). The time-course of cellular viability was assessed by means of 
LDH release over 48 h after the start of irradiation treatment. Significance levels for primed cells as compared 
to the unprimed HNE-POS group are indicated p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***). 
 
mediated cytotoxicity is more pronounced following IL-1α priming compared to C5a priming is 
consistent with these previous results. The finding that priming increased the cytotoxic effect 
of irradiation even in cells without lipofuscin-loading by HNE-POS incubation may be due to 
the accumulation of autophagy-derived lipofuscin as previously described.254,302 In summary, 
our results suggest that inflammasome priming by substances such as C5a or IL-1α increase 
the susceptibility of RPE cells to photooxidative damage-mediated cell death. 
7.4.2 Inflammasome priming changes mechanism of lipofuscin phototoxicity-induced 
cell death from apoptosis to pyroptosis 
The differences between unprimed and primed cells in the time course of cell lysis suggest 
different underlying mechanisms of cell death. To delineate the predominant mechanism of 
cell death in each group, we analyzed additional features of cell death following lipofuscin 
loading and light irradiation (Fig. VII.2). Morphological investigations by light microscopy 
demonstrated the occurrence of plasma membrane blebbing and cell shrinkage in unprimed 
irradiated cells whereas primed cells exhibited early cell swelling after irradiation (Fig. 
VII.2A). Analysis of DNA fragmentation by TUNEL assay revealed a progressive increase in 
TUNEL staining over 24 h after irradiation in unprimed cells (Fig. VII.2B). Primed cells 
likewise exhibited positive TUNEL labeling that, however, was already detectable 
immediately after irradiation. In flow cytometric analysis of cells double-labelled with annexin  
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Fig. VII.2 Inflammasome priming changes the mechanism of lipofuscin phototoxicity-induced cell death from 
apoptosis to pyroptosis. (A) Differences in cell death morphology between unprimed and IL-1α-primed ARPE-
19 cells following HNE-POS/light treatment were assessed by light microscopy. Images of unprimed cells 
demonstrate plasma membrane blebbing (arrowheads) suggestive of apoptosis. In contrast, IL-1α-primed cells 
exhibited early cell swelling (arrowheads). Scale bars represent 100 μm (upper row) and 50 μm (lower row). (B) 
DNA degradation/ fragmentation was analyzed by TUNEL labeling in unprimed and IL-1α-primed ARPE-19 cells 
at different time points after start of irradiation. DNA fragmentation was detectable in both unprimed and IL-
1α-primed cells but occurred earlier in primed cells. Scale bars represent 100 μm. (C) Flow cytometry was 
employed to assess annexin V-FITC and PI staining in unprimed and IL-1α-primed ARPE-19 cells immediately 
following irradiation. 
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V-FITC and PI to differentiate healthy (FITC−/PI−), apoptotic (FITC+/PI−) and 
necrotic/pyroptotic (FITC+/PI+) cells, the majority of unprimed irradiated cells were apoptotic 
whereas primed irradiated cells were predominantly necrotic/pyroptotic (Fig. VII.2C). In 
addition to these findings, we previously demonstrated that HNE-POS/blue light treatment of 
IL-1α primed RPE cells as employed in this study results in caspase-1 activation254 and that 
the treatment induces release of IL-1β and IL-18 in both IL-1α primed and C5a primed but 
not in unprimed RPE cells.301 In summary, unprimed cells exhibited delayed cell lysis, plasma 
membrane blebbing and cell shrinkage, TUNEL-positive DNA fragmentation, predominantly 
annexin V-positive/PI-negative cell staining, and lack of IL-1β and IL-18 release. In contrast, 
primed cells demonstrated cell swelling and early cell lysis, TUNEL-positive DNA 
degradation, predominantly PI-positive cell staining, caspase-1 activation, and release of IL-
1β and IL-18. These combinations of features identify the cell death in unprimed and primed 
cells as apoptosis and pyroptosis, respectively.303 Thus, our results reveal that 
inflammasome priming changes the predominant cell death mechanism induced by 
photooxidative damage in RPE cells from apoptosis to pyroptosis. 
7.4.3 Interleukin-1β release secondary to LMP is closely associated with pyroptotic 
cell lysis  
IL-1β can be released passively during pyroptotic cell lysis (terminal release) as well as by 
active processes not requiring cell death, with the predominant mechanism of release 
depending on cell type and stimulus type and strength.304,305 Elucidating the association of 
inflammasome-mediated IL-1β release and cell death in RPE cells may help to understand 
the role of RPE inflammasome activation in different disease stages of AMD. To determine 
whether IL-1β release by RPE cells secondary to LMP-induced inflammasome activation can 
occur independent of pyroptosis, we simultaneously measured release of IL-1β and LDH in 
cells exposed to increasing durations of lipofuscin/light treatment, increasing durations of the 
chemical LMP-inducer Leu-LeuOMe, or increasing concentrations of Leu-Leu-OMe (Fig. 
VII.3). In all experimental conditions tested, significantly increased IL-1β release was 
detectable only in association with significant LDH release but never without it. This finding 
suggests that at least in our experimental setting, IL-1β release by RPE cells secondary to 
LMP occurs in association with pyroptotic cell lysis, suggesting terminal release of IL-1β as 
the predominant mechanism. 
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Fig. VII.3 Interleukin-1β release secondary to LMP is closely associated with pyroptotic cell lysis. (A) HNE-POS-
treated ARPE-19 cells were primed with IL-1α and irradiated with blue light for increasing durations to induce 
LMP. Alternatively, LMP was induced by treatment of IL-1α-primed ARPE-19 cells with (B) increasing incubation 
times of Leu-Leu-OMe at a concentration of 1 mM or with (C) increasing concentrations of Leu-Leu-OMe for an 
incubation time of 3 h. In all experiments, simultaneous analysis of IL-1β release and cell lysis assessed by LDH 
release was performed. Significance levels compared to the respective untreated control groups are indicated 
as not significant (ns), p b 0.05 (*), p b 0.01 (**), and p b 0.001 (***). 
 
7.4.4 Priming by conditioned media of inflammasome-activated RPE cells increases 
cell death by lipofuscin phototoxicity 
Similar to IL-1α, the inflammasome-regulated cytokine IL-1β can itself induce inflammasome 
priming via the IL-1 receptor and thus initiate a paracrine amplification loop of inflammasome 
activation.288,289,297 We therefore sought to investigate whether cytokine release of RPE cells 
following inflammasome activation increases the susceptibility of neighboring RPE cells to 
photooxidative damage-mediated cell death. For this, we assessed the cytotoxic effect of 
lipofuscin/light treatment in RPE cells after priming with conditioned media of inflammasome-
activated RPE cells (Fig. VII.4). Incubation with conditioned media for 48 h did not itself affect 
cell viability as indicated by the full viability of all treatment groups measured at the beginning  
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Fig. VII.4: Priming by conditioned media of inflammasome-activated RPE cells increases cell death by 
lipofuscin phototoxicity. ARPE-19 cells were incubated with HNE-POS and primed with conditioned media that 
had been collected from IL-1α-primed ARPE-19 cells treated by HNE-POS without irradiation (HNE-POS/0 h 
light) and by HNE-POS and 6 hour irradiation (HNE-POS/6 h light). In control experiments, the IL1R inhibitor 
anakinra was added during priming with conditioned media from HNE-POS/lighttreated cells (HNE-POS/6 h 
light + IL1R inhibitor), or cells were primed with recombinant human IL-1β instead of conditioned media (IL-1β). 
Following priming, all treatment groups as well as an untreated, unprimed control group (Control) were 
subjected to irradiation for 6 h, and the time-course of cellular viability was analyzed by LDH release assay over 
48 h after the start of irradiation. Significance levels of the HNEPOS/6 h light group as compared to the HNE-
POS/0 h light group are indicated as p < 0.01 (**), and p < 0.001 (***). 
 
of irradiation. After irradiation, cells primed with conditioned media of non-irradiated control 
cells demonstrated a delayed time course of cell death. In contrast, cells primed with 
conditioned media of irradiated cells exhibited rapid cell lysis, suggestive of pyroptosis. More 
importantly, the extend of cell death 48 h after irradiation was significantly increased in cells 
primed with conditioned media of irradiated cells as compared with cells primed with 
conditioned media of non-irradiated control cells (viability 45.0% vs. 15.7%, p = 0.0006). 
Inhibition of IL-1 receptor (IL1R) by the drug anakinra during priming completely prevented 
the effect of conditioned media on cytotoxicity whereas recombinant IL-1β had a priming 
effect similar to conditioned media of irradiated cells. These results suggest that cytokines 
such as IL-1β released by RPE cells after inflammasome activation increase the 
susceptibility of bystander RPE cells to photooxidative damage-induced cell death, possibly 
via their previously demonstrated IL1R-mediated priming effect.297 
7.4.5 Inhibition of Inflammasome activation reduces cell death by lipofuscin 
phototoxicity  
Inflammasome activation in RPE cells by photooxidative damage is dependent on lysosomal 
leakage of cathepsins and activation of caspase-1.254 To further delineate the mechanism by 
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which inflammasome  priming increased susceptibility to phototoxic cell death, we subjected 
ARPE-19 cells and pRPE cells to inhibition of cathepsin B/L and caspase-1 during irradiation 
(Fig. VII.5). As expected, apoptotic cell death of unprimed ARPE-19 cells was unaffected by 
cathepsin B or caspase-1 inhibition (Fig. VII.5A). In contrast, pyroptosis of primed ARPE-19 
cells was partially prevented by inhibition of cathepsin B/L or caspase-1 (Fig. VII.5B). 
Moreover, inhibitor treatment changed the time course of cell death in primed cells back 
towards a delayed type similar to that observed in unprimed cells. In pRPE cells, cathepsin 
B/L and caspase-1 inhibition yielded similar results (Fig. VII.5C and Fig. VII.1B). These 
findings demonstrate that the increased susceptibility of primed RPE cells to photooxidative 
cell death is dependent on activity of cathepsin B/L and caspase-1. 
 
 
Fig. VII.5: Inhibition of inflammasome activation reduces cell death by lipofuscin phototoxicity. (A) The time-
course of cell viability was measured in unprimed ARPE-19 cells over 48 h after the start of irradiation 
treatment without prior incubation with POS (Control) or after incubation with HNE-POS. For inhibition of 
caspase-1 and cathepsin B, cells were incubated with ZYVAD-FMK and CA-074, respectively, during irradiation. 
In addition, we analyzed the time-course of viability of (B) IL-1α-primed ARPE-19 cells and (C) IL-1α-primed 
pRPE cells following HNE-POS/light treatment and additional inhibition of caspase-1 and cathepsin B/L by Z-
YVAD-FMK and Z-FF-FMK, respectively. Significance levels of inhibitor-treated cells as compared to the 
respective HNE-POS groups without inhibitor treatment are indicated as not significant (ns), p b 0.05 (*), and p 
b 0.01 (**). 
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7.5 Discussion 
Blue light irradiation of RPE cells in vitro results in lipofuscin-dependent generation of 
reactive oxygen species,277 LMP by oxidative damage,96,97 and cell death.306 We have 
demonstrated that LMP by lipofuscin-mediated photooxidative damage not only results in 
oxidative-damage dependent cell death but also in activation of the NLRP3 inflammasome in 
primed RPE cells.254,297 This mechanism may underlie the inflammasome activation observed 
in the RPE of AMD patients185,232 and may contribute to the progressive RPE damage in 
AMD. Inflammasome activation by photooxidative damage-mediated LMP requires prior 
inflammasome priming that can be induced by substances such as IL-1α or the complement 
activation product C5a.185,297 In the absence of a priming signal, the mechanism of cell death 
secondary to oxidative or photooxidative damage-induced LMP has been identified as 
apoptosis in various cell types other than RPE.307,308 Our combined results of this and 
previous studies demonstrate that LMP-induced cell death in RPE cells likewise occurs by 
apoptosis as characterized by cell membrane blebbing, late loss of cell membrane integrity, 
lack of IL-1β and IL-18 release,301 annexin V-positive/PI-negative staining, and positive 
TUNEL labeling. In contrast, cells exposed to the priming signals IL-1α or C5a prior to 
photooxidative damage-mediated LMP exhibit a distinctly different mechanism of cell death 
that we identified as pyroptosis by means of cell swelling, early loss of cell membrane 
integrity, caspase-1 activation,254 IL-1β and IL-18 release,301 lack of annexin V-positive/PI-
negative staining, and positive TUNEL labeling. Importantly, inflammasome priming resulted 
not only in a different mechanism but also in a significantly higher extent of photooxidative 
cell death. This increased susceptibility to phototoxicity was reversible by treatment of RPE 
cells with inflammasome inhibitors such as caspase-1 inhibitor Z-YVAD-FMK and cathepsin 
B and L inhibitor Z-FFFMK. Evidence from genetic studies indicates an important role for 
complement activation in the pathogenesis of complex, multifactorial AMD. Activated 
complement components such as C5a are abundant both in the sub-RPE space and in 
plasma of AMD patients.149,231 Several inhibitors of C5 or complement components upstream 
of C5 activation such as CFD and C3 are currently under clinical investigation for their 
potential to prevent progressive RPE cell death in patients with GA secondary to AMD. We 
have previously shown that the C5 activation product C5a primes RPE cells for 
inflammasome activation.297 Here, we demonstrate that inflammasome priming by C5a 
increase the susceptibility of RPE cells to oxidative damage-mediated cell death. Thus, our 
results support the rational for therapeutic complement inhibition in atrophic AMD. In 
addition, agents with direct inhibitory effects on inflammasome activation such as small 
 Inflammasome affects cell death in RPE cells 
 
90 
 
molecule NLRP3 inhibitors have been shown to be effective in vivo and, thus, represent 
interesting candidates for future interventional approaches in atrophic AMD.294 IL-1β induces 
expression of its own precursor pro-IL-1β via IL1R.288,289 We previously reported that 
conditioned media of RPE cells collected following inflammasome-mediated IL-1β release 
induces IL1R-dependent inflammasome priming in other RPE cells, thus providing a 
paracrine amplification loop of inflammasome activation.297 Consistently, our current results 
indicate that conditioned media of pyroptotic RPE cells increase cell death by photooxidative 
damage in other RPE cells in an IL1R-dependent fashion. It is conceivable that in situations 
of localized RPE cell death such as in atrophic AMD, this mechanism could result in 
increased susceptibility of bystander RPE cells to inflammasome-mediated cell death and 
thus contribute to the progressive RPE cell loss in atrophic AMD. IL-1β is a major 
inflammatory effector cytokine of inflammasome activation. As IL-1β lacks a secretory signal 
sequence it is not secreted by conventional routes. Rather, its release occurs either actively 
from the living cell via e.g. secretory lysosomes, microvesicles, or exosomes or passively by 
cell lysis during cell death (terminal release).304,305 The prevailing mechanism can differ with 
cell type and stimulus type and strength. To elucidate the predominant mechanism of IL-1β 
release in RPE cells, we subjected RPE cells to increasing durations of lipofuscin/ light 
treatment or increasing concentrations and incubation times of Leu-Leu-OMe, a substance 
that induces inflammasome activation by LMP similar to lipofuscin phototoxicity.185,280 In 
these experiments, IL- 1β release occurred only in association with loss of cell membrane 
integrity as measured by LDH release. This suggests that in our experimental setting, IL-1β 
is released from the cell predominantly during cell death-associated loss of plasma 
membrane integrity rather than by active mechanisms of the living cells. As RPE cell death in 
AMD occurs mainly in late-stage disease, further elucidation of the mechanisms of IL-1β 
release in RPE cells in vivo will help to delineate the AMD stages in which inflammasome 
activation in the RPE may play a pathogenic role. In summary, we examined the 
mechanisms of photooxidative damage-induced cell death in pRPE cells and ARPE-19 cells 
and demonstrated that inflammasome priming by substances such as IL-1α and C5a not only 
changes the cell death mechanism from apoptosis to pyroptosis but also increases the cells' 
susceptibility to photooxidative damagemediated cytotoxicity. These results provide new 
insights into the complex interplay of complement system, inflammasome activation, 
oxidative damage, and RPE cell pathology in diseases such as AMD and suggest inhibition 
of inflammasome priming or activation as potential treatment strategies for atrophic AMD. 
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A key pathogenic factor in AMD is the chronic activation of the innate immune system in the 
sub-RPE space that is detectable by both a local deposition and increased systemic levels of 
activated complement components.149,231 A recent study examined AMD patients with the 
CFH risk genotype and demonstrated that patients showed increased systemic 
concentrations for the inflammasome-related cytokine IL-18, which represents a product of 
inflammasome activation.261 Additionally, NLRP3 inflammasome activation in RPE cells was 
demonstrated in both neovascular and atrophic AMD.185,232 These findings, among others, 
gave rise to the assumption that the inflammasome plays a role in the pathogenesis of AMD. 
The circumstances leading to NLRP3 inflammasome priming and activation in AMD 
pathogenesis are largely unknown. The NLRP3 inflammasome can be activated by a diverse 
range of substances.309 Many of these substances that activate NLRP3 in AMD destabilize 
the lysosomal membrane with subsequent cytosolic leakage of lysosomal 
components.126,199,201,310 This mechanism has also been detected to activate the 
inflammasome in RPE cells following chemical induction of LMP.185 The fact that 
photooxidative damage mediated by intralysosomal accumulation of photoreactive lipofuscin 
results in LMP in RPE cells represent an interesting approach for the study of inflammasome 
activation in the context of AMD.96,97 Thus, we were interested to examine the role of NLRP3 
inflammasome activation by oxidative/ photooxidative damage in human RPE cells as a 
potential link between hallmark pathogenic features in age-dependent macular degeneration. 
 
8.1 Cell culture model of lipofuscin induced photooxidative stress to study 
LMP 
Experimental cell culture models are a valuable tool for understanding pathology of the cell in 
human disease and discovering novel therapeutic targets and drugs. Different cell culture 
models for the in vitro study of lipofuscin effects in RPE cells have been described.246 As A2E 
has been considered as the major fluorophore of macular lipofuscin, A2E-loaded RPE cells 
were used as a model of lipofuscin phototoxicity in previous studies.97 However, owing to an 
inadequacy in correlation between lipofuscin fluorescence and the spatial distribution of A2E 
in the human RPE, the pivotal role of A2E in lipofuscin phototoxicity has been questioned,247 
resulting in a need for a new in vitro model of lipofuscin-photoreactivity for basic and 
therapeutic research investigations. Therefore, we established a new model of lipofuscin 
phototoxicity based on a system of endogenous lipofuscin generation from phagocytosed 
POS in human RPE cells.237 In our study, we employed the stable human RPE cell line 
ARPE-19, which arose spontaneously from a primary culture of RPE cells.311 Altough ARPE-
 General Discussion 
 
93 
 
19 cells are useful in a wide array of research, differences to parental cells may occur. 
Therefore, we confirmed the main findings by the use of human primary RPE cells. Primary 
cultures of RPE cells from various species have been shown to retain many normal 
physiological functions, including the ability to phagocytose rod outer segments.312,313 RPE 
cells were incubated for 7 days daily with porcine POS. As human POS were not available in 
sufficent quantities we relied on porcine POS that are likewise recognized by human 
phagocytosis receptors. Cellular lipofuscinogenesis was reinforced by HNE- or MDA-
modified POS, resulting in lysosomal dysfunction. Modification of retinal proteins with lipid 
peroxidation products such as HNE has been detected in vivo as a result of light irradiation 
and aging.314,315 To allow for biologically meaningful studies of lipid peroxidation effects in 
vitro, it is crucial that the employed levels of lipid peroxidation reflect the in vivo situation. 
During oxidative stress, tissue HNE concentrations were reported in the range of 1-20mM,68 
similar to the concentrations used in our experiments. Within or near oxidized lipid 
membranes, HNE concentrations are estimated to reach 100mM or even higher levels.68 The 
levels of POS protein modifications used in our cell culture were quantified previously80 and 
were chosen to correspond to the range of carbonyl modifications detected in human cells in 
vivo.248 Although our model means to simulate the in vivo situation in aged RPE cells, the 
composition of lipofuscin-like material that was generated in our model during 7 days of POS 
incubation probably differs from the composition of lipofuscin generated in RPE cells in vivo 
in a human lifetime. Nonetheless, blue light irradiation of RPE cells following lipofuscin 
loading induced photooxidative damage, LMP, and leakage of lysosomal enzymes into the 
cytosol. This is in accordance with RPE cells that were loaded with lipofuscin granules 
generated in human RPE in vivo.96 Therefore, our model of lipofuscin generation was 
appropriate to study blue light-induced photooxidative stress in human RPE cells, intensified 
by accumulated lipofuscin, and subsequent lysosomal membrane permeabilization.  
 
8.2 Inflammasome activation by blue light induced photooxidative damage 
Initially we were interested whether lipofuscin-phototoxicity induced LMP plays a role in 
NLRP3 inflammasome activation in RPE cells. For this, we established an in vitro model of 
blue light-induced photooxidative damage. Using this model, we demonstrated 
inflammasome activation by means of caspase-1 activation and secretion of the 
inflammasome-related cytokines IL-1β and IL-18. In addition, inflammasome activation was 
amplified by the photosensitizer lipofuscin, that accumulates in the RPE in vivo with age and 
has the highest concentration in the macula (chapter II). Secondary to light-induced LMP, we 
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detected leakage of lysosomal enzymes into the cytosol of RPE cells. Inhibition of the 
lysosomal proteases cathepsin B and L suppressed inflammasome activation associated 
with light-induced LMP. Similarly, previous studies demonstrated cathepsin dependent 
NLRP3 inflammasome activation secondary to silica crystal induced LMP in macrophages.126 
These results suggest a cytosolic substrate of cathepsin proteolytic activity as a critical 
component of NLRP3 inflammasome activation. However, the molecular mechanism by 
which cytosolic activity of cathepsins or other lysosomal enzymes induce inflammasome 
activation has not yet been resolved. Furthermore, our results from a NLRP3 siRNA 
knockdown experiment revealed that inflammasome activation secondary to lipofuscin 
phototoxicity in RPE cells is mediated by NLRP3 (chapter II). The importance of NLRP3 in 
AMD pathogenesis has been underlined by the observation of activated NLRP3 
inflammasome in the RPE of patients with atrophic and neovascular AMD.185,232 Thus, 
photooxidative damage by visible light could be attributed as a new mechanism of NLRP3 
inflammasome activation in human RPE cells in our model and therefore contribute to our 
understanding of light damage to the RPE. Moreover, this mechanism represents a novel 
molecular link between hallmark features of AMD pathogenesis such as photooxidative 
damage, innate immune response, and RPE cell dysfunction that may provide new 
therapeutic targets against for the blinding disease. 
 
8.3 Inflammasome priming by activated complement component C5a 
For the NLRP3 inflammasome to be activated in RPE cells, it must first be primed by 
activation of the transcription factor nuclear factor-κB (NF-κB) resulting in transcription of pro-
IL-1β and NLRP3. In many studies, NF-κB activation is induced by LPS or IL-1α prior to 
inflammasome activation.185,235,236,254,280 However, the relevance of these substances as 
priming agents of the RPE in vivo in the context of AMD is unclear. Observations of NLRP3 
being expressed in the RPE of eyes affected by advanced AMD but not in non-AMD affected 
control eyes suggests that molecular or cellular changes associated with the development of 
AMD mediate the pathological priming of the RPE. For this study we considered reports that 
demonstrated an association between CFH risk genotype and significantly increased plasma 
levels of the inflammasome-regulated cytokine IL-18, suggesting a role for activated 
complement components like C3a and C5a in inflammasome activation in AMD.261 Indeed, 
activated components of the complement system such as C3a and C5a are detectable both 
locally in the sub-RPE space and systemically in plasma of AMD patients.149,231 Thus, RPE 
cells are in constant, direct contact with these bioactive substances, which therefore 
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represent candidates for the inflammasome priming signal in AMD via anaphylatoxin 
receptors such as C5aR that is expressed on the basolateral side of the RPE.286 
Inflammasome priming by complement activation products has already been proposed in 
other autoinflammatory diseases such as atherosclerosis and gout.281,282 We therefore 
intended to investigate activated complement components as potential priming agents in 
RPE cells. The consecutive implementation of heat-inactivation of complement components, 
C5 depletion, and C5a receptor inhibition delineated C5a as the active priming agent in 
complement-activated human serum (chapter IV). Accordingly, inflammasome priming by 
C5a led to distinct expression of pro-IL-1β protein by ARPE-19 cells and enabled subsequent 
inflammasome activation by lipofuscin-mediated photooxidative damage. Again, 
inflammasome activation was dependent on activity of caspase-1 and cathepsin B. Our 
observations are in accordance with the results of a previous study that likewise reported a 
priming effect of C5a on RPE43 cells.316 A group led by Prof. Joanne A. Matsubara described 
a study that shows the activation of the NF-κB pathway in RPE in vitro by C5a stimulation,155 
highlighting the relevance of our prior published results in terms of activated complement 
components as RPE cell priming agents. With the constitutive expression of the 
anaphylatoxin receptors C5aR, C3aR and C5aL on the human RPE cell line ARPE-19 and 
primary fetal human RPE cells (chapter IV) it is of importance to understand the effects of 
C5a on RPE function.  
Considering our results, we concluded that activated comlement component C5a is capable 
of priming human RPE cells for NLRP3 inflammasome activation by stimuli such as 
lipofuscin-mediated photooxidative damage. This molecular pathway links hallmark events of 
AMD pathogenesis including complement activation, lipofuscin accumulation, oxidative 
damage, and RPE degeneration and may provide novel treatment targets. 
 
8.4 Consequences of NLRP3 inflammasome activation  
Following up on the investigation describing the mechanism of LMP-induced inflammasome 
activation induced by lipofuscin-mediated photooxidative damage in RPE cells, we were 
interested to elucidate the consequences of this mechanism, in particular with regard on 
pathologic processes in the outer retina.  
Initially, we addressed this question by analyzing the profile of cytokines that are secreted by 
RPE cells following inflammasome activation. Using a model of LMP-induced inflammasome 
activation that employs Leu-Leu-OMe for chemical destabilization of lysosomes,185 we 
revealed significant and caspase-1 dependent increase in inflammatory cytokines. In 
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particular, the secretion of the inflammasome-related cytokines IL-1β and IL-18 was 
predominantly directed towards the apical side of the RPE monolayer. This is in accordance 
with previous studies that likewise reported a predominantly apical secretion of inflammatory 
cytokines by RPE cells following induction by various stimuli.269–271 The apical side of RPE 
cell layer corresponds to the neuroretinal side of the normal retina in vivo. This polarized 
secretion raised the question whether cells of the neuroretina may be affected by activation 
of the inflammasome. Retinal cell populations that are most likely affected by apical secretion 
of cytokines include resident microglia cells and infiltrating macrophages. Activation of these 
cell types and their migration into the subretinal space has been observed in AMD patients 
and animal models and has been discussed as a factor contributing to AMD 
pathogenesis.35,272,273 Our results from a microglia chemotaxis experiment (chapter III) 
display a significant chemotactic effect of conditioned media from Leu-Leu-OMe–treated 
RPE cells on microglia cells, supporting a role of inflammasome-related cytokines in 
microglia recruitment during neovascular AMD. VEGF plays a crucial role in CNV formation 
in neovascular AMD, and inflammasome activation has been suggested to be involved in this 
process due to the effects of inflammasome-controlled cytokines on VEGF secretion and 
angiogenesis. However, the reports of the inflammasome-related effects in CNV formation 
are divergent. Doyle and coworkers233 elucidated that incubation with inflammasome-
regulated IL-18 reduces secretion of VEGF in RPE cells, suggesting a protective effect 
against CNV formation. In contrast, another inflammasome-regulated interleukin, IL-1β, has 
been shown to induce VEGF secretion in RPE cells259 and to promote laser-induced CNV 
formation in mice.255 In an attempt to elucidate the angiogenesis-related effects following 
LMP-induced inflammasome activation, we revealed reduced constitutive VEGF secretion by 
RPE cells following inflammasome activation. Conditioned media of RPE cells following 
inflammasome activation consistently reduced proliferation and migration of vascular 
endothelial cells compared to conditioned media of untreated control cells. In addition to the 
reduction in VEGF secretion, the released IL-18 may add to this effect due to its suggested 
antiangiogenic properties.233 While our experiments demonstrate reduced VEGF secretion by 
RPE cells following inflammasome activation, inflammatory cytokines released by RPE cells 
after inflammasome activation in vivo may exert indirect angiogenic effects via other cell 
types such as recruited microglia cells.35 There is now comprehensive evidence proving the 
involvement of immune cells in human neovascular AMD317–319 as well as experimental 
choroidal neovascularization.320–322 In contrast, histological studies demonstrate less immune 
cells in areas of geographic atrophy.323 However, an increasing number of studies indicate a 
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contribution of immune-mediated tissue damage in geographic atrophy, by suggesting 
inflammasome-mediated RPE degeneration as a driving force in geographic atrophy.185,232,236 
To further elucidate the consequences of LMP-induced inflammasome activation, we 
focussed on the effects of inflammasome priming on mechanism and extend of 
photooxidative damage-induced cytotoxicity in RPE cells. Morphological investigations 
indicate apoptosis as the prevailing cell death mechanism secondary to photooxidative 
damage-mediated LMP in the absence of an inflammasome priming signal, that was likewise 
demonstrated in other studies.307,308 However, inflammasome priming with IL-1α or C5a 
ahead of LMP-induced cell death in RPE cells changed the mechanism of cell death from 
apoptosis to pyroptosis (chapter V). Beside a change in cell death mechanism, an increased 
susceptibility to photooxidative cell damage was detected that was manifested by a 
significant higher extend of phototoxic cell death. This increase in susceptibility to 
photooxidative cell death was reversible by treatment of RPE cells with inflammasome 
inhibitors such as caspase-1 inhibitor Z-YVAD-FMK. Inflammasome activation leads to 
secretion of IL-1β, a proinflammatory cytokine that signals through its cognate receptor IL1R 
and is able to induce its own expression by an auto-/paracrine amplification loop.288,289 
Accordingly, the use of conditioned media, collected following inflammasome mediated IL-1β 
release was capable to prime cells for expression of pro-IL-1β protein (chapter IV) and 
enabled inflammasome activation via lipofuscin-induced photooxidative stress (chapter V). 
Inflammasome activation was significantly reduced by application of the IL1R-inhibitory drug 
anakinra, indicating a distinct amplification loop of inflammasome priming in our cell culture 
system that is mediated by an IL1R ligand such as IL-1β. Thus, cell priming by IL-1α or C5a 
not only changes the cell death mechanism from apoptosis to pyroptosis but also increases 
the susceptibility of the cells to photooxidative damage-mediated cytotoxicity (chapter V).  
 
8.5 Therapeutic prospects 
Elucidating the still unresolved pathogenesis of multifactorial, complex AMD will help to 
identify potential targets for therapeutic intervention. While patients with neovascular AMD 
can be effectively treated with VEGF blocking drugs, no effective therapeutic options are 
currently available for atrophic AMD. Incidence and prevalence of the disease are rising, due 
to demographic developments. Therefore, the unmed need for identification of potential 
pharmaceutical targets in atrophic and neovascular AMD is of crucial importance for clinical 
ophthalmology. My work outlined several pathways that appear to play a role in AMD 
pathogenesis and may be suitable for therapeutic interventions.  
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The inflammasome-related cytokines are likely to present therapeutic targets. The cytokine 
IL-18 has been reported to exert a direct cytotoxic effect on RPE cells in vivo,232 but systemic 
or intravitreal administration of physiologically relevant doses of recombinant IL-18 did not 
correlate with pathological effects on mouse RPE cells in vivo.292,325 Indeed, IL-18 
concentrations of up to 10 µg/mL did not induce any cytotoxic effect on RPE cells in vitro,292 
a concentration that is about five orders of magnitude higher than IL-18 concentrations 
measured in conditioned media in our experiments. It is possible that these cytokines are not 
directly responsible for RPE cell death in geographic atrophy but act on cells in an autocrine 
or paracrine fashion. For instance, IL-1β is known to induce its own expression by an auto-
/paracrine amplification loop.288,289 Similarly, our experiments demonstrated that during 
lipofuscin-photoreactivity induced inflammasome activation in RPE cells in vitro, 
inflammasome-regulated cytokines such as IL-1β initiate a paracrine amplification loop of 
inflammasome priming (chapter IV and V). It is conceivable that in situations of localized 
RPE cell death such as in atrophic AMD, this mechanism could result in increased 
susceptibility of immediate bystander RPE cells to inflammasome-mediated cell death, thus 
contributing to the centrifugal progression pattern of RPE cell loss in AMD. Application of the 
IL1R-inhibitory drug anakinra reduced both inflammasome-related cytokine secretion and cell 
death, providing the rational for therapeutic IL-1β inhibition in atrophic AMD. Several biologic 
agents that target the IL-1 pathway are approved for use by the Food and Drug 
Administration. The recombinant IL-1 receptor antagonist Anakinra is approved for treatment 
of rheumatoid arthritis. The monoclonal anti-IL-1β antibody canakinumab and rilonacept, a 
“IL-1 trap” fusion protein, has been approved for the treatment of CAPS.326,327 In contrast to 
the reported anti-angiogenic effects of IL-18 on laser-induced choroidal 
neovascularization,233 IL-1β promotes neovascularization.255 These opposing findings might 
imply that a single factor (IL-18) or pathway (NLRP3 inflammasome activation) can be anti-
angiogenic and destructive to the RPE at the same time.38 Therefore, the potential role of the 
NLRP3 inflammasome in the pathogenesis of AMD, as well as the downstream cytokines 
involved, must be elucidated in order to determine whether targeting the IL-1 pathway will be 
effective. Further investigations demonstrated C5 activation product C5a is capable to prime 
RPE cells for inflammasome activation (chapter IV) demonstrating C5a increase the 
susceptibility of RPE cells to oxidative damage-mediated cell death. Activated complement 
component C5a is detectable both locally in the sub-RPE space and systemically in plasma 
of AMD patients.149,231 RPE cells are in constant, direct contact with these bioactive 
substances that, therefore, represent candidates for the inflammasome priming signal in 
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AMD via anaphylatoxin receptors such as C5aR that is expressed on the basolateral side of 
the RPE.286 Inhibition of the C5a/C5aR axis reduced inflammasome activation by lipofuscin 
phototoxicity in RPE cells in our experiments. This demonstrates that inflammasome priming 
agents such as C5a increase the susceptibility of RPE cells to oxidative damage-mediated 
cell death. Thereby, our results support therapeutic strategies for treatment of atrophic AMD 
by complement inhibition. Inhibitors of C5 and C5a as well as of complement components 
upstream of C5a generation such as CFD and C3 are currently evaluated in clinical studies 
in patients with AMD. These include various protein-binding and inhibiting substances, such 
as antibodies (LFG316, FCFD4514S, eculizumab), peptides (POT-4) or aptamers 
(ARC1905), which target specifically the complement system (for example, C3, C5, CFD). 
The recombinant mAb antibody fragment Lampalizumab that blocks complement factor D 
demonstrated a promising effects in a phase II trial to slow down atrophy progression. In 
addition, agents with direct inhibitory effects on inflammasome activation such as small 
molecule NLRP3 inhibitors provide specific inhibition of NLRP3, representing interesting 
candidates for future interventional approaches in atrophic AMD.294 Further investigation of a 
pathogenic versus a protective role for the inflammasome is required to determine whether 
targeting the inflammasome pathway will be effective in AMD.  
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8.6 Future prospects 
The molecular pathogenesis of AMD is still not completely resolved which hinders the 
development of effective therapies, in particular for the atrophic subtype of the disease. 
Progressive death of retinal pigment epithelium cells is a hallmark of AMD, the leading cause 
of blindness in all developed countries. Several lines of clinical and experimental evidence 
indicate oxidative and lipofuscin-mediated photooxidative stress as well as activation of the 
NLRP3 inflammasome as contributing factors to this process.  
My findings demonstrate a mechanism that links oxidative/photooxidative damage and 
inflammasome activation in RPE cells by demonstrating that lipofuscin phototoxicity results in 
oxidative damage to lysosomal membranes with subsequent cytosolic leakage of lysosomal 
enzymes and activation of the NLRP3 inflammasome.  
To demonstrate that the NLRP3 inflammasome mediates AMD pathogenesis in response to 
RPE lysosomal destabilization via lipofuscin photoreactivity, it will be necessary to 
investigate whether the identified mechanism can be demonstrated in vivo. In accordance to 
our established cell culture model of blue light-induced photooxidative damage, a 
photoreactive effect in the lipofuscin-containing RPE could be induced by illumination of 
mice. Subsequently, RPE cells may be examined for evidence of inflammasome activation 
by measurement of IL-1β secretion, caspase-1 activation or signs of pyroptotic cell death. 
The lipofuscin-mediated effect can be enhanced by the use of ABCA4 knockout mice, an 
animal model for AMD and Stargardt disease that is characterized by the accelerated 
accumulation of lipofuscin in the RPE.328–330 Influencing inflammasome activation may offer 
new therapeutic stragegies. The use of anakinra (Kineret) or drugs that directly inhibit the 
inflammasome may provide a base for clinical trials in patients with AMD. 
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8.7 Conclusion 
In AMD, the RPE becomes progressively dysfunctional and eventually degenerates, resulting 
in photoreceptor death and visual function loss.  
Evidence that the inflammasome is functional in RPE cells and can mediate IL-1β release in 
response to activation is a key finding that may provide new therapeutic targets for AMD. 
However, research on inflammasomes in AMD remains nascent, and many questions 
regarding the role that the NLRP3 inflammasome play in AMD are still unresolved.  
This study aimed to identify a novel mechanism of inflammasome activation by light damage. 
The finding that photooxidative damage to human RPE cells, intensified by accumulated 
lipofuscin, causes NLRP3 inflamamsome activation via LMP confirms blue light damage as a 
new mechanism of inflammasome activation and contributes to our understanding of light 
damage to the RPE. In contrast to inflammasome activation, the mechanism of 
inflammasome priming in AMD has been little investigated so far. Recent studies 
demonstrated the CFH risk genotype to be associated with significantly increased plasma 
levels of the inflammasome-regulated cytokine IL-18, suggesting a role for activated 
complement components like C3a and C5a in inflammasome activation in AMD. We 
investigated whether products of complement activation are capable of providing the priming 
signal for inflammasome activation in RPE cells. Our study identified complement component 
C5a as a priming agent for the inflammasome in RPE cells that enables subsequent NLRP3 
inflammasome activation by stimuli such as lipofuscin-mediated photooxidative damage. 
Furthermore, inhibition of the C5a/C5aR axis reduced inflammasome activation by lipofuscin 
phototoxicity in RPE cells and supports the rational for therapeutic complement inhibition in 
atrophic AMD. Examining the mechanisms of photooxidative damage-induced cell death in 
cultured human RPE cells demonstrated that LMP-induced NLRP3 inflamamsome activation 
in RPE cells results in apical secretion of inflammatory cytokines with chemotactic effects on 
microglia cells and reduced constitutive secretion of VEGF. Via these mechanisms, lipofuscin 
phototoxicity may contribute to local immune processes in the outer retina as observed in 
AMD. In addition, we demonstrated that inflammasome priming with IL-1α or C5a not only 
changes the cell death mechanism from apoptosis to pyroptosis but also increases the 
susceptibility of the cells to photooxidative damage-mediated cytotoxicity. In summary, our 
results provide new insights into the complex interplay of complement system, 
inflammasome activation, oxidative damage, and RPE cell pathology in AMD pathology and 
suggest inhibition of inflammasome priming or activation as potential treatment strategies for 
atrophic AMD. 
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NLR Nucleotide-binding oligomerization domain (Nod)-like receptors  
NLRC NLR family, CARD domain containing 
NLRC4 NOD-, LRR- and CARD-containing 4 
NLRP NLR family, pyrin domain containing 
NLRP3 NLR family, pyrin domain containing 3 
Nm Nanometer 
NOD Nucleotide-binding and oligomerization domain 
P Properdin 
PAMP Pathogen-associated molecular pattern 
PEDF Pigment epithelial-derived factor 
pH Potential hydrogen 
PI Propidium iodide 
POS Photoreceptor outer segments 
pRPE Human fetal primary RPE cells 
PRR Pattern recognition receptor  
PS Phosphatidylserine 
PTX Pertussis toxin 
PUFA Polyunsaturated fatty acids  
PYD Pyrin domain  
PYHIN Pyrin and HIN domain-containing protein 
qPCR Quantitative real-time PCR 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
RPE Retinal pigment epithelium 
sec Second 
siRNA Small interfering RNA 
SNP Single nucleotide polymorphism  
TdT Terminal desoxynucleotidyl transferase  
TLR Toll-like receptor  
TNF-α Tumor necrosis factor α  
TUNEL  TdT-mediated dUTP-biotin nick end labeling 
UV Ultraviolet radiation  
VEGF Vascular endothelial growth factor  
Z-FF-FMK Z-Phe-Phe-fluoromethylketone  
Z-YVAD-FMK Z-Tyr-Val-Ala-Asp-fluoromethylketone 
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